UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): November 29, 2016

 


 

Novelion Therapeutics Inc.

(Exact Name of Registrant as specified in its charter)

 


 

British Columbia, Canada

 

000-17082

 

N/A

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

887 Great Northern Way, Suite 250, Vancouver, B.C.

Canada, V5T 4T5

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (604) 707-7000

 

Not Applicable

(Registrant’s name or former address, if change since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.01.                                         Completion of Acquisition or Disposition of Assets.

 

On November 29, 2016, pursuant to the terms of the Agreement and Plan of Merger, dated as of June 14, 2016 (as amended, the “ Merger Agreement ”), by and among QLT Inc. (“ QLT ”), Aegerion Pharmaceuticals, Inc. (“ Aegerion ”) and Isotope Acquisition Corp. (“ Merger Sub ”), Merger Sub merged with and into Aegerion, with Aegerion continuing as the surviving corporation and an indirect wholly-owned subsidiary of QLT (the “ Merger ”). Following the Merger, QLT changed its name to “Novelion Therapeutics Inc.” (“ Novelion ”).

 

The common shares without par value (“ Common Shares ”) of Novelion commenced trading under the symbol ‘‘NVLN’’ on the NASDAQ Global Select Market (“ NASDAQ ”) on November 30, 2016 and on the Toronto Stock Exchange on December 1, 2016. The common stock of Aegerion (the “ Aegerion Common Stock ”), which previously traded under the symbol “AEGR,” has been delisted from NASDAQ.

 

As a result of the Merger, each outstanding share of Aegerion Common Stock was converted into the right to receive 1.0256 Common Shares. The aggregate consideration delivered to the former holders of Aegerion Common Stock in connection with the Merger was approximately 30,301,442 Common Shares. Based on the Common Shares outstanding and reserved for issuance as of November 29, 2016 and the Common Shares delivered as merger consideration, there were approximately 92,653,562 Common Shares outstanding immediately following the Merger, with an additional 27,078,332 shares reserved for issuance under equity plans, a fully paid-up warrant issued to one of the Investors (as defined below) under the Unit Subscription Agreement (as defined below) and in relation to Aegerion’s 2.00% Convertible Senior Notes due 2019.  Shareholders of QLT as of immediately prior to the Merger, including the Investors under the Unit Subscription Agreement, owned 68% of the outstanding Common Shares upon completion of the Merger and stockholders of Aegerion as of immediately prior to the Merger owned 32% of the outstanding Common Shares upon completion of the Merger.

 

In connection with the Merger, outstanding in-the-money options to acquire shares of Aegerion Common Stock held by Aegerion option holders were exchanged for adjusted options to acquire Common Shares and unvested restricted stock units with respect to Aegerion Common Stock held by Aegerion restricted stock unit holders were exchanged for restricted stock units in respect of Common Shares.

 

As previously disclosed, Novelion also entered into that certain Unit Subscription Agreement, dated June 14, 2016, by and among QLT and certain investors (the “ Investors ”) party thereto (as amended, the “ Unit Subscription Agreement ”), pursuant to which the Investors agreed to one or more equity commitments. Immediately prior to the Merger, QLT issued 12,363,631 units to the Investors pursuant to the Unit Subscription Agreement, each unit comprising one Common Share (or a fully paid-up warrant to acquire one Common Share), one DOJ/SEC Warrant and one Class Action Warrant, each as described below, at a purchase price per unit of US$1.76 and an aggregate subscription price of US$21,760,000.  The DOJ/SEC Warrant is a warrant relating to the preliminary agreements in principle of Aegerion with the Department of Justice (the “ DOJ ”) and the Securities and Exchange Commission (the “ SEC ”) and the Class Action Warrant relates to the Class Action Litigation (as defined below) against Aegerion, each as previously disclosed.  The issuance of the units was completed in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended, afforded by Section 4(a)(2), as a transaction by an issuer not involving a public offering.

 

The foregoing description of the Merger Agreement, the Merger and the Unit Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement and the Unit Subscription Agreement, which are filed, respectively, as Exhibits 2.1 and 10.1 to this Current Report on Form 8-K and are incorporated by reference into this Item 2.01.

 

Item 3.02.                                         Unregistered Sales of Equity Securities.

 

The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

 

2



 

Item 5.02.                                         Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory       Arrangements of Certain Officers.

 

Board of Directors

 

On November 29, 2016, effective upon the consummation of the Merger, Dr. John Kozarich and Mr. Jeffrey Meckler resigned from their positions as directors of QLT. Their resignations were in connection with the Merger and not the result of any disagreement with QLT on any matter relating to QLT’s operations, policies or practices. Mr. Jason Aryeh, Dr. Geoffrey Cox, Dr. Stephen Sabba and Mr. John Thomas continue to serve as directors of Novelion.

 

Also effective on November 29, 2016, Dr. Jorge Plutzky, Mr. Sandford Smith, Mr. Donald Stern, Ms. Mary Szela and Ms. Anne VanLent, each of whom served on the board of directors of Aegerion prior to the Merger, and Mr. Kevin Kotler were appointed to the board of directors of Novelion (the “ Board ”).

 

Except for the provisions of the Merger Agreement pursuant to which QLT, Aegerion and certain significant shareholders have rights to designate members of the Board, there is no arrangement or understanding between Mr. Kotler, Dr. Plutzky, Mr. Smith, Mr. Stern, Ms. Szela or Ms. VanLent, respectively, and any other person pursuant to which any of Mr. Kotler, Dr. Plutzky, Mr. Smith, Mr. Stern, Ms. Szela or Ms. VanLent was appointed as a director.  Except as described herein, there are no existing or currently proposed transactions to which Novelion or any of its subsidiaries is a party in which any of Mr. Kotler, Dr. Plutzky, Mr. Smith, Mr. Stern, Ms. Szela or Ms. VanLent has a direct or indirect material interest. Mr. Kotler, Dr. Plutzky, Mr. Smith, Mr. Stern and Ms. VanLent will be compensated for Board and committee service in accordance with Novelion’s non-employee director cash and equity-based compensation program.  Ms. Szela will not receive additional compensation for her service as a director.

 

The Board appointed the following directors to serve on the following committees of the Board:

 

Committee

 

Directors

Audit Committee

 

John Thomas (Chair), Anne VanLent and Stephen Sabba

Compensation Committee

 

Stephen Sabba (Chair), Kevin Kotler and Jorge Plutzky

Corporate Governance and Nominating Committee

 

Kevin Kotler (Chair), Jason Aryeh and John Thomas

Compliance Committee*

 

Donald Stern (Chair), Anne VanLent and Sandford Smith

 


*formed by the Board on December 1, 2016

 

Executive Officers

 

On November 29, 2016, Ms. Szela was appointed Chief Executive Officer of Novelion.  In this role, Ms. Szela will serve as Novelion’s Principal Executive Officer. Biographical and other information regarding Ms. Szela can be found in the definitive joint proxy statement/prospectus dated October 6, 2016 that forms a part of a registration statement on Form S-4 initially filed by QLT with the SEC on August 8, 2016 under the section entitled “ QLT Proposal No. 2—Election of Directors Proposal .”

 

Ms. Szela succeeds Dr. Cox, who has served as Interim Chief Executive Officer of Novelion since October 23, 2014.  Pursuant to the terms of Dr. Cox’s employment agreement, Dr. Cox will receive two months’ base salary as severance and stock options to purchase 50,000 Common Shares.

 

Mr. Gregory Perry, 56, was appointed Chief Financial and Administrative Officer of Novelion, effective November 29, 2016 and will serve as Principal Financial Officer of Novelion. Mr. Perry served as Aegerion’s Chief Financial and Administrative Officer prior to the Merger and as Chief Financial Officer of Eleven Biotherapeutics, Inc. from

 

3



 

January 2014 until July 2015, when he joined Aegerion as Chief Financial Officer. Prior to joining Eleven Biotherapeutics, Mr. Perry served as the Interim Chief Financial Officer of InVivo Therapeutics Holdings Corp. from September 2013 until December 2013. Before joining InVivo, he served as the Executive Vice President and Chief Financial Officer of ImmunoGen, Inc. Mr. Perry currently serves on the board of directors of Merus N.V. and previously served on the board of directors of Ocata Therapeutics, Inc., prior to its acquisition by Astellas Pharma Inc. in February 2016. He received a B.A. from Amherst College.

 

Ms. Barbara Chan, 53, was appointed President and Chief Accounting Officer of Aegerion, effective December 1, 2016. Ms. Chan will serve as the Principal Accounting Officer of Novelion. Ms. Chan served as Aegerion’s Vice President, Chief Accounting Officer prior to the Merger and held a series of positions with PAREXEL International Corporation, most recently as Senior Director, Worldwide Accounting Services, from September 2013 until May 2016, when she joined Aegerion.  Prior to joining PAREXEL, Ms. Chan served as Director, Americas and Asia Pacific Accounting at Nuance Communications, Inc. from June 2011 through August 2013. Ms. Chan holds B.S. and M.S. degrees from Bentley College and is a Certified Public Accountant in Massachusetts.

 

There is no arrangement or understanding between Ms. Szela, Mr. Perry or Ms. Chan, respectively, and any other person pursuant to which any of Ms. Szela, Mr. Perry or Ms. Chan was appointed to their positions with Novelion and Aegerion, respectively. Except as described herein, there are no existing or currently proposed transactions to which Novelion or any of its subsidiaries is a party and in which Ms. Szela, Mr. Perry or Ms. Chan has a direct or indirect material interest. There are no family relationships between Ms. Szela, Mr. Perry or Ms. Chan, respectively, and any of the directors or officers of Novelion or any of its subsidiaries.

 

Employment Arrangement with Mary Szela

 

The terms of Ms. Szela’s compensation for service as an officer of Novelion and as an officer and employee of Novelion Services USA, Inc., an indirect wholly-owned subsidiary of Novelion (“ Novelion Services ”), have not yet been determined.  Novelion Services is currently compensating Ms. Szela in accordance with the terms of her employment agreement with Aegerion, which is filed as Exhibit 10.1 to Aegerion’s Current Report on Form 8-K filed with the SEC on January 11, 2016.

 

Employment Arrangement with Gregory Perry

 

On November 28, 2016, Mr. Perry entered into an employment agreement with Novelion Services (the “ Perry Employment Agreement ”).  Pursuant to the terms of the Perry Employment Agreement, Mr. Perry will receive an annual base salary of US$450,000 and is eligible to receive an annual target bonus of up to 50% of his base salary. Subject to his continued employment, Mr. Perry also will receive a retention bonus of US$200,000 on December 31, 2016. If Novelion Services terminates Mr. Perry’s employment without Cause or Mr. Perry resigns for Good Reason (as each term is defined in the Perry Employment Agreement), Mr. Perry will be eligible for (i) payment of his accrued but unpaid base salary, any unpaid or unreimbursed expenses and any accrued but unused vacation through the date of termination, (ii) continued payment of his base salary for 12 months following the termination date, (iii) payment at the end of the 12-month severance period of any cash retention bonus awarded to him prior to termination of his employment, and (iv) continued coverage under Novelion Services benefit plans for up to 12 months (collectively, the “ Perry Severance Benefits ”).  Further, if within 18 months following the occurrence of certain corporate transactions, Mr. Perry’s employment is (a) terminated by Novelion Services for any reason (other than as a result of his death or disability or a with Cause termination that occurs for certain specified reasons) or (b) terminated by Mr. Perry with Good Reason, then Mr. Perry will be eligible to receive, in addition to the Perry Severance Benefits, acceleration of the vesting of 100% of Mr. Perry’s then outstanding unvested equity awards.

 

In addition, pursuant to the Perry Employment Agreement, Novelion Services will (i) provide to Mr. Perry an allowance for certain housing and commuting costs for a limited period, (ii) reimburse Mr. Perry for reasonable commuting expenses between Boston, Massachusetts and Canada, including air travel, (iii) offset any tax liability of Mr. Perry associated with such housing and commuting allowance and commuting expense reimbursements and associated with the duties of his employment in Canada and (iv) reimburse Mr. Perry for incurrence of fees for tax and financial planning, including tax consultation in connection with performing duties of employment in Canada, up to US$20,000 on an annual basis, subject to Novelion Services’ receipt of appropriate documentation and substantiation of the same.

 

4



 

Employment Arrangement with Barbara Chan

 

Ms. Chan will continue to be compensated in accordance with the terms of her offer letter agreement with Aegerion, which provides that Ms. Chan will receive an annual base salary of US$265,000 and is eligible to receive an annual target bonus of up to 30% of her base salary.

 

Novelion 2016 Equity Incentive Plan

 

In connection with the Merger, the QLT 2000 Incentive Stock Plan was amended to increase the maximum number of Common Shares issuable under the plan by 12,000,000 Common Shares, to 23,800,000 Common Shares and to change in the name of the plan to the “Novelion 2016 Equity Incentive Plan” (the “ Novelion Plan ”). The amendments were approved by shareholders of QLT at a special meeting held on November 7, 2016. On December 1, the Board approved additional amendments to the Novelion Plan, subject to the approval of the Toronto Stock Exchange, to permit the Compensation Committee of the Board to delegate to an executive officer or officers of Novelion certain authorities and duties with respect to grants to non-executive officer employees under the Novelion Plan.  The foregoing description of amendments to the Novelion Plan does not purport to be complete and is qualified in its entirety by reference to the Novelion Plan, which was filed as Exhibit 99.4 to the Registration Statement on Form S-8 filed by Novelion with the SEC on December 5, 2016 and is incorporated by reference into this Item 5.02.

 

Item 5.03.                                         Amendments to Articles of Incorporation or Bylaws.

 

On November 29, 2016, following the consummation of the Merger, QLT filed a Notice of Alteration altering its Notice of Articles and obtained a certificate of name change reflecting the change of the legal name of QLT to “Novelion Therapeutics Inc.” The foregoing description of amendments to Novelion’s Notice of Articles does not purport to be complete and is qualified in its entirety by reference to the Notice of Articles of Novelion, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 5.03.

 

Item 8.01.                                         Other Events.

 

A copy of the press release announcing the consummation of the Merger and related transactions was filed as Exhibit 99.1 to the Current Report on Form 8-K filed by Novelion with the SEC on November 29, 2016 and is incorporated by reference into this Item 8.01.

 

On December 5, 2016, subject to applicable regulatory approvals, Novelion’s Board approved a 1-for-5 share consolidation of its Common Shares (the “ Share Consolidation ”). If approved by the Toronto Stock Exchange, the Share Consolidation is expected to take effect at 5:00 p.m. eastern time on December 16, 2016. At the effective time of the Share Consolidation, each Common Share issued and outstanding immediately before the effective time of the Share Consolidation will be automatically converted into one-fifth of one Common Share. The Share Consolidation will affect all shareholders uniformly and will not affect any shareholder’s percentage ownership interest in Novelion or proportionate voting power, except for minor changes and adjustments resulting from the treatment of fractional shares. No fractional shares will be issued in connection with the Share Consolidation and any fractional shares that would have otherwise been issued will be rounded down to the nearest whole number.  Shareholders will not receive cash in lieu of fractional shares.  Immediately following the effective time of the Share Consolidation, Novelion is expected to have approximately 18,530,700 Common Shares issued and outstanding.

 

On December 2, 2016, Aegerion entered into a Memorandum of Understanding (the “ Memorandum of Understanding ”) to memorialize an agreement in principle to settle all claims of participating class members with prejudice and without any liability or wrongdoing attributed to Aegerion in the class actions consolidated in the lawsuit KBC Asset Management NV, et al. v. Aegerion Pharmaceuticals, Inc., et al. , Civil Action No. 1:14-CV-10105-MLW, pending in the United States District Court for the District of Massachusetts (the “ Class Action Litigation ”). The Class Action Litigation is more fully described in Aegerion’s Quarterly Report on Form 10-Q filed with the SEC on November 4, 2016.

 

The Memorandum of Understanding provides for an aggregate settlement payment by or on behalf of Aegerion of US$22,250,000, which includes all plaintiffs’ attorneys’ fees and expenses, as well as any other class notice and administrative fees related to the resolution of the Class Action Litigation. The settlement includes the dismissal of all claims against Aegerion and the named individuals in the Class Action Litigation without any liability or wrongdoing attributed to them. It is expected that US$22,000,000 of the settlement will be funded with insurance

 

5



 

proceeds and that US$250,000 will be funded from cash on hand.  The settlement described in the Memorandum of Understanding remains subject to further documentation, court approval, and other customary conditions, including Aegerion’s right to terminate the settlement in the event an agreed-upon percentage of class members do not participate.

 

If and when the settlement is finalized on the terms described above, the Class Action Warrants that were issued by Novelion to its shareholders preceding the closing of the Merger will cease to be exercisable for additional Common Shares.  The outstanding DOJ/SEC Warrants will not be affected.

 

A copy of the press release announcing the Share Consolidation and the Memorandum of Understanding is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

 

Safe Harbor for Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All forward-looking statements included in this report are based upon information available to Novelion as of the date of this report and expectations and assumptions underlying such statements are inherently subject to uncertainties, risks and changes that are difficult to predict. These forward-looking statements are not guarantees of future performance and actual results could differ materially from those expressed or implied in such statements. A variety of factors could cause or contribute to such differences, including risks and uncertainties detailed from time to time in Novelion’s filings with the SEC. Except as required by law, Novelion assumes no obligation to, and does not intend to, update these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Item 9.01.                                         Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired.

 

The audited consolidated financial statements of Aegerion as of December 31, 2015 and 2014, and for the three years ended December 31, 2015, as well as the unaudited consolidated financial statements of Aegerion as of and for the nine months ended September 30, 2016 and 2015, are filed, respectively, as Exhibits 99.3 and 99.4 to this Current Report on Form 8-K.

 

(b) Pro Forma Financial Information.

 

Unaudited pro forma condensed combined financial statements of Novelion and Aegerion as of and for the nine months ended September 30, 2016 and the year ended December 31, 2015 are filed as Exhibit 99.5 to this Current Report on Form 8-K.

 

(d) Exhibits.

 

Exhibit No. 

 

Description

2.1

 

Agreement and Plan of Merger, dated as of June 14, 2016, and Amendment No. 1 thereto, dated as of September 1, 2016, by and among Aegerion Pharmaceuticals, Inc., QLT Inc. and Isotope Acquisition Corp. (incorporated by reference to Annex A to the Joint Proxy Statement/Prospectus forming a part of QLT Inc.’s Amendment No. 1 to Registration Statement on Form S-4 filed with the SEC on September 12, 2016).

 

 

 

3.1

 

Notice of Articles, dated as of November 29, 2016.

 

 

 

10.1

 

Unit Subscription Agreement, dated as of June 14, 2016, by and among QLT Inc., Deerfield International Master Fund, L.P., Deerfield Partners, L.P., Broadfin Healthcare Master Fund, Ltd., JW Partners LP, JW Opportunities Fund, LLC, The K2 Principal Fund L.P., Healthcare Value Partners, L.P., Tiger Legatus Capital Management, LLC, Sarissa Capital Domestic Fund LP, Sarissa Capital Offshore Master Fund LP, Armistice Capital Master Fund, Ltd. and Jason Aryeh, as amended as applied to Broadfin Healthcare Master Fund, Ltd. on September 9, 2016.

 

6



 

10.2

 

Aegerion Pharmaceuticals, Inc. 2006 Stock Option and Grant Plan, as amended, and forms of agreement thereunder (incorporated by reference to Exhibit 10.1 to Aegerion’s Registration Statement on Form S-1, as amended, initially filed with the SEC on August 10, 2010).

 

 

 

10.3

 

Aegerion Pharmaceuticals, Inc. 2010 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 to Aegerion’s Registration Statement on Form S-1, as amended, initially filed with the SEC on August 10, 2010).

 

 

 

10.4

 

Aegerion Pharmaceuticals, Inc. Amended and Restated Inducement Award Stock Option Plan, and form of option agreement thereunder (incorporated by reference to Exhibit 10.1 to Aegerion’s Current Report on Form 8-K filed with the SEC on September 23, 2015).

 

 

 

10.5

 

Novelion 2016 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to Novelion’s Registration Statement on Form S-8 filed with the SEC on December 5, 2016).

 

 

 

10.6

 

Employment Agreement, dated November 28, 2016, by and between Novelion Services USA, Inc. and Gregory Perry.

 

 

 

10.7

 

Offer Letter to Barbara Chan from Aegerion Pharmaceuticals, Inc., dated May 25, 2016.

 

 

 

23.1

 

Consent of Ernst & Young LLP, independent registered public accounting firm of Aegerion.

 

 

 

99.1

 

Press Release, dated November 29, 2016 (incorporated by reference to Exhibit 99.1 to QLT’s Current Report on Form 8-K filed with the SEC on November 29, 2016).

 

 

 

99.2

 

Press Release, dated December 5, 2016.

 

 

 

99.3

 

Audited Consolidated Financial Statements of Aegerion Pharmaceuticals, Inc. as of and for the year ended December 31, 2015 (incorporated by reference to Aegerion’s Annual Report on Form 10-K filed with the SEC on March 15, 2016).

 

 

 

99.4

 

Unaudited Consolidated Financial Statements of Aegerion Pharmaceuticals, Inc. as of and for the nine months ended September 30, 2016 (incorporated by reference to Aegerion’s Quarterly Report on Form 10-Q filed with the SEC on November 4, 2016).

 

 

 

99.5

 

Pro Forma Financial Statements of QLT Inc. and Aegerion Pharmaceuticals, Inc. as of and for the nine months ended September 30, 2016 and the year ended December 31, 2015 (incorporated by reference to Exhibit 99.1 to QLT’s Current Report on Form 8-K filed with the SEC on November 22, 2016).

 

7



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Novelion Therapeutics Inc.

 

 

 

 

 

 

By:

/s/ Benjamin Harshbarger

 

Name:

Benjamin Harshbarger

 

Title:

General Counsel

 

 

 

Date: December 5, 2016

 

 

 

8



 

EXHIBIT INDEX

 

Exhibit No. 

 

Description

2.1

 

Agreement and Plan of Merger, dated as of June 14, 2016, and Amendment No. 1 thereto, dated as of September 1, 2016, by and among Aegerion Pharmaceuticals, Inc., QLT Inc. and Isotope Acquisition Corp. (incorporated by reference to Annex A to the Joint Proxy Statement/Prospectus forming a part of QLT Inc.’s Amendment No. 1 to Registration Statement on Form S-4 filed with the SEC on September 12, 2016).

 

 

 

3.1

 

Notice of Articles, dated as of November 29, 2016.

 

 

 

10.1

 

Unit Subscription Agreement, dated as of June 14, 2016, by and among QLT Inc., Deerfield International Master Fund, L.P., Deerfield Partners, L.P., Broadfin Healthcare Master Fund, Ltd., JW Partners LP, JW Opportunities Fund, LLC, The K2 Principal Fund L.P., Healthcare Value Partners, L.P., Tiger Legatus Capital Management, LLC, Sarissa Capital Domestic Fund LP, Sarissa Capital Offshore Master Fund LP, Armistice Capital Master Fund, Ltd. and Jason Aryeh, as amended as applied to Broadfin Healthcare Master Fund, Ltd. on September 9, 2016.

 

 

 

10.2

 

Aegerion Pharmaceuticals, Inc. 2006 Stock Option and Grant Plan, as amended, and forms of agreement thereunder (incorporated by reference to Exhibit 10.1 to Aegerion’s Registration Statement on Form S-1, as amended, initially filed with the SEC on August 10, 2010).

 

 

 

10.3

 

Aegerion Pharmaceuticals, Inc. 2010 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 to Aegerion’s Registration Statement on Form S-1, as amended, initially filed with the SEC on August 10, 2010).

 

 

 

10.4

 

Aegerion Pharmaceuticals, Inc. Amended and Restated Inducement Award Stock Option Plan, and form of option agreement thereunder (incorporated by reference to Exhibit 10.1 to Aegerion’s Current Report on Form 8-K filed with the SEC on September 23, 2015).

 

 

 

10.5

 

Novelion 2016 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to Novelion’s Registration Statement on Form S-8 filed with the SEC on December 5, 2016).

 

 

 

10.6

 

Employment Agreement, dated November 28, 2016, by and between Novelion Services USA, Inc. and Gregory Perry.

 

 

 

10.7

 

Offer Letter to Barbara Chan from Aegerion Pharmaceuticals, Inc., dated May 25, 2016.

 

 

 

23.1

 

Consent of Ernst & Young LLP, independent registered public accounting firm of Aegerion.

 

 

 

99.1

 

Press Release, dated November 29, 2016 (incorporated by reference to Exhibit 99.1 to QLT’s Current Report on Form 8-K filed with the SEC on November 29, 2016).

 

 

 

99.2

 

Press Release, dated December 5, 2016.

 

 

 

99.3

 

Audited Consolidated Financial Statements of Aegerion Pharmaceuticals, Inc. as of and for the year ended December 31, 2015 (incorporated by reference to Aegerion’s Annual Report on Form 10-K filed with the SEC on March 15, 2016).

 

 

 

99.4

 

Unaudited Consolidated Financial Statements of Aegerion Pharmaceuticals, Inc. as of and for the nine months ended September 30, 2016 (incorporated by reference to Aegerion’s Quarterly Report on Form 10-Q filed with the SEC on November 4, 2016).

 

 

 

99.5

 

Pro Forma Financial Statements of QLT Inc. and Aegerion Pharmaceuticals, Inc. as of and for the nine months ended September 30, 2016 and the year ended December 31, 2015 (incorporated by reference to Exhibit 99.1 to QLT’s Current Report on Form 8-K filed with the SEC on November 22, 2016).

 

9


Exhibit 3.1

 

Mailing Address:

Location:

PO Box 9431 Stn Prov Govt

2nd Floor - 940 Blanshard Street

Victoria BC V8W 9V3

Victoria BC

www.corporateonline.gov.bc.ca

1 877 526-1526

 

 

 

 

CERTIFIED COPY

Of a Document filed with the Province of

British Columbia Registrar of Companies

 

 

Notice of Articles

 

 

 

 

BUSINESS CORPORATIONS ACT

CAROL PREST

 

This Notice of Articles was issued by the Registrar on: November 29, 2016 01:14 PM Pacific Time

 

Incorporation Number:

BC0698743

 

 

Recognition Date and Time:  July 1, 2004 12:01 AM Pacific Time as a result of an Amalgamation

 

NOTICE OF ARTICLES

 

Name of Company:

NOVELION THERAPEUTICS INC.

 

REGISTERED OFFICE INFORMATION

 

Mailing Address:

Delivery Address:

SUITE 2600, OCEANIC PLAZA

SUITE 2600, OCEANIC PLAZA

1066 WEST HASTINGS STREET

1066 WEST HASTINGS STREET

VANCOUVER BC V6E 3X1

VANCOUVER BC V6E 3X1

CANADA

CANADA

 

 

RECORDS OFFICE INFORMATION

 

 

 

Mailing Address:

Delivery Address:

SUITE 2600, OCEANIC PLAZA

SUITE 2600, OCEANIC PLAZA

1066 WEST HASTINGS STREET

1066 WEST HASTINGS STREET

VANCOUVER BC V6E 3X1

VANCOUVER BC V6E 3X1

CANADA

CANADA

 

1



 

DIRECTOR INFORMATION

 

 

 

Last Name, First Name, Middle Name:

 

Cox, Geoffrey F.

 

 

 

Mailing Address:

Delivery Address:

480 BEACON STREET #1

480 BEACON STREET #1

BOSTON MA 02115

BOSTON MA 02115

UNITED STATES

UNITED STATES

 

 

Last Name, First Name, Middle Name:

 

Sabba, Stephen L.

 

 

 

Mailing Address:

Delivery Address:

KNOTT PARTNERS, LP

KNOTT PARTNERS, LP

485 UNDERHILL BLVD.

485 UNDERHILL BLVD.

SYOSSET NY 11791 3419

SYOSSET NY 11791 3419

UNITED STATES

UNITED STATES

 

 

Last Name, First Name, Middle Name:

 

Thomas JR., John C.

 

 

 

Mailing Address:

Delivery Address:

286 SOUTH MAIN STREET

286 SOUTH MAIN STREET

SUITE 200

SUITE 200

ALPHARETTA GA 30009

ALPHARETTA GA 30009

UNITED STATES

UNITED STATES

 

 

Last Name, First Name, Middle Name:

 

Aryeh, Jason M.

 

 

 

Mailing Address:

Delivery Address:

887 GREAT NORTHERN WAY, SUITE 250

887 GREAT NORTHERN WAY, SUITE 250

VANCOUVER BC V5T 4T5

VANCOUVER BC V5T 4T5

CANADA

CANADA

 

 

Last Name, First Name, Middle Name:

 

VanLent, Anne

 

 

 

Mailing Address:

Delivery Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

BOSTON MA 02199-3600

UNITED STATES

UNITED STATES

 

 

Last Name, First Name, Middle Name:

 

Szela, Mary T.

 

 

 

Mailing Address:

Delivery Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

BOSTON MA 02199-3600

UNITED STATES

UNITED STATES

 

2



 

Last Name, First Name, Middle Name:

Stern, Donald K.

 

 

 

Mailing Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

Delivery Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

 

 

Last Name, First Name, Middle Name:

 

Smith, Sandford D.

 

 

 

Mailing Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

Delivery Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

 

 

Last Name, First Name, Middle Name:

Kotler, Kevin

 

 

 

Mailing Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

Delivery Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

 

 

Last Name, First Name, Middle Name:

Plutzky, Jorge

 

 

 

Mailing Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

Delivery Address:

PRUDENTIAL TOWER, 800 BOYLSTON STREET

BOSTON MA 02199-3600

UNITED STATES

 

RESOLUTION DATES:

 

Date(s) of Resolution(s) or Court Order(s) attaching or altering Special Rights and Restrictions attached to a class or a series of shares:

 

May 25, 2005

March 21, 2016

March 21, 2016

 

AUTHORIZED SHARE STRUCTURE

 

 

 

1.

500,000,000

Common Shares

Without Par Value

 

 

 

 

 

 

Without Special Rights or

 

 

 

Restrictions attached

 

3



 

2.

5,000,000

First Preference Shares

Without Par Value

 

 

 

 

 

 

With Special Rights or

 

 

 

Restrictions attached

 

4


Exhibit 10.1

 

Execution Version

 

UNIT SUBSCRIPTION AGREEMENT

 

by and among

 

QLT INC.

 

and

 

THE INVESTORS IDENTIFIED
ON SCHEDULE I HERETO

 


 

Dated as of June 14, 2016

 



 

TABLE OF CONTENTS

 

 

 

 

Page

ARTICLE I

DEFINITIONS

 

1

1.1

CERTAIN DEFINITIONS

 

1

1.2

TERMS DEFINED ELSEWHERE IN THIS AGREEMENT

 

3

1.3

OTHER DEFINITIONAL AND INTERPRETIVE MATTERS

 

3

ARTICLE II

SUBSCRIPTION FOR UNITS; SUBSCRIPTION PRICE; INVESTMENT CLOSING

 

4

2.1

SUBSCRIPTION FOR UNITS

 

4

2.2

PAYMENT OF SUBSCRIPTION PRICE; ALLOTMENT OF UNITS

 

4

2.3

INVESTMENT CLOSING

 

5

2.4

COMPANY DELIVERIES

 

5

2.5

INVESTOR DELIVERIES

 

5

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

6

3.1

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

6

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE INVESTORS

 

9

4.1

REPRESENTATIONS AND WARRANTIES OF THE INVESTORS

 

9

ARTICLE V

COVENANTSAND AGREEMENTS

 

11

5.1

FURNISHING INFORMATION

 

11

5.2

FILINGS; COMMERCIALLY REASONABLE EFFORTS; NOTIFICATION

 

11

5.3

NASDAQ AND TSX LISTING

 

12

5.4

REPORTING ISSUER STATUS

 

12

5.5

FURTHER ASSURANCES

 

12

5.6

ADVICE OF CHANGES

 

12

5.7

INVESTORS’ REGISTRATION RIGHTS

 

12

5.8

INVESTOR AGREEMENT

 

12

5.9

ADDITIONAL COMPANY AGREEMENTS

 

13

ARTICLE VI

CONDITIONS TO INVESTMENT CLOSING

 

15

6.1

MUTUAL CONDITIONS

 

15

6.2

INVESTOR’S CONDITIONS

 

15

6.3

COMPANY CONDITIONS

 

16

ARTICLE VII

TERMINATION

 

17

7.1

TERMINATION

 

17

7.2

PROCEDURE UPON TERMINATION

 

17

7.3

EFFECTS OF TERMINATION

 

17

ARTICLE VIII

MISCELLANEOUS

 

18

 



 

TABLE OF CONTENTS
(continued)

 

 

 

 

Page

8.1

SURVIVAL

 

18

8.2

EXPENSES

 

18

8.3

COUNTERPARTS; EFFECTIVENESS

 

18

8.4

GOVERNING LAW

 

18

8.5

JURISDICTION; SPECIFIC ENFORCEMENT

 

18

8.6

WAIVER OF JURY TRIAL

 

19

8.7

NOTICES

 

19

8.8

ASSIGNMENT; BINDING EFFECT

 

20

8.9

SEVERABILITY

 

20

8.10

INDEPENDENT LEGAL AND INVESTMENT ADVICE

 

20

8.11

ENTIRE AGREEMENT

 

20

8.12

AMENDMENTS; WAIVERS

 

20

8.13

HEADINGS

 

21

8.14

NO THIRD-PARTY BENEFICIARIES

 

21

8.15

OBLIGATIONS OF THE INVESTORS AND THE COMPANY

 

21

 

SCHEDULE I

Schedule of Investors

 

ANNEX A

Investors’ Registration Rights

 

ANNEX B

Form of Warrant Agreement

 

 

ii



 

UNIT SUBSCRIPTION AGREEMENT

 

This UNIT SUBSCRIPTION AGREEMENT , dated as of June 14, 2016 (this “ Agreement ”), is by and among QLT Inc., a corporation formed under the laws of the Province of British Columbia, Canada (the “ Company ”) and the Persons identified on Schedule I hereto (each an “ Investor ” and together, the “ Investors ”).

 

W I T N E S S E T H:

 

WHEREAS , the Company and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“ Aegerion ”), wish to enter into an Agreement and Plan of Merger (the “ Merger Agreement ”), pursuant to which a wholly-owned subsidiary of the Company would merge with and into Aegerion (the “ Merger ”), with Aegerion surviving as a wholly-owned indirect subsidiary of the Company;

 

WHEREAS , the Investors have agreed to provide capital to the Company in support of the Merger;

 

WHEREAS , in furtherance of the foregoing, the Company desires to allot and issue to the Investors, and the Investors desire to subscribe for, up to a maximum of 12,363,636 common shares of the Company (the “ Shares ”) and an equal number of Warrants (together with the Shares, the “ Units ”) for the Subscription Price (as hereinafter defined) as set forth in, and in accordance with the other provisions of, this Agreement;

 

WHEREAS , the Company has agreed to grant the Investors the registration rights provided for herein; and

 

WHEREAS , certain terms used in this Agreement are defined in Section 1.1 .

 

NOW, THEREFORE , in consideration of the premises and the mutual covenants and agreements hereinafter contained, the parties hereby agree as follows:

 

ARTICLE I

 

DEFINITIONS

 

1.1                                Certain Definitions .  Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Merger Agreement.

 

In addition, for purposes of this Agreement, the following terms shall have the meanings specified in this Section 1.1 :

 

Canadian Securities Laws ” means all applicable Canadian securities laws, rules, regulations, notices, instruments, blanket orders and policies in each Province of Canada in which the Company is a reporting issuer or equivalent.

 

Commission ” means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 



 

Deerfield ” means Deerfield Partners, L.P., a Delaware limited partnership, and Deerfield International Master Fund, L.P., a limited partnership formed under the laws of the British Virgin Islands.

 

Governmental Authority ” means any international, multinational, federal, provincial, territorial, state, regional, municipal, local or other government or governmental body and any ministry, department, division, bureau, agent, official, agency, commission, board or authority of any government, governmental body, quasi-governmental or private body (including the TSX, the NASDAQ or any other applicable stock exchange), domestic or foreign, exercising any statutory, regulatory, expropriation or taxing authority under the authority of any of the foregoing and any domestic, foreign or international judicial, quasi-judicial or administrative court, tribunal, commission, board, panel, arbitrator or arbitral body acting under the authority of any of the foregoing.

 

Investor Shares ” with respect to each Investor means the number of Shares to be issued to such Investor pursuant to this Agreement at the Investor Closing, equal to the quotient obtained by dividing the Subscription Price of such Investor by the Per Share Subscription Price.

 

Investor Units ” with respect to each Investor means, together, such Investor’s Investor Shares and such Investor’s Investor Warrants.

 

Investor Warrants ” with respect to each Investor means the number of Warrants to be issued to such Investor pursuant to this Agreement at the Investor Closing, equal to the number of such Investor’s Investor Shares.

 

Law ” any and all laws, statutes, codes, ordinances (including zoning), approvals, rules, regulations, instruments, by-laws, notices, policies, protocols, guidelines, guidance, manuals, treaties or other requirements of any Governmental Authority having the force of law and any legal requirements arising under the common law or principles of law or equity.

 

NASDAQ ” means the NASDAQ Global Select Market.

 

Per Share Subscription Price ” means $1.76.

 

Securities Act ” means the Securities Act of 1933, as amended, or any successor Law thereto, and the rules and regulations issued pursuant to that statute or any successor Law.

 

TSX ” means the Toronto Stock Exchange.

 

Warrants ” means the warrants to be issued in accordance with the provisions of a warrant agreement, substantially in the form attached hereto as Annex B (the “ Warrant Agreement ”).

 

Warrant Shares ” means the common shares of the Company to be issued upon exercise of the Warrants.

 

2



 

1.2                                Terms Defined Elsewhere in this Agreement .  For purposes of this Agreement, the following terms have meanings set forth in the sections indicated:

 

Term

 

Section

Agreement

 

Preamble

Company

 

Preamble

Company SEC Documents

 

3.1(f)

Confidentiality Agreement

 

5.1

Consents

 

5.2(a)

Investment Closing

 

2.3

Investment Closing Date

 

2.3

Investors

 

Preamble

Investors’ Disclosure Schedule

 

ARTICLE IV

Investor Registration Expenses

 

Annex A

Investor Registration

 

Annex A

Investor Registration Statement

 

Annex A

Losses

 

1.2(f)

Merger

 

Recitals

Merger Agreement

 

Recitals

register, registered, registration

 

Annex A

Registrable Securities

 

Annex A

Selling Expenses

 

Annex A

Shares

 

Recitals

Subscription Price

 

2.1(d)

Transfer Agent

 

2.2(b)

 

1.3                                Other Definitional and Interpretive Matters .

 

(a)                                  Unless otherwise expressly provided, for purposes of this Agreement, the following rules of interpretation shall apply:

 

Calculation of Time Period .  When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded.  If the last day of such period is a non-Business Day, the period in question shall end on the next succeeding Business Day.

 

Dollars .  Any reference in this Agreement to $ shall mean U.S. dollars.

 

Schedules and Annexes .  The Schedules and Annexes to this Agreement are hereby incorporated and made a part hereof and are an integral part of this Agreement.  All Schedules and Annexes annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein.  Any capitalized terms used in any Schedule or Annex but not otherwise defined therein shall be defined as set forth in this Agreement.

 

Gender and Number .  Any reference in this Agreement to gender shall include all genders, and words imparting the singular number only shall include the plural and vice versa.

 

3



 

Headings .  The provision of a Table of Contents, the division of this Agreement into Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement.  All references in this Agreement to any “Section” are to the corresponding Section of this Agreement unless otherwise specified.

 

Herein .  The words such as “ herein ,” “ hereinafter ,” “ hereof ,” and “ hereunder ” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires.

 

Including .  The word “ including ” or any variation thereof means “ including, without limitation ” and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it.

 

(b)                                  The parties hereto have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.

 

ARTICLE II

 

SUBSCRIPTION FOR UNITS; SUBSCRIPTION PRICE; INVESTMENT CLOSING

 

2.1                                Subscription for Units .

 

(a)                                  Subject to the terms and conditions hereof, at the Investment Closing, each Investor hereby agrees to subscribe for such Investor’s Investor Units.

 

(b)                                  Subject to the terms and conditions hereof, at the Investment Closing, the Board of Directors (the “ Board ”) of the Company will approve the allotment and issue to each Investor of such Investor’s Investor Units, consisting of such Investor’s Investor Shares and Investor Warrants and procure that the Company’s shareholder register reflects the allotment and issue and that share certificates and warrant certificates (or evidence of book entry) are delivered to the Investors.

 

(c)                                   The aggregate amount that each Investor will pay to the Company for the Units it subscribes for hereunder shall be set forth opposite such Investor’s name under the heading “Subscription Price” on Schedule I hereto (with respect to each Investor, the “ Subscription Price ”).

 

2.2                                Payment of Subscription Price; Allotment of Units .

 

(a)                                  At the Investment Closing, each Investor shall pay its respective Subscription Price to the Company by wire transfer of immediately available funds into an account designated in writing by the Company.  The Company shall provide written notice to the Investors of such account not less than three (3) Business Days prior to the Investment Closing Date.

 

4



 

(b)                                  At the Investment Closing, the Company will (i) irrevocably instruct its transfer agent (the “ Transfer Agent ”) to deliver to each Investor, such Investor’s Investor Shares, in certificate or book entry form, in each case registered in the name of such Investor and (ii) deliver to each Investor such Investor’s Investor Warrants.

 

2.3                                Investment Closing .  Subject to the satisfaction or waiver of the conditions set forth in ARTICLE VI (other than conditions that by their nature are to be satisfied at the Investment Closing, but subject to the satisfaction or waiver of those conditions at such time), the consummation of the allotment and issue of the Units provided for in Section 2.1 hereof (the “ Investment Closing ”) shall occur immediately prior to and at the same location as the Closing under the Merger Agreement.  The date the Investment Closing occurs is referred to as the “ Investment Closing Date ”.

 

2.4                                Company Deliveries .  At the Investment Closing, subject to the terms and conditions hereof, the Company shall deliver, or cause to be delivered, to each Investor:

 

(a)                                  copies of resolutions, certified by an officer of the Company, as to the authorization by the board of directors and shareholders of the Company of this Agreement and all of the transactions contemplated hereby, including, but not limited to, the Company’s issuance and sale of the Shares and the Warrants;

 

(b)                                  a certificate in form and substance reasonably satisfactory to each Investor, dated the Investment Closing Date and signed by an executive officer of the Company, stating that the conditions set forth in Sections 6.2(a)  and 6.2(b)  hereof are satisfied;

 

(c)                                   the Shares as set forth in Section 2.2(b)  hereof, in certificate or book entry form (except in the case of Deerfield, who will receive certificated Units), in each case registered in the name of such Investor, which Shares shall be free and clear of any Liens, and evidence that a book entry representing the issuance of such Investor’s Investor Shares has been established on the books and records of the Company at the Transfer Agent;

 

(d)                                  the Warrants, represented by the Warrant Agreement, as set forth in Section 2.2(b)  hereof, duly executed on behalf of the Company and registered in the name of such Investor, which Warrants shall be free and clear of any Liens; and

 

(e)                                   the Units as set forth in Section 2.2(b)  hereof, in certificate or book entry form (except in the case of Deerfield, who will receive certificated Units), in each case registered in the name of such Investor, which Units shall be free and clear of any Liens; and

 

(f)                                    following the Investor’s receipt of the Investor Units, a cross-receipt, executed by the Company and delivered to each Investor certifying that it has received the Subscription Price from such Investor as of the Investment Closing Date.

 

2.5                                Investor Deliveries .  At the Investment Closing, subject to the terms and conditions hereof, each Investor will deliver, or cause to be delivered, to the Company:

 

(a)                                  payment to the Company of such Investor’s respective Subscription Price by wire transfer of immediately available funds to the account designated by the Company;

 

5



 

(b)                                  a cross-receipt executed by each Investor and delivered to the Company certifying that, as of the Investment Closing Date, it has received, in the case of each Investor, such Investor’s Investor Units; and

 

(c)                                   a certificate in form and substance reasonably satisfactory to the Company, dated the Investment Closing Date and signed by an authorized signatory of such Investor, stating that the conditions in Sections 6.3(a) and 6.3(b)  hereof have been satisfied and/or complied with by each Investor.

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

3.1                                Representations and Warranties of the Company .  In order to induce the Investors to enter into this Agreement, the Company represents and warrants to each Investor as follows:

 

(a)                                  Corporate Existence; Authority .

 

(i)                                      The Company is a corporation duly incorporated and validly existing under the Laws of British Columbia, Canada.  The Company has the corporate power and authority to own or lease all of its properties and assets and to carry on its business as it is now being conducted.

 

(ii)                                   The Company has the corporate power and authority to enter into, execute and deliver this Agreement, to perform its obligations under this Agreement, and to consummate the transactions contemplated hereby (including, without limitation, the issuance of the Shares and the Warrants, and the reservation for issuance and issuance of the Warrant Shares).  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and validly approved by the Board of the Company.  The Board of the Company has determined that this Agreement is advisable to and is in the best interests of the Company and its shareholders and, other than requisite shareholder approval, no other corporate proceedings on the part of the Company are necessary to approve this Agreement and to consummate the transactions contemplated hereby.  This Agreement has been duly and validly executed and delivered by the Company and (assuming the due authorization, execution and delivery by each of the Investors) constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and to general principles of equity).

 

(b)                                  Conflicts; Consents and Approvals .  Neither the execution and delivery of this Agreement by the Company nor the consummation of the transactions contemplated by this Agreement will:

 

(i)                                      conflict with, or result in a breach of, any provision of the Notice of Articles and Articles of the Company;

 

6



 

(ii)                                   violate, or conflict with, or result in a breach of any provision of, or constitute a default (or an event which, with the giving of notice, the passage of time or otherwise, would constitute a default) under, or entitle any party (with the giving of notice, the passage of time or otherwise) to terminate, accelerate, adversely modify or call a default under, or result in the creation of any Liens upon any of the properties or assets of the Company or any of its Subsidiaries under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, contract, undertaking, agreement, lease or other instrument or obligation to which the Company or any of its Subsidiaries is a party;

 

(iii)                                violate any Laws applicable to the Company or any of its Subsidiaries or any of their respective properties or assets; or

 

(iv)                               require any action or consent or approval of, or review by, other than registrations or other actions required under federal and state securities Laws and the Canadian Securities Laws as are contemplated by this Agreement or any post-closing notice filings required under applicable United States federal or state securities laws.

 

(c)                                   Capitalization .  As of the date of this Agreement, the authorized capital of the Company consists of 500,000,000 common shares and 5,000,000 preferred shares, without par value, of which 52,829,398 common shares are issued and outstanding as of June 7, 2016, all of which have been duly authorized and validly issued and are fully paid and non-assessable.  As of the date of this Agreement, (i) 3,432,194 common shares are reserved for issuance pursuant to the Company’s stock option plan (including nil common shares reserved for issuance upon settlement of outstanding Company restricted stock units and 425,152 common shares reserved for issuance upon exercise of outstanding Company stock options) and (ii) 69,734,288 common shares are reserved for issuance pursuant to the Warrant Agreement.  Except as set forth in the Company SEC Documents (as defined below), there are no stockholders agreements, voting agreements (except for those Voting Agreements to be entered between the Investors and Aegerion) or other similar agreements with respect to the Company’s capital stock to which the Company is a party.

 

(d)                                  Merger Agreement .  The Company has provided the Investors with true, correct and complete copies of the Merger Agreement and any annexes, exhibits, schedules (excluding disclosure schedules) thereto.

 

(e)                                   Investor Registration Statement .  None of the information supplied or to be supplied by the Company for inclusion or incorporation by reference in the Investor Registration Statement to be filed with the Commission by the Company under the Securities Act at the time the Investor Registration Statement becomes effective will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (it being understood that no representation or warranty is made by the Company with respect to statements made or incorporated by reference therein based on written information supplied by the Investors expressly for inclusion or incorporation by reference in the Investor Registration Statement). The Investor Registration Statement, except for such portions thereof that relate only to Investors, will comply as to form in all material respects with the provisions of the Securities Act.

 

7



 

(f)                                    Valid Issuance .  The Shares and the Warrants to be issued pursuant to this Agreement will be duly authorized and validly issued and, at the Investment Closing, all such Shares will be fully paid, non-assessable and free of preemptive rights, with no personal liability attaching to the ownership thereof, and will be free and clear of all Liens (other than restrictions on transfer imposed by U.S. federal and state securities laws and Canadian Securities Laws), and all such Warrants will constitute valid and legally binding obligations of the Company in accordance with their terms and will be free of preemptive rights or similar rights, with no personal liability attaching to the ownership thereof, and will be free and clear of all Liens (other than restrictions on transfer imposed by U.S. federal and state securities laws and Canadian Securities Laws).  The Warrant Shares to be issued upon exercise of the Warrants will be duly authorized and validly issued and, at the time of such issuance, all such Shares will be fully paid, non-assessable and free of preemptive rights, with no personal liability attaching to the ownership thereof, and will be free and clear of all liens (other than restrictions on transfer imposed by U.S. federal and state securities laws and Canadian Securities Laws).

 

(g)                                   SEC Filings .  The Company has timely filed or received the appropriate extension of time within which to file with the Commission all forms, reports, schedules, statements and other documents required to be filed by it since January 1, 2016 under the Exchange Act or the Securities Act (such documents, as supplemented and amended since the time of filing, collectively, the “ Company SEC Documents ”).  The Company SEC Documents, including any financial statements or schedules included therein, at the time filed (and, in the case of registration statements and proxy statements, on the dates of effectiveness and the dates of mailing, respectively) (i) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (ii) complied in all material respects with the applicable requirements of the Exchange Act and the Securities Act, as the case may be.  The financial statements of the Company included in the Company SEC Documents at the time filed complied as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto, were prepared in accordance with GAAP during the periods involved (except as may be indicated in the notes thereto, auditor’s report thereon or, in the case of unaudited statements, as permitted by Form 10-Q of the Commission), and fairly present in all material respects (subject in the case of unaudited statements to normal audit adjustments and subject to restatements filed with the Commission prior to the date of this Agreement) the consolidated financial position of the Company and its consolidated Subsidiaries as at the dates thereof and the consolidated results of their operations and cash flows for the periods then ended.  No Subsidiary of the Company is subject to the periodic reporting requirements of the Exchange Act other than as part of the Company’s consolidated group or required to file any form, report or other document with the Commission, NASDAQ, the TSX, any other stock exchange or comparable Governmental Authority.

 

(h)                                  Private Placement .  Assuming that the representations of each Investor set forth in Section 4.1(c)  are true and correct, the initial allotment and issuance of the Units in conformity with the terms of this Agreement are exempt from both (i) the registration requirements of Section 5 of the Securities Act and (ii) the prospectus requirements of the Canadian Securities Laws.  Neither the Company nor, to the Company’s knowledge, any person acting on behalf of the Company has offered or sold any of the Units by any form of “general

 

8



 

solicitation” or “general advertising”, as such terms are used in Rule 502(c) of Regulation D under the Securities Act.

 

ARTICLE IV

 

REPRESENTATIONS AND WARRANTIES OF THE INVESTORS

 

4.1                                Representations and Warranties of the Investors .  In order to induce the Company to enter into this Agreement, each Investor severally for itself and not jointly with any one or more of the other Investors represents and warrants to the Company as follows:

 

(a)                                  Corporate Existence; Authority; No Violation .

 

(i)                                      Investor is a legal entity validly existing under the Laws of the jurisdiction of its organization.  Investor has the corporate power and authority to own or lease all of its properties and assets and to carry on its business as it is now being conducted.

 

(ii)                                   Investor has the corporate power and authority to enter into, execute and deliver this Agreement, to perform its obligations under this Agreement and to consummate the transactions contemplated hereby.  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized and validly approved by all necessary corporate action on the part of Investor.  No other corporate proceedings on the part of Investor are necessary to approve this Agreement and to consummate the subscription for such Investor’s Investor Units.  This Agreement has been duly and validly executed and delivered by Investor and (assuming the due authorization, execution and delivery by the Company and the other Investors) constitutes the valid and binding obligation of Investor, enforceable against Investor in accordance with its terms (subject to applicable bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and similar Laws affecting creditors’ rights generally and to general principles of equity).

 

(b)                                  Conflicts; Consents and Approvals .  Neither the execution and delivery of this Agreement by Investor nor the consummation of the subscription for such Investor’s Investor Units, will:

 

(i)                                      conflict with, or result in a breach of, any provision of the organizational documents of Investor;

 

(ii)                                   violate any Laws applicable to Investor or any of its Subsidiaries or any of their respective properties or assets; or

 

(iii)                                require any action or consent or approval of, or review by, or registration or filing by Investor or any of its Affiliates with, any third party or any Governmental Authority, other than registrations, beneficial ownership filings or other actions required under federal and state securities Laws as are contemplated by this Agreement.

 

9



 

(c)                                   Certain Securities Law Matters .

 

(i)                                      Investor is acquiring its Units as principal for its own account, or for one or more investor accounts for which it is acting as a fiduciary or agent, and, in each case, not with a view to the distribution thereof within the meaning of the Securities Act and Canadian Securities Law.

 

(ii)                                   Investor is resident in the jurisdiction stated in Schedule I applicable thereto.

 

(iii)                                Investor understands that the Units issued to it will not be transferable except (a) pursuant to an effective registration statement under the Securities Act and compliance with Canadian Securities Laws as applicable (b) pursuant to an available exemption from, or in a transaction not subject to, the Securities Act or applicable Canadian Securities Laws as evidenced by receipt by the Company of a written opinion of counsel for Investor reasonably satisfactory to the Company to the effect that the proposed transfer is exempt from the registration requirements of the Securities Act and relevant state securities laws and exempt from the prospectus requirements of applicable Canadian Securities Laws, as applicable, or (c) pursuant to Rule 144 under the Securities Act (“ Rule 144 ”) and after expiry of all “hold periods” or “seasoning periods” in Canada.  A restrictive legend shall be placed on certificates representing the Units to be delivered to Investor at the Investment Closing, substantially as follows:

 

“NO TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY BE MADE EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THE RULES AND REGULATIONS IN EFFECT THEREUNDER AND ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS, (B) PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE SECURITIES ACT AS EVIDENCED BY THE CORPORATION BEING FURNISHED WITH AN OPINION OF COUNSEL FOR THE HOLDER, WHICH OPINION AND COUNSEL SHALL BE REASONABLY SATISFACTORY TO THE CORPORATION, TO THE EFFECT THAT SUCH TRANSFER, SALE, ASSIGNMENT, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION IS EXEMPT FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT, OR (C) PURSUANT TO RULE 144 UNDER THE SECURITIES ACT.”

 

(d)                                  Investor Status .

 

(i)                                      At the time Investor was offered the Units, it was, and at the date hereof it is, either (a) a “qualified institutional buyer”, as defined in Rule 144A under the Securities Act, or (b) an “accredited investor”, as defined in Rule 501(a) of Regulation D.

 

(ii)                                   Investor is an “accredited investor” as defined in National Instrument 45-106 - Prospectus Exemptions promulgated under applicable Canadian Securities Laws.

 

10



 

(e)                                   Sufficiency of Funds .  The Investor has sufficient cash on hand or other sources of immediately available funds to enable it to make payment of the Subscription Price and consummate the transactions contemplated by this Agreement.

 

(f)                                    No Bad Actor .  No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act is applicable to the Investor.

 

(g)                                   No General Solicitation .  Neither the Investor, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer, sale or contemplated distribution of the Units.

 

(h)                                  Investors Acknowledgement .  Each Investor represents that it has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks of its investment in the Company pursuant to this Agreement and is able to bear the economic risk of loss of its investment in the Company pursuant to this Agreement.  Each Investor acknowledges that it is not relying upon any Person, other than the Company and their officers and directors, in making its investment or decision to invest in the Company pursuant to this Agreement.

 

ARTICLE V

 

COVENANTS AND AGREEMENTS

 

5.1                                Furnishing Information .  The parties hereto hereby agree that all information received by them or their respective officers, directors, employees or representatives in connection with this Agreement and the consummation of the transactions contemplated hereby shall be governed in accordance with the respective confidentiality agreement entered into by such receiving party and any of the other parties hereto (collectively, the “ Confidentiality Agreements ”), each of which shall continue in full force and effect in accordance with its terms.

 

5.2                                Filings; Commercially Reasonable Efforts; Notification .

 

(a)                                  Upon the terms and subject to the conditions of this Agreement, each of the parties shall use its respective commercially reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective, as soon as practicable, the transactions contemplated by this Agreement, including (i) obtaining and maintaining all necessary actions or nonactions, waivers, consents, licenses, permits, authorizations, orders and approvals (collectively, “ Consents ”) from applicable Governmental Authorities and the making of all other necessary registrations and filings, (ii) obtaining all Consents from third parties that are reasonably necessary in connection with the transactions contemplated by this Agreement, (iii) obtaining all required Consents from third parties, including required Consents from the Company’s shareholders, and (iii) the execution and delivery of any additional instruments reasonably necessary to consummate any of the transactions contemplated by, and to fully carry out the purposes of, this Agreement.

 

11



 

(b)                                  The Company shall (i) use commercially reasonable efforts to make or cause to be made such filings with applicable Governmental Authorities as are required in connection with the transactions contemplated by this Agreement as soon as reasonably practicable after the date of this Agreement and (ii) cooperate in good faith with the other parties in obtaining any Consents from Governmental Authorities and in connection with resolving any investigation or other inquiry of any Governmental Authority with respect to such filings.

 

(c)                                   The Company shall use commercially reasonable efforts to ensure that none of the information supplied or to be supplied for inclusion or incorporation by reference in the Investor Registration Statement to be filed with the Commission by the Company under the Securities Act at the time the Investor Registration Statement becomes effective will contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading (it being understood that no representation or warranty is made by the Company or the Investors with respect to statements made or incorporated by reference therein based on written information supplied by the other parties hereto expressly for inclusion or incorporation by reference in the Investor Registration Statement).

 

5.3                                NASDAQ and TSX Listing .  The Company shall use commercially reasonable efforts to cause the Shares and the Warrant Shares to be approved for listing on NASDAQ and conditionally approved for listing on the TSX prior to the Investment Closing, as mutually agreed by the parties, subject to official notice of issuance in respect of NASDAQ and subject to compliance with all of the customary requirements of the TSX, including receipt of all documentation required by the TSX.

 

5.4                                Reporting Issuer Status .  The Company shall have the status of a reporting issuer not in default immediately preceding the Investment Closing.

 

5.5                                Further Assurances .  Subject to, and not in limitation of, Section 5.2 , the Company shall use its commercially reasonable efforts to (i) take, or cause to be taken, all actions necessary or appropriate to consummate the transactions contemplated by this Agreement and (ii) cause the fulfillment at the earliest practicable date of all of the conditions to their respective obligations to consummate the transactions contemplated by this Agreement.

 

5.6                                Advice of Changes .  The Company shall promptly advise the Investors of any fact, change, event or circumstance that the Company believes would cause any condition to the Investment Closing not to be satisfied; provided that any failure to give notice in accordance with the foregoing shall not be deemed to constitute a violation of this Section 5.6 or the failure of the condition set forth in Section 6.2(b)  hereof to be satisfied.

 

5.7                                Investors’ Registration Rights .  The Investors shall have the registration rights set forth on Annex A hereto.

 

5.8                                Investor Agreement .  Each of the Investors agrees that, it will not acquire securities of the Company which result in, or following conversion would result in, such Investor holding thirty-five (35%) percent or greater of the total issued and outstanding voting securities of the Company after giving effect to the Merger and the issuance of the Shares to the Investors

 

12



 

contemplated hereby; provided that the voting securities held by such Investor shall include for purposes of this Section 5.8 any shares beneficially owned (as determined pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)) by all other persons who together with such Investor constitute a “group” within the meaning of Section 13(d)(3) of the Exchange Act.

 

5.9                                Additional Company Agreements .

 

(a)                                  The Company acknowledges and agrees that an Investor may from time to time make a bona fide pledge pursuant to an effective margin agreement with a registered broker-dealer or grant a security interest in some or all of the Investor Shares to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under the terms of such arrangement, such Investor may transfer pledged or secured securities to the pledgees or secured parties.  Such a pledge or transfer would not be subject to the approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith.  Further, no notice shall be required of such pledge.  At the applicable Investor’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of securities may reasonably request in connection with a pledge or transfer of the securities, including, if the securities are subject to registration pursuant to this Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of selling stockholders thereunder.

 

(b)                                  Legends (including the legend set forth in Section 4.1(c)  hereof) shall be removable from certificates evidencing the Units, Shares, Warrants and the Warrant Shares in the following circumstances: (i) while a registration statement (including the Investor Registration Statement) covering the resale of such security is effective under the Securities Act (provided that, if the Investor is selling pursuant to the effective registration statement registering the securities for resale, the Investor agrees to only sell such securities during such time that such registration statement is effective and not withdrawn or suspended, and only as permitted by such registration statement), (ii) following any sale of such securities pursuant to Rule 144, (iii) if such securities are eligible for sale under Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission).  Promptly following a request by the Investor, which must be directed to the Company’s chief financial officer and general counsel, the Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly if required by the Transfer Agent to effect the removal of the legend hereunder, provided that, upon reasonable request and upon delivery of a form of certificate, customary in form and substance, by the Company to the Investors, the Investors shall deliver a back-up certificate to the Company in connection with the removal of such legend. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Warrant Shares, or if such Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144, or if the Warrant Shares may be sold under Rule 144 without the requirement for the Company to be in compliance with the

 

13



 

current public information required under Rule 144 as to such Warrant Shares and without volume or manner-of-sale restrictions or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends.  The Company agrees that following the effective date of the initial registration statement covering the resale of any of such securities or at such time as such legend is no longer required under Section 4.1(c)  of this Section 5.9 and subject to the conditions set forth above, it will, no later than three trading days following the delivery by an Investor to the Company or the Transfer Agent of a certificate representing the Shares or Warrant Shares, as applicable, issued with a restrictive legend (such third trading day, the “ Legend Removal Date ”), deliver or cause to be delivered to such Investor a certificate representing such shares that is free from all restrictive and other legends.  The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in Section 4.1 and this Section 5.9 .  Certificates for Shares and Warrant Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to an Investor by crediting the account of the Investor’s prime broker with the Depository Trust Company System as directed by such Investor, provided that, upon notice by the Company to an Investor of transmission of Shares or Warrant Shares through the Depository Trust Company System, such Investor shall instruct its prime broker to receive such Shares or Warrant Shares through the Depository Trust Company System.

 

(c)                                   In addition to such Investor’s other available remedies, the Company shall pay to an Investor, in cash, the greater of (i) as partial liquidated damages and not as a penalty, for each $1,000 of Units, Shares, Warrants or Warrant Shares, as the case may be, (based on the VWAP of the Shares on the date such securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c) , $10 per trading day for each trading day after the fifth trading day after the Legend Removal Date until such certificate is delivered without a legend.  Nothing herein shall limit such Investor’s right to pursue actual damages for the Company’s failure to deliver certificates representing any such securities as required by this Agreement, and such Investor shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.

 

(d)                                  Each Investor, severally and not jointly with the other Investors, agrees with the Company that such Investor will sell any Units, Shares, Warrants or Warrant Shares pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Shares are sold pursuant to an Investor Registration Statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Shares as set forth in this Section 5.9 is predicated upon the Company’s reliance upon this understanding.

 

14



 

ARTICLE VI

 

CONDITIONS TO INVESTMENT CLOSING

 

6.1                                Mutual Conditions .  The respective obligations of each Investor and the Company to consummate the subscription and issuance of the Units shall be subject to the satisfaction on or prior to the Investment Closing Date of each of the following conditions (any or all of which may be waived by a party on behalf of itself in writing, in whole or in part, to the extent permitted by applicable Law):

 

(a)                                  No Law shall have been enacted or promulgated, and no action shall have been taken, by any Governmental Authority of competent jurisdiction that remains in effect and temporarily, preliminarily or permanently restrains, precludes, enjoins or otherwise prohibits the consummation of the transactions contemplated hereby or makes the transactions contemplated hereby illegal;

 

(b)                                  No outstanding judgment, injunction, order or decree of a competent Governmental Authority shall have been entered and shall continue to be in effect, and no Law shall have been adopted or be effective, in each case that prohibits, enjoins or makes illegal the consummation of the transactions contemplated by this Agreement;

 

(c)                                   No material amendment, modification or waiver of a material right under the Merger Agreement in the form as executed by the Parties thereto as of the date of this Agreement has occurred;

 

(d)                                  Any required approvals of the Company’s shareholders relating to the issuance of the Units pursuant to this Agreement shall have been obtained at a meeting of the Company’s shareholders in accordance with applicable Laws; and

 

(e)                                   The conditions set forth in ARTICLE VIII of the Merger Agreement shall have been satisfied or waived, and the Parties to the Merger Agreement shall have irrevocably committed, subject to no further conditions, to effect the Closing under the Merger Agreement  immediately after the Investment Closing.

 

6.2                                Investor’s Conditions .  The obligations of each Investor to consummate the subscription of such Investor’s Investor Units shall be subject to the satisfaction on or prior to the Investment Closing Date of each of the following additional conditions (any or all of which may be waived by such Investor on behalf of itself in writing, in whole or in part, to the extent permitted by applicable Law):

 

(a)                                  The representations and warranties of the Company set forth in Sections 3.1 , respectively, qualified as to materiality shall be true and correct, and those not so qualified shall be true and correct in all material respects, in each case, as of the date of this Agreement and as of the Investment Closing as though made at and as of the Investment Closing, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties qualified as to materially shall be true and correct, and those not so qualified shall be true and correct in all material respects, on and as of such earlier date);

 

(b)                                  the Company shall have performed and complied in all material respects with its respective obligations and agreements required in this Agreement to be performed or complied with by it on or prior to the Investment Closing Date;

 

15



 

(c)                                   the Shares shall have been approved for listing on NASDAQ and the TSX, subject to official notice of issuances in respect of NASDAQ and subject to compliance with all of the customary conditions of the TSX, including receipt of all documentation required by the TSX;

 

(d)                                  the Company shall have delivered, or caused to be delivered, to such Investor at the Investment Closing, the Company’s closing deliverables described in Section 2.4 ; and

 

(e)                                   there shall not be pending any suit, action or proceeding by any Person seeking to restrain, preclude, enjoin or prohibit the transactions contemplated by this Agreement, which suit, action or proceeding is reasonably likely to have a material adverse effect on such Investor.

 

6.3                                Company Conditions .  The obligation of the Company to consummate the allotment and issuance of the Units to each Investor shall be subject to the satisfaction on or prior to the Investment Closing Date of each of the following conditions with respect to such Investor (any or all of which may be waived by the Company in writing, in whole or in part, to the extent permitted by applicable Law):

 

(a)                                  the representations and warranties of such Investor set forth in this Agreement qualified as to materiality shall be true and correct, and those not so qualified shall be true and correct in all material respects, in each case, as of the date of this Agreement and as of the Investment Closing as though made at and as of the Investment Closing, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties qualified as to materiality shall be true and correct, and those not so qualified shall be true and correct in all material respects, on and as of such earlier date);

 

(b)                                  such Investor shall have performed and complied in all material respects with all obligations and agreements required by this Agreement to be performed or complied with by such Investor on or prior to the Investment Closing Date;

 

(c)                                   there shall not be pending any suit, action or proceeding by any Person seeking to restrain, preclude, enjoin or prohibit the transactions contemplated by this Agreement, which suit, action or proceeding is reasonably likely to have a material adverse effect on the Company; and

 

(d)                                  such Investor shall have delivered, or caused to be delivered, to the Company at the Investment Closing such Investor’s closing deliverables described in Section 2.5 .

 

16



 

ARTICLE VII

 

TERMINATION

 

7.1                                Termination .

 

(a)                                  This Agreement shall automatically terminate, without the need for any further action by the Company or any Investor, upon the valid termination of the Merger Agreement.

 

(b)                                  Notwithstanding anything in this Agreement to the contrary, this Agreement may be terminated and abandoned at any time prior to the Investment Closing with respect to the applicable parties as follows:

 

(i)                                      by mutual written consent of the Company, on the one hand, and one or more Investors, on the other hand, which termination shall be effective as between or among the Company and such Investor(s);

 

(ii)                                   by the Company or any of the Investors (but only with respect to such terminating Investor’s rights and obligations hereunder) if there shall be any Law that makes consummation of the transactions contemplated by this Agreement illegal or otherwise prohibited, or if any judgment, injunction, order or decree of a competent Governmental Authority enjoining the Company or such Investor from consummating the transactions contemplated by this Agreement shall have been entered and such judgment, injunction, order or decree shall have become final and nonappealable; provided that the party seeking to terminate this Agreement pursuant to this Section  7.1(b)(ii)  shall have used its commercially reasonable efforts to render inapplicable such Law or regulation or remove such judgment, injunction, order or decree as required by Section 5.2 ; or

 

(iii)                                by any of the Investors (but only with respect to such terminating Investor’s rights and obligations hereunder) if the Investment Closing shall not have occurred on or before the eight month anniversary of the date of this Agreement.

 

7.2                                Procedure Upon Termination .  In the event of termination and abandonment by the Company or any Investor pursuant to Section 7.1 , written notice thereof specifying the provision of this Agreement pursuant to which such termination is effected, shall forthwith be given to the other parties hereto, and, solely with respect to a termination by the Company or all of the Investors, this Agreement shall terminate, and the subscription for the Units hereunder shall be abandoned and any consideration received by the Company from such Investor for such Investor’s Investor Units subscribed for hereunder shall be immediately returned to such Investor.  For the avoidance of doubt, a termination by any Investor shall only terminate the rights and obligations of such Investor hereunder and shall not affect the rights and obligations of the other parties hereto.  The parties acknowledge that the failure by any one Investor to consummate the subscription for such Investor’s Investor Units shall not affect or modify the obligations of the Company or the other Investors to consummate the transactions contemplated hereby.

 

7.3                                Effects of Termination .  In the event of any termination of this Agreement as provided in Section 7.1 by the Company or all of the Investors, this Agreement, except for the provisions of Section 5.1 , this Section 7.3 and ARTICLE VIII, shall terminate and become void and have no effect, without any liability on the part of any party or its directors, officers or stockholders with respect thereto.  Notwithstanding the foregoing, nothing in this Section 7.3 shall relieve any party to this Agreement of liability for fraud or any material breach of any

 

17



 

covenant or agreement set forth in this Agreement.  No termination of this Agreement shall affect the obligations of the parties contained in any of the Confidentiality Agreements, all of which obligations shall survive termination of this Agreement in accordance with its terms.

 

ARTICLE VIII
MISCELLANEOUS

 

8.1                                Survival .  Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company or the Investors herein shall survive for one year following the Investment Closing, other than any covenants or agreements that by their terms survive for a longer period of time.

 

8.2                                Expenses .  Except as otherwise provided in this Agreement, whether or not the transactions contemplated by this Agreement are consummated, all costs and expenses incurred in connection with the negotiation and execution of this Agreement and the transactions contemplated hereby shall be paid by the party incurring or required to incur such expenses, including the Investor Registration Expenses (which shall be from the account of the Company).

 

8.3                                Counterparts; Effectiveness .  This Agreement may be executed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by telecopy, electronic delivery or otherwise) to the other parties.  Signatures to this Agreement transmitted by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.

 

8.4                                Governing Law .  This Agreement, and all claims or causes of action (whether at Law, in contract or in tort or otherwise) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.

 

8.5                                Jurisdiction; Specific Enforcement .  Each of the parties hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other party hereto or its successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware).  Each of the parties hereto hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by

 

18



 

this Agreement in any court other than the aforesaid courts.  Each of the parties hereto hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above named courts, (b) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted by applicable Law, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.  To the fullest extent permitted by applicable Law, each of the parties hereto hereby consents to the service of process in accordance with Section 8.7 ; provided , however , that nothing herein shall affect the right of any party to serve legal process in any other manner permitted by Law.

 

8.6                                WAIVER OF JURY TRIAL .  EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

 

8.7                                Notices .  All notices and other communications hereunder shall be in writing and shall be deemed given (a) upon personal delivery to the party to be notified; (b) when received when sent by email or facsimile by the party to be notified, provided , however , that notice given by email or facsimile shall not be effective unless either (i) a duplicate copy of such email or fax notice is promptly given by one of the other methods described in this Section 8.7 or (ii) the receiving party delivers a written confirmation of receipt for such notice either by email or fax or any other method described in this Section 8.7 ; or (c) when delivered by a courier (with confirmation of delivery); in each case to the party to be notified at the following address:

 

If to the Company, to:

 

QLT Inc.

887 Great Northern Way, Suite 250
Vancouver, BC V5T 4T5
Canada

Facsimile:  (604) 707-7001

Attention:  Geoffrey Cox, Interim Chief Executive Officer

Dori Assaly, Senior Vice President, Legal

Email:  gfcox@qltinc.com

dassaly@qltinc.com

 

with copies (which shall not constitute notice) to:

 

Weil, Gotshal & Manges LLP

767 Fifth Avenue

New York, New York 10153

Facsimile:  (212) 310-8007

 

19



 

Attention:  Raymond O. Gietz

Email:  raymond.gietz@weil.com

 

If to an Investor, at its address set forth under its name on Schedule I hereto, or to such other address as any party shall specify by written notice so given, and such notice shall be deemed to have been delivered as of the date so telecommunicated or personally delivered.  Any party to this Agreement may notify any other party of any changes to the address or any of the other details specified in this Section 8.7 ; provided , however , that such notification shall only be effective on the date specified in such notice or five (5) Business Days after the notice is given, whichever is later.  Rejection or other refusal to accept or the inability to deliver because of changed address of which no notice was given shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.

 

8.8                                Assignment; Binding Effect .  Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned or delegated by any of the parties hereto without the prior written consent of the other parties; provided , however , that any Investor may assign any of its rights hereunder to any of its Affiliates without the prior written consent of the Company, but no such assignment shall relieve such Investor of any of its obligations hereunder.  Subject to the first sentence of this Section 8.8 , this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.  Any purported assignment not permitted under this Section 8.8 shall be null and void.

 

8.9                                Severability .  Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement in any other jurisdiction.  If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.

 

8.10                         Independent Legal and Investment Advice .  In addition, each party to this Agreement acknowledges having had the opportunity to obtain independent legal advice and independent investment advice in connection with the execution of this Agreement and the transactions contemplated hereby, prior to the execution of this Agreement, and further, each party to this Agreement represents to the other parties that it has either sought independent legal advice and independent investment advice or has waived its right to seek such advice.

 

8.11                         Entire Agreement .  This Agreement together with the annexes, schedules and exhibits hereto and, with respect to the Company and each Investor, the Confidentiality Agreement between the Company and such Investor, shall constitute the entire agreement, and supersede all other prior agreements and understandings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof and thereof, and this Agreement is not intended to grant standing to any Person other than the parties hereto.

 

8.12                         Amendments; Waivers .  At any time prior to the Effective Time, any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by the Company and each of the Investors; provided , however , that (i) any amendment or waiver of any of the provisions of

 

20



 

Annex A shall require only the signature of the Company and the affected Investor, (ii) the amendment of this Agreement in order to have Units comprised of the Warrants and a Derivative Security in lieu of the Shares shall require only the signature of the Company and the affected Investor and (iii) that the consent of the Investors will not be required in connection with an amendment of this Agreement to add additional Investors and to issue additional Units provided that the Per Share Subscription Price is not less than $1.76.  Notwithstanding the foregoing, no failure or delay by any party hereto in exercising any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise of any other right hereunder. “ Derivative Security ” shall mean a derivative security that is exercisable for, or convertible into, Shares and which shall (i) be on economic terms substantially similar to the Shares, (ii) in the case of a capital stock, be non-voting (other than relating to the amendments to the terms of such security and as otherwise required by law), (iii) be exercisable for, or convertible into, Shares without the payment of any additional consideration (other than the requirement to pay a de minimis amount of consideration if required by law) and (iv) contain provisions, in substantially similar form to those contained in the Warrants, limiting the exercise or conversion thereof in a manner designed to prevent such Investor from beneficially owning the underlying shares for purposes of Section 16 of the Exchange Act.

 

8.13                         Headings .  Headings of the Articles and Sections of this Agreement are for convenience of the parties only and shall be given no substantive or interpretive effect whatsoever.  The table of contents to this Agreement is for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

 

8.14                         No Third-Party Beneficiaries .  Each of the Investors and the Company agrees that (a) their respective representations, warranties, covenants and agreements set forth herein are solely for the benefit of the other party hereto, in accordance with and subject to the terms of this Agreement, and (b) this Agreement is not intended to, and does not, confer upon any Person other than the parties hereto any rights or remedies hereunder, including the right to rely upon the representations and warranties set forth herein.

 

8.15                         Obligations of the Investors and the Company .  The obligations of the Investors are several and not joint and the breach by any Investor of its obligations hereunder shall not result in any liability being incurred by any one or more of the other Investors as a result of such breach.  The Company acknowledges and agrees that should one or more Investors not be ready, willing and able to subscribe for its respective Units hereunder, any of the other Investors may subscribe for such Units in lieu of the non-performing Investor.

 

** REMAINDER OF PAGE INTENTIONALLY LEFT BLANK**

 

21



 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first written above.

 

 

 

QLT INC.

 

 

 

 

 

By:

/s/ Glen Ibbott

 

 

Name: Glen Ibbott

 

 

Title: Chief Financial Officer

 

[Signature Page to Unit Subscription Agreement]

 



 

 

BROADFIN HEALTHCARE MASTER FUND

 

LTD

 

 

 

 

 

By:

/s/ Kevin Kotler

 

 

Name: Kevin Kotler

 

 

Title: Managing Partner of Broadfin Capital

 

 

LLC, Investment Manager of Broadfin

 

 

Healthcare Master Fund Ltd.

 

[Signature Page to Unit Subscription Agreement]

 



 

 

SARISSA CAPITAL DOMESTIC FUND LP

 

 

 

 

 

By:

/s/ Mark DiPaolo

 

 

Name: Mark DiPaolo

 

 

Title: Authorized Signatory

 

 

 

 

 

SARISSA CAPITAL OFFSHORE MASTER

 

FUND LP

 

 

 

 

 

By:

/s/ Mark DiPaolo

 

 

Name: Mark DiPaolo

 

 

Title: Authorized Signatory

 

[Signature Page to Unit Subscription Agreement]

 



 

 

ARMISTICE CAPITAL MASTER FUND, LTD.

 

 

 

 

 

By:

/s/ Steven Boyd

6/13/16

 

 

Name: Steven Boyd

 

 

Title: Managing Member, Armistice Capital

 

 

LLC, investment manager to Armistice

 

 

Capital Master Fund, Ltd.

 

[Signature Page to Unit Subscription Agreement]

 



 

 

HEALTHCARE VALUE PARTNERS, LP

 

 

 

By:

General Partner of Healthcare Value

 

 

Partners, LP

 

 

 

 

 

 

 

By:

/s/ Joseph Riccardo

 

 

Name: Joseph Riccardo

 

 

Title: Managing Member

 

 

Healthcare Value Capital General Partner,

 

 

LLC

 

[Signature Page to Unit Subscription Agreement]

 



 

 

TIGER LEGATUS CAPITAL MANAGEMENT,

 

 

LLC

 

 

 

 

 

 

 

By:

/s/ Jesse Ro

 

 

Name: Jesse Ro

 

 

Title: Managing Member

 

[Signature Page to Unit Subscription Agreement]

 



 

 

Levcap Alternative Fund, LP

 

 

 

 

 

Ulysses Partners, L.P.

 

 

 

 

 

Ulysses Offshore Fund, Ltd.

 

 

 

 

 

By:

/s/ Sam Hendel

 

 

Name: Sam Hendel

 

 

Title:   Portfolio Manager

 



 

 

THE K2 PRINCIPAL FUND L.P.

 

 

 

By:

K2 Genpar Ltd. by its General Partner K2

 

 

Genpar 2009 Inc.

 

 

 

 

 

 

 

By:

/s/ Shawn Kimel

 

 

Name: Shawn Kimel

 

 

Title: President

 

[Signature Page to Unit Subscription Agreement]

 



 

 

JW PARTNERS, LP

 

 

 

By:

JW GP, LLC, its General Partner

 

 

 

 

 

 

 

By:

/s/ Jason Wild

 

 

Name: Jason Wild

 

 

Title: Managing Member

 

 

 

 

 

J.W. OPPORTUNITIES MASTER FUND, LTD.

 

 

 

By:

JW GP, LLC, its Manager

 

 

 

 

 

 

 

By:

/s/ Jason Wild

 

 

Name: Jason Wild

 

 

Title: Managing Member

 

[Signature Page to Unit Subscription Agreement]

 



 

 

DEERFIELD PARTNERS, L.P.

 

 

 

By:

Deerfield Mgmt, L.P., its General Partner

 

 

 

 

By:

J.E. Flynn Capital, LLC, its General Partner

 

 

 

 

 

 

 

By:

/s/ David J. Clark

 

 

Name: David Clark

 

 

Title:   Authorized Signatory

 



 

 

DEERFIELD INTERNATIONAL MASTER

 

FUND, L.P.

 

 

 

By:

Deerfield Mgmt, L.P., its General Partner

 

 

 

 

By:

J.E. Flynn Capital, LLC, its General Partner

 

 

 

 

 

 

 

By:

/s/ David J. Clark

 

 

Name: David Clark

 

 

Title:   Authorized Signatory

 



 

 

[INVESTOR]

 

 

 

 

 

By:

/s/ Jason Aryeh

 

 

Name: Jason Aryeh

 

 

Title:   (individual)

 



 

SCHEDULE I

 

SCHEDULE OF INVESTORS

 

Investor — Name (Jurisdiction) and Address

 

Subscription Price

 

 

 

 

 

Deerfield Partners, L.P. (Delaware)

 

$

660,000.00

 

 

 

 

 

Deerfield International Master Fund, L.P. (British Virgin Islands)

 

$

840,000.00

 

 

 

 

 

780 Third Avenue, 37th Floor

 

 

 

New York, New York 10017

 

 

 

 

 

 

 

Attn: David J. Clark

 

 

 

Fax: (212) 599-3075

 

 

 

Email: dclark@deerfield.com

 

 

 

 

 

 

 

JW Partners LP (Delaware)

 

$

37,500.00

 

 

 

 

 

JW Opportunities Master Fund, Ltd. (Cayman Islands)

 

$

12,500.00

 

 

 

 

 

515 Madison Ave., 14B

 

 

 

New York, New York 10022

 

 

 

 

 

 

 

Attn: Jason Wild

 

 

 

Fax: (212) 207-4674

 

 

 

Email: jwild@jwfunds.com

 

 

 

 

 

 

 

Broadfin Healthcare Master Fund, LTD (Cayman Islands)

 

$

5,000,000.00

 

 

 

 

 

P.O. Box 1344

 

 

 

20 Genesis Close

 

 

 

Ansbacher House, 2nd Fl

 

 

 

Grand Cayman, KY1-1108

 

 

 

 

 

 

 

Attn: Kevin Kotler

 

 

 

Fax: (212) 808-2464

 

 

 

 

 

 

 

The K2 Principal Fund L.P. (Ontario)

 

$

1,000,000.00

 

 

 

 

 

2 Bloor Street West, Suite 801

 

 

 

M4W 3E2

 

 

 

Ontario, Canada

 

 

 

 

 

 

 

Attn. Shawn Kimel

 

 

 

Fax # 416-703-4443

 

 

 

 



 

Investor — Name (Jurisdiction) and Address

 

Subscription Price

 

 

 

 

 

Healthcare Value Partners, LP (Delaware)

 

$

3,520,000.00

 

 

 

 

 

50 Tice Blvd., Suite 140

 

 

 

Woodcliff Lake, NJ 07677

 

 

 

 

 

 

 

Attn: Thomas DesChamps,

 

 

 

Fax: 201-391-5376

 

 

 

 

 

 

 

Tiger Legatus Capital Management, LLC (Delaware)

 

$

250,000.00

 

 

 

 

 

330 Madison Avenue, 24th Floor

 

 

 

New York, NY 10017

 

 

 

 

 

 

 

Attn: Mike Spero

 

 

 

Fax: 212-716-2361

 

 

 

Email: mspero@tigerlegatus.com

 

 

 

 

 

 

 

Jason Aryeh

 

$

2,000,000.00

 

 

 

 

 

5811 Murphy Way

 

 

 

Malibu, California 90265

 

 

 

 

 

 

 

Fax: (203) 918-4174

 

 

 

 

 

 

 

Sarissa Capital Domestic Fund LP (Delaware)

 

$

2,398,891.25

 

 

 

 

 

Sarissa Capital Offshore Master Fund LP (Cayman Islands)

 

$

2,601,108.75

 

 

 

 

 

C/o Sarissa Capital Management LP

 

 

 

660 Steamboat Road, 3rd Floor

 

 

 

Greenwich, CT 06830

 

 

 

 

 

 

 

Attn: Mark Dipaolo

 

 

 

 

 

 

 

Armistice Capital Master Fund, Ltd. (Cayman Islands)

 

$

2,999,999.20

 

 

 

 

 

dms Corporate Services

 

 

 

DMS House, 2nd Floor

 

 

 

Genesis Close

 

 

 

Grand Cayman, KY1-1208

 

 

 

 

 

 

 

Attn: Steven Boyd

 

 

 

Fax: (212) 231-4939

 

 

 

Email: sboyd@armisticecapital.com

 

 

 

 



 

Investor — Name (Jurisdiction) and Address

 

Subscription Price

 

 

 

 

 

Levcap Alternative Fund, L.P. (Delaware)

 

$

140,418.08

 

 

 

 

 

c/o Levin Capital Strategies, LP

 

 

 

595 Madison Avenue, 16th Floor

 

 

 

New York, New York 10022

 

 

 

 

 

 

 

Attn: Sam Hendel

 

 

 

 

 

 

 

Ulysses Partners, L.P. (Delaware)

 

$

241,079.52

 

 

 

 

 

One Rockefeller Plaza, 20th Floor

 

 

 

New York, New York 10020

 

 

 

 

 

 

 

Attn: Eric Squire

 

 

 

 

 

 

 

Ulysses Offshore Fund, Ltd. (Cayman Islands)

 

$

58,502.40

 

 

 

 

 

c/o Ulysses Management Offshore LLC

 

 

 

One Rockefeller Plaza, 20th Floor

 

 

 

New York, New York 10020

 

 

 

 

 

 

 

Attn: Eric Squire

 

 

 

Total:

 

$

21,759,999.20

 

 


 


 

ANNEX A

 

INVESTORS’ REGISTRATION RIGHTS

 

1.1                                Certain Definitions .

 

(a)                                  Investor Prospectus ” shall mean the prospectus (including any preliminary, final or summary prospectus) included in the Investor Registration Statement, all amendments and supplements to such prospectus and all other material incorporated by reference in such prospectus.

 

(b)                                  Investor Registration Expenses ” shall mean any and all expenses incurred by the Company and its Subsidiaries in effecting the Investor Registration pursuant to this Agreement, including, all (a) Investor Registration and filing fees, and all other fees and expenses payable in connection with the listing of securities on any securities exchange or automated interdealer quotation system, (b) fees and expenses of compliance with any securities or “Blue Sky” Laws (including reasonable fees and disbursements of counsel in connection with “Blue Sky” qualifications of the Investor Shares), (c) expenses in connection with the preparation, printing, mailing and delivery of the Investor Registration Statement, Investor Prospectus and other documents in connection therewith and any amendments or supplements thereto, (d) printing expenses, (e) internal expenses of the Company (including, all salaries and expenses of its officers and employees performing legal or accounting duties), (f) fees and disbursements of counsel for the Company and fees and expenses for independent certified public accountants retained by the Company and (g) fees and expenses of any special experts retained by the Company in connection with such Investor Registration.  Investor Registration Expenses shall not include, and the Company shall not have any obligation to pay, any out-of-pocket expenses of any Investor, including the attorneys’ fees of any such Investor.

 

(c)                                   Investor Registration ” shall mean the registration effected by preparing and filing (a) the Investor Registration Statement in compliance with the Securities Act (and any post-effective amendments filed or required to be filed) and the declaration or ordering of effectiveness of such Investor Registration Statement, or (b) an Investor Prospectus and/or Investor Prospectus supplement in respect of the effective Investor Registration Statement.

 

(d)                                  The terms “ register ,” “ registered ” and “ registration ” shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.

 

(e)                                   Registrable Securities ” shall mean:  (i) the Investor Shares and any Shares issued or issuable to each Investor (A) upon any distribution with respect to, any exchange for or any replacement of such Investor Shares, or (B) upon any conversion, exercise or exchange of any securities issued in connection with any such distribution, exchange or

 

A- 1



 

replacement; (ii) securities issued or issuable upon any stock split, stock dividend, recapitalization or similar event with respect to the foregoing; and (iii) any other security issued as a dividend or other distribution with respect to, in exchange for or in replacement of the securities referred to in the preceding clauses, except that any such Shares or other securities shall cease to be Registrable Securities when (A) they have been sold to the public or (B) they may be sold by such Investor without restriction pursuant to Rule 144.

 

(f)                                    Selling Expenses ” shall mean all selling commissions and transfer taxes applicable to the sale, transfer, issuance or allotment of Registrable Securities and all fees and disbursements of counsel for Investors.

 

1.2                                Registration Requirements .  The Company shall use its commercially reasonable efforts to effect the registration of the resale of the Registrable Securities (including, without limitation, the execution of an undertaking to file post-effective amendments, appropriate qualification under applicable Blue Sky or other state securities laws and appropriate compliance with applicable regulations issued under the Securities Act) as would permit or facilitate the resale of all the Registrable Securities in the manner (including manner of sale) and in all states reasonably requested by the Investors, provided that in no event shall the Company be required to register the resale of the Registrable Securities in an underwritten offering.  Such commercially reasonable efforts by the Company shall include, without limitation, the following:

 

(a)                                  The Company shall use commercially reasonable efforts to, as expeditiously as possible:

 

(i)                                     prepare and promptly following the date on which the Form S-4 (as defined in the Merger Agreement) is declared effective by the SEC (and in no event later than the tenth (10th) Business Day following the date of effectiveness of the Form S-4), file a registration statement with the Commission pursuant to Rule 415 under the Securities Act covering resales by the Investors as selling stockholders (not underwriters) of the Registrable Securities (the “ Investor Registration Statement ”).  The Company shall use its commercially reasonable efforts to cause such Investor Registration Statement and other filings to be declared effective as soon as possible following its filing.

 

(ii)                                 respond to all Commission comments, inquiries and requests, and shall request acceleration of effectiveness of the Investor Registration Statement at the earliest possible date.  The Company shall provide the Investors reasonable opportunity to review the portions of any such Investor Registration Statement or amendment or supplement thereto containing disclosure regarding the Investors prior to filing (such reasonable opportunity being no less than 3 Business Days prior to the initial filing of any Investor Registration Statement and one Business Day prior to the filing of any amendment or supplement thereto).

 

(iii)                             prepare and file with the Commission such amendments and supplements to such

 

A- 2



 

Investor Registration Statement and the Investor Prospectus used in connection with such Investor Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Investor Registration Statement and notify the Investors of the filing and effectiveness of such Investor Registration Statement and any amendments or supplements.

 

(iv)                              furnish or otherwise make available to each Investor copies of a current prospectus included in the Investor Registration Statement conforming with the requirements of the Securities Act, copies of the Investor Registration Statement, any amendment or supplement thereto and any documents incorporated by reference therein and such other documents as such Investor may reasonably require in order to facilitate the disposition of Registrable Securities owned by such Investor.

 

(v)                                  register and qualify the securities covered by the Investor Registration Statement under the securities or “Blue Sky” Laws of all domestic jurisdictions, to the extent required; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions.

 

(vi)                              notify each Investor of the happening of any event (but not the substance or details of any such events) as a result of which the Investor Prospectus (including any supplements thereto or thereof) included in such Investor Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and use its commercially reasonable efforts to promptly update and/or correct such prospectus.

 

(vii)                          notify each Investor of the issuance by the Commission or any state securities commission or agency of any stop order suspending the effectiveness of the Investor Registration Statement or the threat or initiation of any proceedings for that purpose.  The Company shall use its commercially reasonable efforts to prevent the issuance of any stop order and, if any stop order is issued, to obtain the lifting thereof at the earliest possible time.

 

(viii)                      if required by the NASDAQ or the principal securities exchange and/or market on which the Company’s common shares are then listed, qualify the Registrable Securities covered by such Investor Registration Statement for listing on the NASDAQ or the principal securities exchange and/or market on which the Company’s common shares are then listed, including the preparation and filing of any required filings with such principal market or exchange.

 

(ix)                              Promptly notify each Investor who holds Registrable Securities covered by the Investor Registration Statement of (i) the Company’s submission of an acceleration request with respect to the Investor Registration Statement; (ii) the

 

A- 3



 

effectiveness on the actual effective date thereof; and (iii) the issuance of any “stop order” or order preventing or suspending the use of any prospectus relating to the Registrable Securities.

 

(b)                                The Company may suspend the use of any Investor Prospectus used in connection with the Investor Registration Statement only in the event, and for such period of time as, (i) such a suspension is required by the rules and regulations of the Commission or any self-regulatory organization, or (ii) it is determined in good faith by the Board of the Company that because of valid business reasons (not including the avoidance of the Company’s obligations hereunder), it is in the best interests of the Company to suspend such use, and prior to suspending such use in accordance with this clause (b) the Company provides the Investors with written notice of such suspension, which notice need not specify the nature of the event giving rise to such suspension.  The Company will use commercially reasonable efforts to cause such suspension to terminate at the earliest possible date.  Notwithstanding the foregoing, the use of any Investor Prospectus may be suspended by reason of clause (ii) of this subsection (b) for a period of time not to exceed (A) sixty (60) consecutive days for any one such suspension or (B) an aggregate of ninety (90) days during the Investor Registration Period; provided that the Company shall not utilize this right more than twice in any 12-month period.

 

(c)                                 The Company shall prepare and file with the Commission such amendments (including post-effective amendments) and supplements to the Investor Registration Statement and the Investor Prospectus used in connection with the Investor Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep the Investor Registration Statement effective at all times during the Investor Registration Period (as defined below), and, during such period, comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities of the Company covered by the Investor Registration Statement.  In the case of amendments and supplements to the Investor Registration Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 1.2(c) ) by reason of the Company filing a report on Form 10-K, Form 10-Q or Form 8-K or any analogous report under the Exchange Act, the Company shall have incorporated such report by reference into the Investor Registration Statement, if applicable, or shall file such amendments or supplements with the Commission on the same day on which the Exchange Act report is filed which created the requirement for the Company to amend or supplement the Investor Registration Statement.

 

(d)                                  Each Investor agrees by its acquisition of the Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Sections 1.2(a)(vi)  or (a)(vii) , and upon notice of any suspension under Section 1.2(b) , such Investor will forthwith discontinue disposition of such Registrable Securities under the Investor Registration Statement until such Investor’s receipt of the copies of the supplemented prospectus and/or amendment to the Investor Registration Statement contemplated by this Section 1.2 , or until it is advised in writing by the Company that the use of the applicable prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such prospectus or the Investor Registration Statement.  The

 

A- 4



 

Company may provide appropriate stop orders to enforce the provisions of this paragraph.

 

(e)                                   If requested by an Investor, the Company shall (i) as soon as practicable incorporate in a prospectus supplement or post-effective amendment such information as an Investor reasonably requests to be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the Subscription Price being paid therefor and any other terms of the offering of the Registrable Securities to be sold in such offering, (ii) as soon as practicable make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment, and (iii) as soon as practicable, supplement or make amendments to the Investor Registration Statement if reasonably requested by an Investor holding any Registrable Securities.

 

1.3                                Expenses of Investor Registration .  All Investor Registration Expenses in connection with any registration, qualification or compliance with registration pursuant to this Agreement shall be borne by the Company, and all Selling Expenses of an Investor shall be borne by such Investor.

 

1.4                                Investor Registration Period .

 

(a)                                  In the case of the Investor Registration, the Company shall keep such registration effective from the date on which the Investor Registration Statement initially became effective until the earlier of: (i) the date on which all the Investors have completed the sales or distribution described in the Investor Registration Statement relating to the Registrable Securities registered for resale thereunder; (ii) until such Registrable Securities may be sold by the Investors without restriction pursuant to Rule 144 (or any successor thereto); or (iii) one year from the effective date of the Investor Registration Statement, other than with respect to any Investor who is an “affiliate” (as defined in Rule 144(a)(1) of the Securities Act) of the Company (the “ Investor Registration Period ”).  Thereafter, the Company shall be entitled to withdraw such Investor Registration Statement and the Investors shall have no further right to offer or sell any of the Registrable Securities registered for resale thereon pursuant to the Investor Registration Statement (or any prospectus relating thereto).

 

(b)                                  An Investor’s registration rights hereunder shall expire at such time as it no longer holds any Registrable Shares.  Termination of such registration rights shall be conditioned upon the Company’s action to remove the restrictive legends from any Registrable Securities held by such Investor and the reissuance of unlegended certificates, in physical or electronic format, to such Investor prior to the effective termination of the Agreement.

 

1.5                                Indemnification .

 

(a)                                  Indemnification by the Company .  The Company agrees to indemnify and hold harmless, to the fullest extent permitted by Law, (i) each Investor and its officers, directors, stockholders, employees, advisors, agents and Affiliates, (ii) each Investor’s Affiliates’

 

A- 5



 

officers, directors, stockholders, employees, advisors, agents, and (iii) each Person who controls (within the meaning of the Securities Act, the Exchange Act) such Persons, against any and all claims, losses, damages, penalties, judgments, suits, costs, liabilities and expenses (or actions in respect thereof) (collectively, the “ Losses ”) arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact contained in the Investor Registration Statement (including any Investor Prospectus) or any other document incorporated by reference therein, (B) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not false or misleading (in the case of any Investor Prospectus, in light of the circumstances under which they were made), or (C) any violation by the Company of the Securities Act, the Exchange Act, the Canadian Securities Laws or any state securities or “Blue Sky” Laws applicable to the Company, and will reimburse each of the Persons listed above, for any reasonable and documented out-of-pocket legal and any other expenses reasonably incurred in connection with investigating and defending any such Losses; provided , that the Company will not be liable in any such case to the extent that any such Losses arise out of or are based on any untrue statement or omission based upon written information furnished to the Company by such Person and stated to be specifically for use in such Investor Registration Statement or Investor Prospectus.

 

(b)                                  Indemnification by Investors .  Each Investor agrees to indemnify and hold harmless, to the fullest extent permitted by Law, (i) the Company and its officers, directors, stockholders, employees, advisors, agents and Affiliates, (ii) each of the Company’s Affiliates’ officers, directors, stockholders, employees, advisors, agents, and (iii) each Person who controls the Company (within the meaning of the Securities Act, the Exchange Act or the Canadian Securities Laws), against any and all Losses arising out of or based on (A) any untrue statement (or alleged untrue statement) of a material fact made by such Investor contained in the Investor Registration Statement (including any Investor Prospectus) or any other document incorporated by reference therein or (B) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements by such Investor therein not false or misleading (in the case of any Investor Prospectus, in light of the circumstances under which they were made), and will reimburse the Persons listed above for any reasonable and documented legal or any other expenses reasonably incurred in connection with investigating or defending any such Losses, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in reliance upon and in conformity with written information furnished to the Company by such Investor and stated to be specifically for use in such Investor Registration Statement or Investor Prospectus, provided , however , that the obligations of each Investor hereunder shall be limited to such Investor’s respective Subscription Price.

 

(c)                                   Conduct of the Indemnification Proceedings .  Each Person entitled to indemnification under this Section 1.5 (the “ Indemnified Party ”) shall give notice to the Person required to provide indemnification (the “ Indemnifying Party ”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom; provided , that counsel for the Indemnifying Party, who shall conduct

 

A- 6



 

the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld) and the Indemnified Party may participate in such defense at such Indemnified Party’s expense (unless the Indemnified Party shall have reasonably concluded that there may be a conflict of interest between the Indemnifying Party and the Indemnified Party in such action, in which case the fees and expenses of counsel shall be at the expense of the Indemnifying Party); and provided , further , that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1.5 unless the Indemnifying Party is actually and materially prejudiced thereby.  It is understood and agreed that the Indemnifying Party shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate legal counsel for all Indemnified Parties; provided , however , that where the failure to be provided separate legal counsel would be reasonably likely to result in a conflict of interest on the part of such legal counsel for all Indemnified Party, separate counsel shall be appointed for the Indemnified Parties to the extent needed to alleviate such potential conflict of interest.  No Indemnifying Party, in the defense of any such claim or litigation shall, except with the prior written consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect of such claim or litigation.  Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnified Party may reasonably request in writing and as shall be reasonably required in connection with the defense of such claim and litigation resulting therefrom.

 

(d)                                  Contribution .  If the indemnification provided for in this Section 1.5 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any Losses, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party, on the one hand, and the Indemnified Party, on the other, in connection with the statements or omissions (or alleged statements or omissions) which resulted in such Losses, as well as any other relevant equitable considerations.  The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue (or alleged untrue) statement of a material fact or the omission (or alleged omission) to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and such parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided , however , that the obligations of each Investor shall be limited to an amount equal to the such Investor’s respective Subscription Price; and provided , further , that no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) or gross negligence shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation or gross negligence.

 

(e)                                   Exclusivity .  Subject to the limitations on each Investor’s liability set forth in Section 1.5(b)  and Section 1.5(d) , the remedies provided for in this Section 1.5 are not exclusive

 

A- 7



 

and shall not limit any rights or remedies which may otherwise be available to any Indemnified Party at Law or equity.  The remedies shall remain in full force and effect regardless of any investigation made by or on behalf of an Investor or any Indemnified Party and survive the transfer of the Investor Shares by an Investor.

 

1.6                                Survival .  The indemnity and contribution agreements contained in Section 1.5 shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation made by or on behalf of any Indemnified Party or by or on behalf of the Company, and (iii) the consummation of the sale or successive resales of the Registrable Securities.

 

1.7                                Information by Investors .  Each Investor shall promptly furnish to the Company such information regarding such Investor and the distribution and/or sale proposed by such Investor as the Company may from time to time reasonably request in writing in connection with any Investor Registration, qualification or compliance referred to in this Agreement, and the Company may exclude from such Investor Registration the Registrable Securities of any Investor who unreasonably fails to furnish such information within a reasonable time after receiving such request.  The intended method or methods of disposition and/or sale of such securities as so provided by such purchaser shall be included without alteration in the Investor Registration Statement covering the Registrable Securities and shall not be changed without written consent of such Investor.  Each Investor agrees that, other than ordinary course brokerage arrangements, in the event it enters into any arrangement with a broker dealer for the sale of any Registrable Securities through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, such Investor shall promptly deliver to the Company in writing all applicable information required in order for the Company to be able to timely file a supplement to the Investor Prospectus pursuant to Rule 424(b), or take any other action, under the Securities Act, to the extent that such supplement or other action is legally required.  Such information shall include a description of (i) the name of such Investor and of the participating broker dealer(s), (ii) the number of Registrable Securities involved, (iii) the price at which such Registrable Securities were or are to be sold, and (iv) the commissions paid or to be paid or discounts or concessions allowed or to be allowed to such broker dealer(s), where applicable.

 

A- 8



 

ANNEX B

 

FORM OF WARRANT AGREEMENT

 

A- 9



 

EXECUTION VERSION

 

AMENDMENT NO. 1 TO UNIT SUBSCRIPTION AGREEMENT

 

THIS AMENDMENT NO. 1 TO UNIT SUBSCRIPTION AGREEMENT (this “ Amendment ”) is made as of September 9, 2016, by and among QLT Inc., a corporation formed under the laws of the Province of British Columbia, Canada (the “ Company ”) and Broadfin Healthcare Master Fund, Ltd. (“ Broadfin ,” and, together with QLT, the “ Parties ,” each a “ Party ”).  Capitalized terms used, but not defined, herein shall have the meanings ascribed to them in the Original Agreement (as defined below).

 

RECITALS

 

WHEREAS , the Company and Aegerion Pharmaceuticals, Inc., a Delaware corporation (“ Aegerion ”), have entered into an Agreement and Plan of Merger (as the same may be amended, restated, supplemented or modified, the “ Merger Agreement ”), pursuant to which a wholly-owned subsidiary of the Company would merge with and into Aegerion (the “ Merger ”), with Aegerion surviving as a wholly-owned indirect subsidiary of the Company;

 

WHEREAS, Broadfin has agreed to provide capital to the Company in support of the Merger by entering into the Unit Subscription Agreement, dated June 14, 2016, by and among the Company and the Investors  (the “ Original Agreement ” and, as the same may be amended, restated, supplemented or modified, the “ Agreement ”);

 

WHEREAS , pursuant to the Original Agreement, the Company agreed to allot and issue to Broadfin, and Broadfin agreed to subscribe for, 2,840,909 units, each consisting of one common share of the Company (collectively, the “ Shares ”), one DOJ/ SEC Matter Warrant and one Class Action Lawsuit Warrant (both as defined in the Warrant Agreement);

 

WHEREAS , Broadfin wishes to purchase, in lieu of the Shares, fully paid-up warrants to purchase the Shares substantially in the form attached hereto as Exhibit A (the “ Share Warrants ”);

 

WHEREAS , the Share Warrants constitute a Derivative Security, as defined in Section 8.12 of the Original Agreement;

 

WHEREAS , pursuant to Section 8.12 of the Original Agreement, the amendment of the Original Agreement to substitute the Share Warrants for the Shares to be purchased by Broadfin requires only the signature of the Company and the affected Investor, viz ., Broadfin;

 

WHEREAS , the Company and Broadfin desire to amend the Original Agreement to provide for the issuance to Broadfin of 2,840,909 units, each consisting of one Share Warrant, one DOJ/SEC Matter Warrant and one Class Action Lawsuit Warrant;

 

NOW THEREFORE in consideration of the premises and the covenants and agreements contained herein, the Parties agree as follows:

 

1.              Purchase of Units Comprising the Share Warrants and the Warrants .  (a)  Instead of purchasing the Units allocable to Broadfin under the Original Agreement, Broadfin will instead purchase an equal number of Units, each consisting of one Share Warrant, substantially in the

 

1



 

form attached hereto as Exhibit A , one DOJ/ SEC Matter Warrant and one Class Action Lawsuit Warrant (the “ Broadfin Units ”).  Accordingly, the Original Agreement shall be interpreted, solely with respect to the rights and obligations of Broadfin and the Company (as pertains to Broadfin) as follows:

 

(i)            at the Investment Closing, the Company will deliver the Share Warrants to Broadfin in lieu of Broadfin’s Investor Shares;

 

(ii)           at the Investment Closing, the Company shall be obligated to deliver or cause to be delivered, to Broadfin, the Share Warrants, substantially in the form attached hereto as Exhibit A , duly executed on behalf of the Company and registered in the name of Broadfin, which Share Warrants shall be free and clear of any Liens;

 

(iii)          the Company shall use commercially reasonable efforts to cause the Shares underlying the Share Warrants to be approved for listing on NASDAQ and conditionally approved for listing on the TSX prior to the Investment Closing, as mutually agreed by the parties, subject to official notice of issuance in respect of NASDAQ and subject to compliance with all of the customary requirements of the TSX, including receipt of all documentation required by the TSX;

 

(iv)          all references made in Section 2.3(a), 3.1, 5.9 and 6.2(c) of the Original Agreement to “Warrants” shall be deemed to include the Share Warrants and all references to “Warrant Shares” shall be deemed to include the Shares underlying the Share Warrants;

 

(v)           all references made in Annex A to the Original Agreement to “Investor Shares” shall be deemed to refer to the Shares underlying the Share Warrants and not the Share Warrants; and

 

(vi)          for the avoidance of doubt, the number of Shares underlying the Share Warrants shall be included in the aggregate number of Investor Shares included in the calculation of  the “Pre-Merger QLT Share Number” as such term is used in the Warrant Agreement.

 

(vii)         all references made in Section 3.1 of the Original Agreement to “Units” shall be deemed to refer to the Broadfin Units.

 

2.              Full Force and Effect .  Except as amended by this Amendment, the Original Agreement shall continue in full force and effect pursuant to its terms.

 

3.              Counterparts; Effectiveness .  This Amendment may be executed in two or more counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by telecopy, electronic delivery or otherwise) to the other parties.  Signatures to this Amendment transmitted by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.

 

2



 

4.              Governing Law .  This Amendment, and all claims or causes of action (whether at Law, in contract or in tort or otherwise) that may be based upon, arise out of or relate to this Amendment or the negotiation, execution or performance hereof, shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Delaware.

 

5.              Severability .  Any term or provision of this Amendment which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Amendment in any other jurisdiction.  If any provision of this Amendment is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.

 

[The remainder of this page is left intentionally blank]

 

3



 

IN WITNESS WHEREOF the Parties have executed this Amendment as of the date first written above.

 

 

QLT INC.

 

 

 

 

 

 

By:

/s/ Glen Ibbott

 

 

Name: Glen Ibbott

 

 

Title: Chief Financial Officer

 

[SIGNATURE PAGE TO AMENDMENT NO. 1 TO UNIT SUBSCRIPTION AGREEMENT]

 



 

 

BROADFIN HEALTHCARE MASTER FUND, LTD.

 

 

 

 

 

 

By:

/s/ Kevin Kotler

 

 

Name: Kevin Kotler

 

 

Title: Managing Partner of Broadfin Capital LLC,

 

 

Investment Manager of Broadfin Healthcare Mater Fund Ltd.

 

[SIGNATURE PAGE TO AMENDMENT NO. 1 TO UNIT SUBSCRIPTION AGREEMENT]

 



 

EXHIBIT A — SHARE WARRANTS

 



 

FINAL FORM

 

WARRANT CERTIFICATE

 

FULLY PAID WARRANTS

to acquire Common Shares of
QLT INC.

 

(incorporated pursuant to the laws of the Province of British Columbia)

 

Warrant Certificate No.: [ · ]

[2,840,909] Warrants

 

Issue Date: [ · ], 2016

 

THIS WARRANT CERTIFICATE (“WARRANT CERTIFICATE”) IS TO CERTIFY THAT, for value received, Broadfin Healthcare Master Fund, LTD. (the “ Holder ”) is the registered holder of the number of fully paid-up warrants (the “ Warrants ”) to acquire common shares in the capital of QLT Inc. (the “ Company ”) specified above, and is entitled, on exercise of each Warrant upon and subject to the terms and conditions set forth herein, to acquire at any time, and from time to time, from and after the issuance of the Warrants and before 5:00 p.m. (Pacific Time) on [ enter DATE that is the tenth anniversary of the issuance date ] (the “ Expiration Date ”), one (1) (the “ Exercise Number ”) fully paid and non-assessable common share without par value in the capital of the Company as constituted on the date hereof (“ Common Shares or “ Common Stock ”).

 

1.                                       Exercise

 

1.1.                             Exercise. The right to acquire Common Shares may only be exercised by the Holder within the time set forth above by duly completing and executing the notice of exercise in the form attached hereto (the “ Notice of Exercise ”) and delivering it to the Company at its principal office as set out in Section 4.1, together with, if applicable, a completed Canada Revenue Agency - Form NR301 - Declaration of eligibility for benefits under a tax treaty for a non-resident taxpayer.

 

1.2.                             Notice of Exercise. The duly completed Notice of Exercise will be deemed to have been received only on personal delivery thereof to, or if sent by mail or other means of transmission on actual receipt thereof by, the Company at its principal office as set out in Section 4.1.

 

1.3.                             Exercise Price. Notwithstanding anything herein to the contrary, the Warrants are fully paid-up warrants and no exercise price need be paid on the exercise of the Warrants.

 

1.4.                             Beneficial Ownership. The Company shall not effect any exercise of the Warrants, and the Holder shall not have the right to exercise any portion of the Warrants, to the extent that after giving effect to such issuance after exercise as set

 

1



 

forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of the Warrants with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of the Warrants beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 1.4, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “ Exchange Act ”), it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 1.4 applies, the determination of whether the Warrants are exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of the Warrants are exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether the Warrants are exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of the Warrants are exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall not have any obligation to verify or confirm the accuracy of such determination and the Company shall not have any liability for exercise of the Warrants that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 1.4, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Securities and Exchange Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of the Holder, the Company shall within two trading days confirm in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrants, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “ Beneficial Ownership Limitation ” shall be

 



 

9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of the Warrants; provided, however, that the Holder may, by written notice to the Company, increase or decrease the Beneficial Ownership Limitation applicable to the Holder to any other percentage specified in such notice, provided that (i) any such increase will not be effective until the 61st day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and not to any other holder of Warrants. The provisions of this Section 1.4 shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1.4 to correct this Section 1.4 (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this Section 1.4 shall apply to a successor holder of the Warrants.

 

1.5.                             Certificates. Certificates for the Common Shares subscribed for will be mailed to the persons specified in the Notice of Exercise at their respective addresses specified therein or, if so specified in the Notice of Exercise, delivered to such persons at the office where this Warrant Certificate is surrendered.

 

1.6.                             Registry of Warrants. The Company shall maintain a registry (the “ Warrant Registry ”) showing the address of the Holder and the date and number of Warrants held by the Holder. Except as otherwise provided in this Warrant Certificate, the Company may deem and treat any Registered Holder of a Warrant as the absolute owner thereof (notwithstanding any notation of ownership or other writing thereon made by anyone).

 

1.7.                             Exchange of Warrant Certificates. Each Warrant Certificate may be exchanged for another Warrant Certificate or Certificates of like tenor and representing the same aggregate number of Warrants. Any Holder desiring to exchange a Warrant Certificate or Certificates shall deliver a written request to the Company and shall properly endorse and surrender the Warrant Certificate or Certificates to be so exchanged. Thereupon, the Company shall countersign and deliver to the Holder a new Warrant Certificate or Certificates, as so requested, in such name or names as the Holder shall designate.

 

1.8.                             Cancellation of Warrant Certificates. If and when any Warrant Certificate has been exercised in full, the Company shall promptly cancel such Warrant Certificate following its receipt from the Holder or, to the extent required by Applicable Law, retain such Warrant Certificate. Upon exercise of a Warrant Certificate in part and not in full, the Company shall issue and deliver or shall cause to be issued and delivered to the Holder a new Warrant Certificate or Certificates evidencing the Holder’s remaining Warrants. The Company and no one else may cancel Warrant Certificates surrendered for transfer, exchange, replacement, cancellation or exercise. The Company may not issue new Warrant Certificates to replace cancelled Warrant Certificates that have been exercised or purchased by it.

 



 

1.9.                             No Fractional Common Shares or Scrip. No fractional Common Shares or scrip representing fractional Common Shares shall be issued upon any exercise of Warrants. The number of Common Shares to be issued to the Holder upon the exercise of Warrants shall be rounded down to the nearest whole number. The Holder shall receive no consideration in lieu of fractional Common Shares.

 

1.10.                      Lost, Stolen, Destroyed or Mutilated Warrants. If any of the Warrant Certificates shall be mutilated, lost, stolen or destroyed, the Company shall countersign and deliver, in exchange and substitution for, and upon cancellation of the mutilated Warrant Certificate, or in lieu of and substitution for the Warrant Certificate lost, stolen or destroyed, a new Warrant Certificate of like tenor and representing an equivalent number of Warrants, but only upon receipt of evidence reasonably satisfactory to the Company of the loss, theft or destruction of such Warrant Certificate and an affidavit and the posting of an open penalty bond satisfactory to it. Applicants for such substitute Warrant Certificates shall also comply with such other reasonable regulations and pay such other reasonable charges as the Company may prescribe.

 

1.11.                      Transferability and Assignment. At the option of the Holder thereof, the Warrants and all rights attached thereto may be sold, assigned, transferred, pledged, encumbered or in any other manner transferred or disposed of, in whole or in part, by the Holder or by duly authorized attorney, and one or more new Warrant Certificates shall be made and delivered and registered in the name of one or more transferees, upon surrender and upon compliance with all Applicable Laws and subject to the Holder’s presenting due evidence of authority to transfer which shall include a signature guarantee from an eligible guarantor institution participating in a signature guarantee program approved by the Securities Transfer Association, and any other evidence of authority that may be reasonably required by the Company. Warrants may only be transferred upon surrender of this Warrant Certificate to the Company or other registrar accompanied by a written instrument of transfer in form and execution satisfactory to the Company or other registrar and upon compliance with the conditions prescribed in the Warrant Certificate and with such reasonable requirements as the Company may prescribe and upon the transfer being duly noted thereon by the Company. Time is of the essence hereof.

 

1.12.                      Issuance of Warrant Certificates. When the Holder, transferee of the Holder or other designee of the Holder is entitled to receive a new or replacement Warrant Certificate, the Company shall issue or shall cause to be issued such new or replacement Warrant Certificate as promptly as reasonably practicable.

 

1.13.                      Issuance of Common Shares. Upon the exercise of any Warrants, the Company shall deliver or shall cause to be delivered the number of full Common Shares to which the Holder shall be entitled as promptly as reasonably practicable. All Common Shares shall be issued in such name or names as the Holder may designate and delivered to the Holder or its nominee or nominees.

 



 

1.14.                      Charges, Taxes and Expenses. The Company shall pay all documentary stamp taxes, if any, attributable to the initial issuance of Common Shares upon the exercise of Warrants; provided, however, the Company shall not be required to pay any tax or taxes which may be payable in respect of any transfer involved in the issue or delivery of any Warrants or certificates (if any) for Common Shares in a name other than that of the registered holder of such Warrants. The Company shall be responsible for calculating any withholding taxes payable under Applicable Law in respect of the issuance of the Common Shares upon the exercise of the Warrants and the Company shall be entitled to, deduct and withhold from the Common Shares such number of Common Shares as the Company may determine is required to be deducted and withheld under Applicable Law, and any such withheld shares of Common Stock shall be treated for all purposes of this Warrant Certificate as having been distributed or sold to the Holder in respect of whom such deduction and withholding was made.

 

1.15.                      Issued Common Shares. The Company hereby represents and warrants that all Common Shares issued in accordance with the terms of this Warrant Certificate will be duly and validly authorized and issued, fully paid and nonassessable and free from all taxes, liens and charges (other than liens or charges created by the Holder, income and franchise taxes incurred in connection with the exercise of the Warrant or taxes in respect of any transfer occurring contemporaneously therewith). The Company agrees that the Common Shares so issued will be deemed to have been issued to the Holder as of the close of business on the date on which the Warrants were duly exercised, notwithstanding that the stock transfer books of the Company may then be closed or certificates (if any) representing such Warrant Shares may not be actually delivered on such date.

 

1.16.                      Reservation of Sufficient Common Shares. There have been reserved, and the Company shall at all times through the Expiration Date keep reserved, out of its authorized but unissued Common Stock, solely for the purpose of the issuance of Common Shares in accordance with the terms of this Warrant Certificate, a number of shares of Common Stock sufficient to provide for the exercise of the rights of purchase represented by the outstanding Warrants. The transfer agent for the Common Stock and every subsequent transfer agent for any shares of the Company’s capital stock issuable upon the exercise of any of the rights of purchase aforesaid shall be irrevocably authorized and directed at all times to reserve such number of authorized shares as shall be required for such purpose. If applicable, the Company shall supply such transfer agents with duly executed stock certificates for such purposes. The Company shall furnish such transfer agent with a copy of all notices of adjustments and certificates related thereto, transmitted to the Holder pursuant to Section 4.1.

 

1.17.                      No Impairment. The Company will not, and the Company will cause its Subsidiaries not to, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed by the Company under this Warrant Certificate. The Company shall at all times in good faith assist in the carrying out of all provisions of this Warrant Certificate and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder.

 



 

1.18.                      CUSIP Numbers. The Company, in issuing the Warrants, may use “ CUSIP numbers (if then generally in use) and, if so, the Company shall use “ CUSIP numbers in notices as a convenience to the Holder; provided, however, that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Warrant Certificates or as contained in any notice and that reliance may be placed only on the other identification numbers printed on the Warrant Certificates.

 

1.19.                      No Rights as Shareholders. A Warrant shall not, prior to its exercise, confer upon the Holder or the Holder’s transferee, in the Holder’s or such transferee’s capacity as a Holder, the right to vote or receive dividends (other than as contemplated by Section 2 herein), or consent or receive notice as shareholders in respect of any meeting of shareholders for the election of directors of the Company or any other matter, or any rights whatsoever as shareholders of the Company. In no event will the Warrants or the Common Shares issuable hereunder be considered to constitute a class separate and distinct from the common shares of the Company for the purposes of the Business Corporations Act (British Columbia), and the Holder expressly agrees that it will not at any time seek, in a court proceeding or otherwise, to have them considered as such.

 

1.20.                      Registration. Unless all of the Common Shares underlying this Warrant are eligible for sale under Rule 144 under the Securities Act of 1933, as amended, (the “ Securities Act ”) without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such securities and without volume or manner-of-sale restrictions, the Company shall (a) use commercially reasonable efforts to register, under the Securities Act, such Common Shares for resale, and (b) use commercially reasonable efforts to maintain such registration of such Common Shares on terms consistent with those included in the Investor Registration Statement (as defined in the Unit Subscription Agreement dated June 14, 2016, as amended).

 

2.                                       Antidilution Provisions

 

2.1.                             Adjustments and Other Rights. The Exercise Number shall be subject to adjustment from time to time as provided by this Section 2; provided, however, that if more than one Section of this Section 2 is applicable to a single event, the Section shall be applied that produces the largest adjustment, and no single event shall cause an adjustment under more than one Section of this Section 2 so as to result in duplication; and provided further that no issuance of Warrant Shares, as defined in that certain Warrant Agreement, dated [ · ], 2016, by and between the Company and Computershare Trust Company of Canada, shall result in any adjustment under this Section 2.

 

2.2.                             Stock Splits, Subdivisions, Reclassifications or Combinations. If the Company shall, prior to the Expiration Date, (a) declare and pay a dividend or make a distribution on its Common Stock in shares of Common Stock, (b) subdivide or reclassify the

 



 

outstanding shares of Common Stock into a greater number of shares, or (c) combine or reclassify the outstanding shares of Common Stock into a smaller number of shares, the Exercise Number at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be adjusted by multiplying the Exercise Number effective immediately prior to such event by a fraction (x) the numerator of which shall be the total number of outstanding shares of Common Stock immediately after such event and (y) the denominator of which shall be the total number of outstanding shares of Common Stock immediately prior to such event.

 

2.3.                             Business Combinations or Reclassifications of Common Stock. In case of any Business Combination or reclassification of Common Stock (other than a reclassification of Common Stock referred to in Section 2.2), a Holder’s right to receive shares upon exercise of a Warrant shall be converted into the right to exercise such Warrant to acquire the number of shares of stock or other securities or property (including cash) that the Common Stock issuable (at the time of such Business Combination or reclassification) upon exercise of such Warrant immediately prior to such Business Combination or reclassification would have been entitled to receive upon consummation of such Business Combination or reclassification; and in any such case, if necessary, the provisions set forth herein with respect to the rights and interests thereafter of the Holder shall be appropriately adjusted so as to be applicable, as nearly as may reasonably be, to such Holder’s right to exercise a Warrant in exchange for any shares of stock or other securities or property pursuant to this section. In determining the kind and amount of stock, securities or the property receivable upon exercise of a Warrant following the consummation of such Business Combination, if the holders of Common Stock have the right to elect the kind or amount of consideration receivable upon consummation of such Business Combination, then the consideration that a Holder shall be entitled to receive upon exercise shall be deemed to be the types and amounts of consideration received by the majority of all holders of the shares of Common Stock that affirmatively make an election (or of all such holders if none make an election). In connection with the consummation of a Business Combination or reclassification, in determining the number of shares Common Stock deemed exercisable under this Warrant, such number shall be determined without regard to the provisions of Section 1.4 herein.

 

2.4.                             Rounding of Calculations; Minimum Adjustments. All calculations under this Section 2 shall be made to the nearest one-hundredth (1/100th) of a share. Any provision of this Section 2 to the contrary notwithstanding, no adjustment in the Exercise Number shall be made if the amount of such adjustment would be less than one-tenth (1/10th) of a share of Common Stock, but any such amount shall be carried forward and an adjustment with respect thereto shall be made at the time of and together with any subsequent adjustment which, together with such amount and any other amount or amounts so carried forward, shall aggregate 1/10th of a share of Common Stock, or more, or on exercise of a Warrant if it shall earlier occur. The provisions of this Section 2.4 shall not be deemed to supersede the provisions of Section 1.9.

 



 

2.5.                             Timing of Issuance of Additional Common Stock Upon Certain Adjustments. In any case in which the provisions of this Section 2 shall require that an adjustment shall become effective immediately after a record date for an event, the Company may defer until the occurrence of such event issuing to the Holder of Warrants exercised after such record date and before the occurrence of such event the additional shares of Common Stock issuable upon such exercise by reason of the adjustment required by such event over and above the shares of Common Stock issuable upon such exercise before giving effect to such adjustment; provided, however, that the Company upon request shall deliver to the Holder a due bill or other appropriate instrument evidencing the Holder’s right to receive such additional shares upon the occurrence of the event requiring such adjustment, subject to any retroactive readjustment in accordance with Section 2.6.2.

 

2.6.                             Other Events; Provisions of General Applicability.

 

2.6.1. The Exercise Number shall not be adjusted in the event of (i) a change in the par value of the Common Stock, (ii) a change in the jurisdiction of incorporation of the Company or (iii) any conversion of shares of any other class of common stock of the Company outstanding as of the date of this Warrant Certificate into shares of Common Stock in accordance with the conversion mechanisms set forth in the Company’s certificate of incorporation as of the date of this Warrant Certificate.

 

2.6.2. In the event that any dividend or distribution described in Section 2.2 is not so made, the Exercise Number then in effect shall be readjusted, effective as of the date when the Board of Directors determines not to distribute such shares, evidences of indebtedness, assets, rights, cash or warrants, as the case may be, to the Exercise Number that would then be in effect if such record date had not been fixed.

 

2.7.                             Statement Regarding Adjustments. Whenever the Exercise Number shall be adjusted as provided in this Section 2, the Company shall forthwith file at the principal office of the Company a statement showing in reasonable detail the facts requiring such adjustment and the Exercise Number after such adjustment. The Company shall cause a copy of such statement to be sent or communicated to the Holder pursuant to Section 4.1.

 

2.8.                             Notice of Adjustment Event. In the event that the Company shall propose to take any action of the type described in this Section 2 (but only if the action of the type described in this Section 2 would result in an adjustment in the Exercise Number or a change in the stock of the Company to be delivered upon exercise of a Warrant), the Company shall cause a notice to be sent or communicated to the Holder in the manner set forth in Section 4.1, which notice shall specify the record date, if any, with respect to any such action and the approximate date on which such action is to take place. Such notice shall also set forth the facts with respect thereto as shall be reasonably necessary to indicate the effect on the Exercise Number and the number, kind or class

 



 

of shares which shall be deliverable upon exercise of a Warrant. In the case of any action which would require the fixing of a record date, such notice shall be given at least ten (10) days prior to the date so fixed, and in case of all other action, such notice shall be given at least fifteen (15) days prior to the taking of such proposed action. Failure to give such notice, or any defect therein, shall not affect the legality or validity of any such action.

 

2.9.                             Proceedings Prior to Any Action Requiring Adjustment. As a condition precedent to the taking of any action which would require an adjustment pursuant to this Section 2, the Company shall take any action which may be necessary, including obtaining regulatory or shareholder approvals or exemptions, in order that the Company may thereafter validly and legally issue as fully paid and nonassessable all Common Shares that the Holder is entitled to receive upon exercise of a Warrant pursuant to this Section 2.

 

2.10.                      Adjustment Rules. Any adjustments pursuant to this Section 2 shall be made successively whenever an event referred to herein shall occur.

 

2.11.                      Prohibited Actions. The Company agrees that it will not take any action which would entitle the Holder to an adjustment of the Exercise Number if the total number of shares of Common Stock issuable after such action upon exercise of the Warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon the exercise of all outstanding options, warrants, conversion and other rights, would exceed the total number of shares of Common Stock then authorized by its Notice of Articles.

 

2.12.                      Accuracy of Notice of Exercise. The Company shall not be responsible for making any investigations into the accuracy of a declaration made by the Holder in a Notice of Exercise and the Company shall not incur any liability or responsibility whatever or be in any way responsible for the consequences of such declaration being false.

 

3.                                       Miscellaneous

 

3.1.                             Notices. Any notice pursuant to this Warrant Certificate by the Holder to the Company shall be in writing and shall be delivered by facsimile transmission, or mailed first class, postage prepaid, to the Company, at its offices at 887 Great Northern Way, Suite 250, Vancouver, B.C. V5T 4T5, Canada, Attention: Senior Vice President, Legal. Each party to this Warrant Certificate may from time to time change the address to which notices to it are to be delivered or mailed by notice to the other party. Any notice mailed pursuant to this Warrant Certificate by the Company shall be in writing and shall be mailed first class, postage prepaid, or otherwise delivered, to the Holder at its address on the registry of the Company.

 



 

3.2.                             Supplements and Amendments. The Company and the Holder may from time to time supplement or amend this Warrant Certificate by one or more substantially concurrent written instruments duly signed by the Company and the Holder.

 

3.3.                             Successors. All the covenants and provisions of this Warrant Certificate by or for the benefit of the Company or the Holder shall bind and inure to the benefit of the respective successors and assigns of the Company or the Holder under this Warrant Certificate.

 

3.4.                             Governing Law; Jurisdiction. THIS WARRANT CERTIFICATE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE PROVINCE OF BRITISH COLUMBIA AND THE FEDERAL LAWS OF CANADA APPLICABLE THEREIN, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICT OF LAWS. IN CONNECTION WITH ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT CERTIFICATE, THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE PROVINCE OF BRITISH COLUMBIA RESIDING IN THE CITY OF VANCOUVER, BRITISH COLUMBIA. NOTICE MAY BE SERVED UPON THE COMPANY AT THE ADDRESS SET FORTH IN SECTION 4.1 AND UPON THE HOLDER AT THE ADDRESS FOR THE HOLDER SET FORTH IN THE REGISTRY MAINTAINED BY THE COMPANY PURSUANT TO SECTION 1.6. TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO HEREBY UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS WARRANT CERTIFICATE.

 

3.5.                             Benefits of this Warrant Certificate. This Warrant Certificate shall be for the sole and exclusive benefit of the Company and the Holder.  Nothing in this Warrant  Certificate shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or claim under this Warrant Certificate.

 

3.6.                             Counterparts. This Warrant Certificate may be executed in any number of counterparts, and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

3.7.                             Table of Contents; Headings. The table of contents and headings of the Sections of this Warrant Certificate have been inserted for convenience of reference only, are not intended to be considered a part of this Warrant Certificate and shall not modify or restrict any of the terms or provisions of this Warrant Certificate.

 

3.8.                             Severability. The provisions of this Warrant Certificate are severable, and if any clause or provision shall be held invalid, illegal or unenforceable in whole or in part in any jurisdiction, then such invalidity or unenforceability shall affect in that jurisdiction only such clause or provision, or part thereof, and shall not in any manner affect such clause or provision in any other jurisdiction or any other clause or provision of this Warrant Certificate in any jurisdiction.

 



 

3.9.                             Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a business day, then such action may be taken or such right may be exercised on the next succeeding day that is a business day.

 

3.10.                      Termination. This Warrant Certificate and all obligations hereunder will terminate automatically and have no further force or effect, without any further action by any party, upon the Expiration Date.

 

3.11.                      Force Majeure. No party shall be liable to the other, or held in breach of this Warrant Certificate, if prevented, hindered, or delayed in the performance or observance of any provision contained herein by reason of act of God, riots, terrorism, acts of war, epidemics, governmental action or judicial order, earthquakes, or any other similar causes (including, but not limited to, mechanical, electronic or communication interruptions, disruptions or failures). Performance times under this Warrant Certificate shall be extended for a period of time equivalent to the time lost because of any delay that is excusable under this Section 3.11.

 

3.12.                      English Language. The parties hereto have declared that they have required that these presents and all other documents related hereto be in the English language. Les parties aux présentes déclarent qu’elles ont exigé que la présente convention, de même que tous les documents s’y rapportant, soient rédigés en anglais.

 

3.13.                      Legend. The following legend, in substantially the following form, shall appear on the face of all Warrants and/or Warrant Shares as appropriate (and all Warrants and Warrant Shares issued in exchange therefor or substitution thereof) issued under this Agreement:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR (II) AN APPLICABLE EXEMPTION FROM REGISTRATION UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS.”

 

The foregoing legend shall appear on the face of all Warrant Shares issued upon exercise of this Warrant Certificate.

 

3.14.                      Definitions

 

Applicable Law ” in respect of any person, property, transaction or event, means all laws, statutes, codes, ordinances (including zoning), approvals, rules, regulations, instruments, by-laws, notices, policies, protocols, guidelines, guidance, manuals,

 



 

treaties or other requirements of any governmental authority having the force of law and any legal requirements arising under the common law or principles of law or equity.

 

Affiliate means, with respect to any Person, any Person directly or indirectly controlling, controlled by or under common control with, such other Person. For purposes of this definition, “ control ” (including, with correlative meanings, the terms “controlled by” and “under common control with”) when used with respect to any Person, means the possession, directly or indirectly, of the power to cause the direction of management and/or policies of such Person, whether through the ownership of voting securities by contract or otherwise.

 

Beneficial Ownership Limitation has the meaning set forth in Section 1.4.

 

“Board of Directors means the board of directors of the Company, including any duly authorized committee thereof.

 

Business Combination means a merger, consolidation, statutory share exchange or similar transaction that requires the approval of the Company’s shareholders, other than the Merger.

 

business day means any day except Saturday, Sunday and (i) at any time when the Warrants are listed on the NASDAQ Stock Market or the New York Stock Exchange, any day on which the NASDAQ Stock Market or the New York Stock Exchange, as applicable, is authorized or required by law or other governmental actions to close or (ii) at any time when the Warrants are not listed on the NASDAQ Stock Market or the New York Stock Exchange, any day on which banking institutions in the Province of British Columbia or the State of New York are authorized or required by law or other governmental actions to close.

 

Common Stock has the meaning set forth in the preamble.

Company has the meaning set forth in the preamble.

CUSIP has the meaning set forth in Section 1.18.

 

Exchange Act has the meaning set forth in Section 1.4.

Exercise Number has the meaning set forth in the preamble.

Expiration Date has the meaning set forth in the preamble.

Holder has the meaning set forth in the preamble.

 

Merger Agreement has the meaning set forth in the preamble.

Notice of Exercise has the meaning set forth in Section 1.1.

 



 

Person has the meaning given to it in Section 3(a)(9) of the Exchange Act and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act.

 

Subsidiary means any corporation, limited liability company, partnership, association, trust or other entity the accounts of which would be consolidated with those of such party in such party’s consolidated financial statements if such financial statements were prepared in accordance with U.S. GAAP, as well as any other corporation, limited liability company, partnership, association, trust or other entity of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power (or, in the case of a partnership, more than 50% of the general partnership interests or, in the case of a limited liability company, the managing member) are, as of such date, owned by such party or one or more Subsidiaries of such party or by such party and one or more Subsidiaries of such party.

 

trading day means (i) if the shares of Common Stock are not traded on any national or regional securities exchange or association or over-the-counter market, a business day or (ii) if the shares of Common Stock are traded on any national or regional securities exchange or association or over-the-counter market, a business day on which such relevant exchange or quotation system is scheduled to be open for business and on which the shares of Common Stock (x) are not suspended from trading on any national or regional securities exchange or association or over-the-counter market for any period or periods aggregating one half hour or longer; and (y) have traded at least once on the national or regional securities exchange or association or over-the-counter market that is the primary market for the trading of the shares of Common Stock. The term “trading day” with respect to any security other than the Common Stock shall have a correlative meaning based on the primary exchange or quotation system on which such security is listed or traded.

 

U.S. GAAP means United States generally accepted accounting principles.

 

Warrant and “ Warrants has the meaning set forth in the preamble.

 

Warrant Certificate and “ Warrant Certificates has the meaning set forth in the preamble.

 

Warrant Registry has the meaning set forth in Section 1.6.

 



 

IN WITNESS WHEREOF the Company and the Holder have caused this Warrant Certificate to be duly executed as of the date first written above.

 

 

 

QLT INC.

 

 

 

 

 

By:

 

 

 

Name: Glen Ibbott

 

 

Title: Chief Financial Officer

 

[Signature Page to Warrant Certificate]

 



 

 

Broadfin Healthcare Master Fund, LTD.

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

[Signature Page to Warrant Certificate]

 



 

NOTICE OF EXERCISE — WARRANTS
(To be executed upon exercise of Warrants)

 

To: QLT INC. (the “ Company ”)

 

887 Great Northern Way, Suite 250
Vancouver, B.C. V5T 4T5, Canada
Attention: Senior Vice President, Legal

 

The fully paid-up Warrants represented by this Warrant Certificate have been issued pursuant to the Warrant Certificate dated                     , 2016 by and between the Company and the Holder (the “ Warrant Certificate ”) and the undersigned hereby irrevocably elects to exercise the right of acquisition represented by the within Warrant Certificate, and to acquire thereunder,                            Common Shares without par value in the capital of the Company as provided for therein, by electing to receive                             Common Shares without the requirement to pay any exercise price in respect thereof.

 

Any capitalized term in this Notice of Exercise that is not otherwise defined herein shall have the meaning ascribed thereto in the Warrant Certificate.

 

o                                     By checking this box, the Holder hereby irrevocably declares that it has reviewed and applied the terms set out in Section 1.4 of the Warrant Certificate and has conclusively determined that it is entitled to exercise the Warrants described above. This box must be checked in order for the Warrants to be exercised. By checking this box, the Holder acknowledges that the Company shall not be responsible for making any investigations into the accuracy of the declaration made by the Holder above and the Company shall not incur any liability or responsibility whatever or be in any way responsible for the consequences of the Holder making a false declaration.

 

o                                          If the undersigned holder of the Warrant Certificate is not a Canadian resident, check this box. Non-resident holders should consult their own tax advisors concerning their ultimate Canadian tax liability. If applicable, non-resident holders should deliver, with this Notice of Exercise, a completed Canada Revenue Agency (“ CRA ”) - Form NR301 - Declaration of eligibility for benefits under a tax treaty for a non-resident taxpayer (“ NR301 ”). Failure to supply a completed NR301 will result in the Company withholding the statutory 25% withholding tax rate on any payment made to you. At that point, should you decide to, it will be your responsibility to claim the difference back from CRA.

 



 

Please issue a certificate or certificates for such shares of Common Shares in the name of:

 

 

NAME:

 

 

 

 

 

 

 

ADDRESS:

 

 

 

 

 

 

 

Please print full name in which certificates representing the Common Shares are to be issued. If any Common Shares are to be issued to a person or persons other than the registered holder, the registered holder must pay to the Company all eligible transfer taxes or other government charges, if any, and the Form of Transfer must be duly executed, with signature guaranteed.

 

Once completed and executed, this Notice of Exercise must be mailed or delivered to the Company at the address given above.

 

DATED this        day of       , 20     .

 

 

)

 

 

)

 

 

)

 

 

)

 

Witness

)

(Signature of Holder, to be the same as

 

)

appears on the face of this Warrant Certificate)

 

)

 

 

 

 

 

 

 

 

 

Name of Registered Holder

 

Certificates will be delivered or mailed to the address of the Holder as soon as practicable after the delivery of this Exercise Form, duly executed, to the Company.

 



 

FORM OF TRANSFER — WARRANTS

 

(To be executed only upon transfer of Warrant Certificate to the extent such transfer is
permissible under the terms thereof)

 

To:                                   QLT Inc. (the “ Company ”)

887 Great Northern Way, Suite 250
Vancouver, B.C. V5T 4T5, Canada
Attention: Senior Vice President, Legal

 

FOR VALUE RECEIVED the undersigned hereby sells, assigns and transfers to

 

 

(print name and address) the Warrants represented by this Warrant Certificate and hereby irrevocably constitutes and appoints                                 as its attorney with full power of substitution to transfer the said securities on the appropriate register of the Company.

 

o                                     If transfer is to a U.S. Person, check this box.

 

DATED this          day of              , 20  .

 

SPACE FOR GUARANTEES OF
SIGNATURES (BELOW)

)

 

 

)

 

 

 

 

 

)

Signature of Transferor

 

 

 

 

)

 

 

 

 

 

)

 

 

 

 

Guarantor’s Signature/Stamp

)

Name of Transferor

 

 

 

 

)

 

 

REASON FOR TRANSFER — For US Residents only (where the individual(s) or corporation receiving the securities is a US resident). Please select only one (see instructions below).

 

o

Gift

 

o

Estate

 

o

Private Sale

 

o

Other (or no change in ownership)

 



 

Date of Event (Date of gift, death or sale):

Value per Warrant on the date of event:

 

o        

o        

 

 

CAD OR

USD

 

The signature(s) of the transferor(s) must correspond with the name(s) as written upon the face of this certificate(s), in every particular, without alteration or enlargement, or any change whatsoever. The signature(s) on this form must be guaranteed by an authorized officer of Royal Bank of Canada, Scotia Bank or TD Canada Trust whose sample signature(s) are on file with the transfer agent, or by a member of an acceptable Medallion Signature Guarantee Program (STAMP, SEMP, NYSE, MSP). Notarized or witnessed signatures are not acceptable as guaranteed signatures. The Guarantor must affix a stamp bearing the actual words: “SIGNATURE GUARANTEED”, “MEDALLION GUARANTEED” OR “SIGNATURE & AUTHORITY TO SIGN GUARANTEE”, all in accordance with the transfer agent’s then current guidelines and requirements at the time of transfer. For corporate holders, corporate signing resolutions, including certificate of incumbency, will also be required to accompany the transfer unless there is a “SIGNATURE & AUTHORITY TO SIGN GUARANTEE” Stamp affixed to the Form of Transfer obtained from an authorized officer of the Royal Bank of Canada, Scotia Bank or TD Canada Trust or a “MEDALLION GUARANTEED” Stamp affixed to the Form of Transfer, with the correct prefix covering the face value of the certificate.

 

REASON FOR TRANSFER — FOR US RESIDENTS ONLY

 

Consistent with US IRS regulations, the Company is required to request cost basis information from US securityholders. Please indicate the reason for requesting the transfer as well as the date of event relating to the reason. The event date is not the day in which the transfer is finalized, but rather the date of the event which led to the transfer request (i.e. date of gift, date of death of the securityholder, or the date the private sale took place).

 


Exhibit 10.6

 

Novelion Services USA, Inc.
2711 Centerville Road
Suite 400
Wilmington, DE 19808

 

November 28, 2016

 

Gregory Perry

c/o Aegerion Pharmaceuticals, Inc.

One Main Street

Suite 800
Cambridge, MA 02142

 

Dear Greg:

 

RE:  Offer of Employment

 

As you are aware, Aegerion Pharmaceuticals, Inc. (“ Aegerion ”), QLT Inc. and Isotope Acquisition Corp. have agreed to carry out a merger (the “ Merger ”) on the terms set out in the Agreement and Plan of Merger dated June 14, 2016 (the “ Merger Agreement ”).

 

Following the Merger, Aegerion will become an indirect subsidiary of Novelion Services USA, Inc., a Delaware corporation (“ Novelion Services ”).  Novelion Services is currently a subsidiary of QLT Inc., a British Columbia company, which we anticipate will change its name to “Novelion Therapeutics Inc.” (“ Novelion Canada ”).

 

We are pleased to offer you employment with Novelion Services in the position of Chief Financial and Administrative Officer, commencing effective on the completion of the Merger, which is currently anticipated to be November 29, 2016 (the “ Commencement Date ”).

 

Should you choose to accept this offer, the terms and conditions of your employment with Novelion Services will be the same as those set out in your current employment agreement with Aegerion which is attached as Schedule “A” to this letter (the “ Aegerion Agreement ”), except that the terms and conditions of the Aegerion Agreement will be modified and supplemented as follows:

 

1.                                       Defined Terms:  In the Aegerion Agreement, references to the “ Company ” or “ Aegerion ” (or any other references indicating your employer) will be deemed to be references to Novelion Services, references to the “ Board ” will be deemed to be references to the Board of Directors of Novelion Services, and references to the “ Agreement ” or the “ Employment Agreement ” (or any other references to the terms and conditions of your employment) will mean the Aegerion Agreement as modified and supplemented by this letter.  In this letter, “ Affiliate ” has the meaning given to it in the Delaware General Corporation Law, and any other capitalized terms that are not defined in this letter will have the meanings given to them in the Aegerion Agreement.

 



 

2.                                       Responsibilities and Reporting:  As, Chief Financial and Administrative Officer, you will have the duties and responsibilities set out in Section 3(a) of the Aegerion Agreement in respect of Novelion Services.  As described below, under the Master Service Agreement between Novelion Canada and Novelion Services that will be entered into on or about the completion date of the Merger, as amended from time to time (the “ Service Agreement ”) you may also be required to perform services to Novelion Canada and other Affiliates of Novelion Canada, including holding an office in Novelion Canada.  For certainty, you will be an employee of Novelion Services and not an employee of Novelion Canada, and when you provide services to Novelion Canada you will be doing so as an employee of Novelion Services in the context of certain management services it provides to Novelion Canada under the Service Agreement.  You will report to the Chief Executive Officer of Novelion Services.

 

3.                                       Base Salary:  You will be paid the Base Salary reflected in the Aegerion Agreement, subject to adjustment by the Board or Compensation Committee thereof from time to time.

 

4.                                       Length of Service:  Novelion Services will recognize your length of service with Aegerion for all purposes related to your employment with Novelion Services, including for the purpose of determining your entitlements on termination of your employment pursuant to the Aegerion Agreement.

 

5.                                       Accrued Obligations:  Your employment with Aegerion will cease immediately prior to the Commencement Date and Aegerion will be responsible for providing you with all accrued but unpaid Base Salary and unreimbursed expenses incurred in accordance with the Aegerion Agreement up to such date. Aegerion will also be responsible for making the Incentive Payment set out in Section 4(e)(iii) of the Aegerion Agreement and paying any Retention Bonus Amount Aegerion agreed to pay you and that remains unpaid as of the Commencement Date.  Any vacation time that you have accrued under Aegerion’s vacation policy as of the Commencement Date, but not used as of such date, will be “rolled over” to Novelion Services.  Novelion Services will credit you with this time for purposes of its vacation policy.  By accepting this offer, you consent to the rollover of this vacation time and acknowledge and agree that you are not entitled to any payment for this vacation time in connection with the transfer of your employment from Aegerion to Novelion Services.  For certainty, you will continue to be obligated to repay your Relocation Transition Allowance pursuant to Section 6 of the Aegerion Agreement if you resign from employment with Novelion Services other than for Good Reason or are terminated for Cause, and you will pay such amount to Aegerion and/or Novelion Services at the direction of Novelion Services.

 

6.                                       No Severance or Good Reason:   You agree that (a) the transfer of your employment from Aegerion to Novelion Services and any other changes to the terms and conditions of your employment that are expressly contemplated by this letter, and/or (b) any changes to your duties or responsibilities that directly result from the Merger (including without limitation any such changes directly resulting from your new status as an

 

2



 

executive officer of a subsidiary of Novelion Canada) shall not, individually or in the aggregate, constitute Good Reason for purposes of the Aegerion Agreement or the Employment Agreement or entitle you to any Severance Benefits, Accelerated Equity Benefit, Retention Bonus Amount or any other severance benefits or the acceleration of any vesting or other rights, to which you might otherwise be entitled.  You agree that, to the extent required by law to permit Aegerion to rely on this paragraph 6, Novelion Services is and will be deemed to be acting as agent or trustee on behalf of and for the benefit of Aegerion.

 

7.                                       Stock Options / Equity Grants:  Any stock options, restricted stock units, or other equity awards that you may have been granted pursuant to the Inducement Plan or 2010 Stock Option and Incentive Plan will be dealt with as set out in the Merger Agreement.  Once the Merger is completed, any such outstanding entitlements will be governed by and subject to the applicable stock option plan and stock option agreement.

 

8.                                       Right to Work in Canada:   You will cooperate with Novelion Services to seek, obtain, and maintain the right to work in Canada to provide services on behalf of Novelion Services to Novelion Canada and any of its other Affiliates.  Novelion Services will pay the reasonable costs associated with obtaining a permit to work in Canada.

 

9.                                       Commuting to Canada:  You acknowledge that travel will be required in connection with your employment, including commuting on a regular basis to such locations in Canada as are required for Novelion Services to provide its management services to Novelion Canada and its Canadian Affiliates.

 

10.                                Tax Consultation Expenses:  Each year so long as you are providing management services, you will be entitled to reimbursement for your reasonable expenses up to a maximum of USD $5,000 for an independent tax consultation regarding the Canadian tax implications of your work on behalf of Novelion Services in Canada and/or preparation of your Canadian tax return.

 

11.                                Tax Equalization:

 

(a)          As you will be subject to income tax and social security obligations arising from your services performed in Canada on behalf of Novelion Services, Novelion Services is prepared to address the overall tax and social security burden that you experience with the intention that your total tax and social security burden while working in both the United States and Canada will be equal to what your tax and social security burden would have been had you remained working solely in your Equalization State, as defined in subparagraph (b) below. Novelion Services will provide you with tax equalization in connection with all income tax and social security liabilities arising from the performance of your employment duties within Canada. Novelion Services intends that the income taxes and social security levies payable by you on all taxable employment income and related benefits, as prescribed by the applicable tax and social security laws, should be no better or worse than the personal taxes and social security levies you would have been required to pay on such amounts if your

 

3



 

employment duties had been performed solely in your Equalization State. Where your annual tax and social security obligation yields a higher total obligation than if your employment duties were solely performed in your Equalization State, Novelion Services will reimburse you for the difference.  Where your annual tax and social security obligations yields a lower total tax and social security impact than if your employment duties were solely performed in your Equalization State, you will reimburse Novelion Services for the difference.

 

(b)          “Equalization State” means, at your election, either Massachusetts or Rhode Island or in the absence of an election by you within 30 days of the Commencement Date, Novelion Services may choose which of those two states will be your Equalization State.

 

(c)           You will provide all information necessary for the preparation of a tax equalization calculation.

 

(d)          Novelion Services will pay all reasonable costs and professional fees related to calculating this equalization payment, and reserves the discretion to establish the process and criteria for determining the tax equalization calculation. For clarity, the tax equalization payments described in this paragraph 11 will not take into consideration or apply to any taxable income from sources other than your employment with Novelion Services, and you will remain responsible for all income taxes arising from your personal income.

 

(e)           If you establish your primary residence in Canada, Novelion Services’ obligations under this paragraph 11 will cease, provided that there will be a pro-rated adjustment for any partial year.

 

(f)            If your employment is terminated for any of the reasons described under Section 7 of the Aegerion Agreement, then between January 1 and July 31 of the calendar year following the calendar year in which such termination occurs, Novelion Services will pay you any remaining tax equalization payments owed in accordance with this paragraph 11 or, in the event that the reconciliation results in you owing money to Novelion Services, you will make such payment to Novelion Services.

 

12.                                Release:   The form of Release of Claims contemplated in the Aegerion Agreement will be the form attached as Schedule “B” to this Agreement.

 

13.                                Employment Standards:   This provision applies only if and to the extent that the employment laws of Canada apply to your employment.  If the minimum standards in the British Columbia Employment Standards Act or Ontario Employment Standards Act, 2000 , or any other applicable employment standards legislation, as they exist from time to time are more favorable to you in any respect than provided for in the Employment Agreement, including but not limited to the provisions in respect of notice of termination, the provisions of the applicable Employment Standards Act or legislation will apply.

 

4



 

14.                                Confidentiality, Assignment of Intellectual Property and Non-Competition:   As a condition of your employment with Novelion Services, and in consideration of the commitments set forth in this letter, you agree to execute and deliver to Novelion Services the Confidentiality, Assignment of Intellectual Property and Non-Competition Agreement attached as Schedule “C” to this letter (the “ Ancillary Agreement ”), which will take effect on the Commencement Date, following which any references to the “Confidentiality Agreement” in the Aegerion Agreement will be deemed to be references to the Ancillary Agreement. Your acceptance of this offer of employment or execution of the Ancillary Agreement does not affect your obligations to Aegerion or the rights of Aegerion under the Confidentiality Agreement arising from your employment with Aegerion prior to the Commencement Date.

 

15.                                Priority:  If there is any conflict or inconsistency between these Supplementary Terms and the Aegerion Agreement, these Supplementary Terms will take precedence.

 

If the terms and conditions of your employment described in this letter and the terms and conditions of the Ancillary Agreement are acceptable to you, please sign this letter (where indicated on the next page) and the enclosed Ancillary Agreement, and return signed copies of the foregoing to us by November 28, 2016.

 

If you have any questions or concerns, please do not hesitate to contact Geoffrey Cox.

 

[ Remainder of this page intentionally left blank ]

 

5



 

Yours truly,

 

NOVELION SERVICES USA, INC.

 

Per:

/s/ Dr. Geoffrey F. Cox

 

 

Authorized Signatory

 

 

I, Gregory Perry, have read, understand and agree with the terms and conditions of employment referenced in this letter.  I have had a reasonable opportunity to consider these terms and conditions and seek independent legal advice, and I accept employment with Novelion Services on these terms and conditions.

 

/s/ Gregory Perry

 

November 28, 2016

Signature

 

Date

 

Gregory Perry – Employment Agreement

 



 

SCHEDULE “A”

 

AEGERION AGREEMENT

 

[See attached]

 



 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (this “ Agreement ”) is made and entered into as of this 26th day of June 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), and Gregory Perry (the “ Employee ”).

 

W   I   T   N   E   S   S   E   T   H :

 

WHEREAS, the Company desires to employ Employee and to enter into this Agreement embodying the terms of such employment, and Employee desires to enter into this Agreement and to accept such employment, subject to the terms and provisions of this Agreement.

 

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are mutually acknowledged, the Company and Employee hereby agree as follows:

 

Section 1. Definitions.

 

(a) “ Accrued Obligations ” shall mean (i) all accrued but unpaid Base Salary through the Date of Termination, (ii) any unpaid or unreimbursed expenses incurred in accordance with Section 6 hereof, and (iii) any accrued but unused vacation time through the Date of Termination.

 

(b) “ Base Salary ” shall mean the salary provided for in Section 4(a) hereof.

 

(c) “ Board ” shall mean the Board of Directors of the Company.

 

(d) “ Confidentiality Agreement ” shall mean the Company’s Confidentiality, Assignment and Noncompetition Agreement attached hereto as Exhibit A .

 

(e) “ Cause ” shall mean (i) Employee’s failure (except where due to a Disability), neglect, or refusal to perform in any material respect Employee’s duties and responsibilities, (ii) any act of Employee that has, or could reasonably be expected to have, the effect of injuring the business of the Company or its affiliates in any material respect, (iii) Employee’s conviction of, or plea of guilty or no contest to: (x) a felony or (y) any other criminal charge that has, or could be reasonably expected to have, an adverse impact on the performance of Employee’s duties to the Company or otherwise result in material injury to the reputation or business of the Company, (iv) the commission by Employee of an act of fraud or embezzlement against the Company, or any other act that creates or reasonably could create negative or adverse publicity for the Company; (v) any violation by Employee of the policies of the Company, including but not limited to those relating to sexual harassment or business conduct, and those otherwise set forth in the manuals or statements of policy of the Company, (vi) Employee’s violation of federal or state securities laws, or (vii) Employee’s breach of this Agreement or breach of the Confidentiality Agreement.

 

(f) “ Code ” shall mean the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

 

(g) “ Date of Termination ” shall mean the date on which Employee’s employment terminates.

 

(h) “ Disability ” shall mean any physical or mental disability or infirmity of Employee that prevents the performance of Employee’s duties for a period of (i) ninety (90) consecutive days or (ii) one hundred twenty (120) non-consecutive days during any twelve (12) month period. Any question as to the existence, extent, or potentiality of Employee’s Disability upon which Employee and the Company cannot agree shall be determined by a qualified, independent physician selected by the Company and approved by Employee (which approval shall not be unreasonably withheld). The determination of any such physician shall be final and conclusive for all purposes of this Agreement.

 

(i) “ Effective Date ” shall mean July 6, 2015.

 

(j) “ Good Reason ” shall mean, without Employee’s consent, (i) a material diminution in Employee’s duties, or responsibilities, (ii) a material reduction in Base Salary as set forth in Section 4(a) hereof (other than pursuant to an across-the-board reduction applicable to all similarly situated executives), (iii) the relocation of Employee’s principal place of employment more than fifty (50) miles from its current location, or (iv) any other material breach of a provision of this Agreement by the Company (other than a provision that is covered by clause (i), (ii), or (iii) above). Employee acknowledges and agrees that Employee’s exclusive remedy in the event of any breach of this Agreement shall be to assert Good Reason pursuant to the terms and conditions of Section 7(e) hereof. Notwithstanding the foregoing, during the Term, in the event that the Company reasonably believes that Employee may have engaged in conduct that could constitute Cause hereunder, the Company may, in its sole and absolute discretion, suspend Employee from performing Employee’s duties hereunder, and in no event shall any such suspension constitute an event pursuant to which Employee may terminate employment with Good Reason or otherwise constitute a breach hereunder; provided , that no such suspension shall alter the Company’s obligations under this Agreement during such period of suspension.

 

(k) “ Release of Claims ” shall mean a separation agreement in a form acceptable to the Company under which Employee releases the Company from any and all claims and causes of action and the execution of which is a condition precedent to Employee’s eligibility for Severance Benefits in the event his employment is terminated by the Company without Cause or by Employee for Good Reason, as described in Sections 7(d) and 7(e).

 

(l) “ Severance Benefits ” shall mean (i) continued payment of Base Salary during the Severance Term, payable in accordance with the Company’s regular payroll practices, and (ii) subject to the Employee’s timely election of COBRA and copayment of premium amounts at the active employees’ rate, payment of the employer portion of the premiums for the

 



 

Company’s group health and dental program for the Employee in order to allow him to continue to participate in the Company’s group health and dental program until the earlier of (Y) 12 months from the Date of Termination, and (Z) the date the Employee becomes re-employed and eligible for health and/or dental insurance; provided, however , that this subsection (ii) is to be modified, as required, and by mutual agreement of the parties, to comply with the non-discrimination rules and other provisions and requirements of the Patient Protection and Affordable Care Act.

 

(m) “ Severance Term ” shall mean the twelve (12) month period, which commences on the first pay day that is at least thirty-five (35) days from the Date of Termination following termination by the Company without Cause or by Employee for Good Reason.

 

Section 2. Acceptance and Term.

 

The Company agrees to employ Employee on an at-will basis, and Employee agrees to accept such employment and serve the Company, in accordance with the terms and conditions set forth herein. The term of employment (referred to herein as the “ Term ) shall commence on the Effective Date and shall continue until terminated by either party at any time, subject to the provisions herein.

 

Section 3. Position, Duties, and Responsibilities; Place of Performance.

 

(a)  Position, Duties, and Responsibilities . During the Term, Employee shall be employed and serve as Chief Financial Officer of the Company (together with such other position or positions consistent with Employee’s title or as the Company shall specify from time to time) and shall have such duties and responsibilities commensurate therewith, and such other duties as may be assigned and/or prescribed from time to time by the Chief Executive Officer and/or the Board.

 

(b)  Performance . Employee shall devote his full business time, attention, skill, and best efforts to the performance of his duties under this Agreement and shall not engage in any other business or occupation during the Term, including, without limitation, any activity that (x) conflicts with the interests of the Company, (y) interferes with the proper and efficient performance of Employee’s duties for the Company, or (z) interferes with Employee’s exercise of judgment in the Company’s best interests. Notwithstanding the foregoing, nothing herein shall preclude Employee from (i) serving, with the prior written consent of the Board, as a member of the boards of directors or advisory boards (or their equivalents in the case of a non-corporate entity) of non-competing businesses and charitable organizations, (ii) engaging in charitable activities and community affairs, and (iii) managing Employee’s personal investments and affairs; provided , however , that the activities set out in clauses (i), (ii), and (iii) shall be limited by Employee so as not to interfere, individually or in the aggregate, with the performance of Employee’s duties and responsibilities hereunder. Employee represents that he has provided the Company with a comprehensive list of all outside professional activities with which he is currently involved or reasonably expects to become involved. In the event that, during his employment by the Company, the Employee desires to engage in other outside professional activities, not included on such list, Employee will first seek written approval from the CEO or President and such approval shall not be unreasonably withheld.

 

Section 4. Compensation.

 

(a)  Base Salary . In exchange for Employee’s satisfactory performance of his duties and responsibilities, Employee initially shall be paid a semi-monthly Base Salary of $16,250 ($390,000 on an annualized basis), payable in accordance with the regular payroll practices of the Company. All payments in this Agreement are on a gross, pre-tax basis and shall be subject to all applicable federal, state and local withholding, payroll and other taxes.

 

(b)  Bonus . In addition to the Base Salary, Employee will be eligible for the following bonus compensation:

 

(i)  Target Bonus : Employee will be eligible to earn an annual target bonus of up to 45% of his Base Salary (the “ Target Bonus ”), prorated in 2015 to reflect his start date. The actual amount of such bonus, if any, including any overachievement component, will be determined by the Board and Employee’s manager in their sole discretion, based upon Company performance, Employee’s achievement of a series of mutually agreed upon performance milestones, and any other factors that the Board, in its discretion, deem appropriate. Employee’s achievement of such milestones, as well as the amount of any bonus, shall be determined by the Board and Employee’s manager in their sole discretion. For 2015, the individual portion of Employee’s target bonus (20% of eligible pro-rated earnings) shall be guaranteed to be paid in full at target; provided that, if the Company’s executive team, in its entirety, does not receive a 2015 bonus payout, Employee shall not receive any portion of his 2015 bonus target. Typically, bonuses, if any, are paid out no later than March 15 of the year following the applicable bonus year. Employee must be employed by Aegerion at the time of any such bonus payment in order to be eligible for any such payment.

 

(c)  Signing Bonus . In addition to the above bonus, Employee will be eligible to receive a one-time cash sign-on bonus in the amount of $85,000, which will be paid out as soon as practical following the Effective Date. Employee must be employed by Aegerion at the time of the bonus payment in order to be eligible for any such payment. If, prior to the 12-month anniversary of the Effective Date, Employee resigns other than for Good Reason or Aegerion terminates Employee’s employment for Cause, then Employee agrees to repay to Aegerion the net amount of the signing bonus within 30 days of such termination of employment.

 

(d)  Stock Options/Equity Grants . Subject to Board approval, the Company will offer to Employee the option (the “ Option Award ”) to purchase 200,000 shares of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”). The Option Award shall have an exercise price equal to the fair market value of the Common Stock on the date of grant (as determined by the Board or Compensation Committee thereof). The Option Award shall be subject to vesting and shall be issued pursuant to the terms of the Company’s 2010 Stock Option and Incentive Plan (or a successor plan, if any) and subject to the terms of a stock option agreement thereunder (collectively the “ Equity Documents ”). The vesting schedule for Employee’s Option Award will be the vesting schedule outlined in the Equity Documents (i.e., the option to purchase 200,000 shares will vest as follows: 25% of the option subject to the Option Award to vest on the first anniversary of the grant date, with the remaining 75% to vest in equal monthly installments over the three year period thereafter). The full terms and conditions related to these option grants shall be set forth in the Equity Documents and to the extent that there is any inconsistency between this Agreement and the Equity Documents, the Equity Documents shall control.

 



 

Section 5. Employee Benefits.

 

During the Term, Employee shall be eligible to participate in health insurance and other benefits provided generally to similarly situated employees of the Company, subject to the terms and conditions of the applicable benefit plans (which shall govern). Employee also shall be eligible for the same number of holidays and vacation days as well as any other benefits, in each case as are generally allowed to similarly situated employees of the Company in accordance with the Company policy as in effect from time to time. Nothing contained herein shall be construed to limit the Company’s ability to amend, suspend, or terminate any employee benefit plan or policy at any time without providing Employee notice, and the right to do so is expressly reserved.

 

Section 6. Reimbursement of Business Expenses; Relocation and Temporary Living Assistance.

 

During the Term of Employment, the Company shall pay (or promptly reimburse Employee) for documented, out-of-pocket expenses reasonably incurred by Employee in the course of performing his duties and responsibilities hereunder, which are consistent with the Company’s policies in effect from time to time with respect to business expenses, subject to the Company’s requirements with respect to reporting of such expenses.

 

In addition, during a period ending on the earlier of (i) 24 months from the Effective Date or (ii) termination of Employee’s employment, Employee shall be eligible for a relocation transition allowance to cover the following expenses: (a) temporary housing, not to exceed $4,500 per month, for his use towards renting a suitable apartment in the Cambridge, Massachusetts area; and (b) commuting costs to include airfare/train fare not to exceed $250 weekly round trip, and taxi/car services to and from the airport/train station, which comply with the Company’s Global mobility policy (collectively with (a), the “ Relocation Transition Allowance ”); and (c) a “gross-up” payment in the amount necessary to offset the tax liability associated with the Relocation Transition Allowance outlined in (a) and (b); provided, that (x) Employee shall submit expense reports with supporting documentation in such form and containing such information as the Company may request to be reimbursed for all Relocation Transition Allowance expenses, and (y) if, prior to the 12-month anniversary of the payment of any Relocation Transition Allowance, the Employee resigns other than for Good Reason or the Company terminates the Employee’s employment for cause, the Employee shall repay to the Company the appropriate pro-rated amount of such Relocation Transition Allowance within 30 days of such termination of employment. For the avoidance of doubt, Employee’s eligibility for any Relocation Transition Allowance shall terminate on July 6, 2017.

 

Section 7. Termination of Employment.

 

(a)  General . Employee’s employment with the Company shall terminate upon the earliest to occur of: (i) Employee’s death, (ii) a termination by reason of a Disability, (iii) a termination by the Company with or without Cause, and (iv) a termination by Employee with or without Good Reason. Notwithstanding anything herein to the contrary, the payment (or commencement of a series of payments) hereunder of any nonqualified deferred compensation (within the meaning of Section 409A of the Code) upon a termination of employment shall be delayed until such time as Employee has also undergone a “separation from service” as defined in Treas. Reg. 1.409A-1(h), at which time such nonqualified deferred compensation (calculated as of the date of Employee’s termination of employment hereunder) shall be paid (or commence to be paid) to Employee on the schedule set forth in this Section 7 as if Employee had undergone such termination of employment (under the same circumstances) on the date of Employee’s ultimate “separation from service.”

 

(b)  Termination Due to Death or Disability . Employee’s employment under this Agreement shall terminate automatically upon Employee’s death. The Company also may terminate Employee’s employment immediately upon the occurrence of a Disability, such termination to be effective upon Employee’s receipt of written notice of such termination. In the event of Employee’s termination as a result of Employee’s death or Disability, Employee or Employee’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations, and Employee shall have no further rights to any compensation or any other benefits under this Agreement.

 

(c)  Termination by the Company with Cause .

 

(i) The Company may terminate Employee’s employment at any time with Cause, effective upon Employee’s receipt of written notice of such termination; provided , however , that with respect to any Cause termination relying on clause (i) or (ii) of the definition of Cause set forth in Section 1(d) hereof, to the extent that such act or acts or failure or failures to act are curable, Employee shall be given ten (10) days’ written notice by the Company of its intention to terminate him with Cause, such notice to state the act or acts or failure or failures to act that constitute the grounds on which the proposed termination with Cause is based, and such termination shall be effective at the expiration of such ten (10) day notice period unless Employee has fully cured such act or acts or failure or failures to act, to the Company’s complete satisfaction, that give rise to Cause during such period.

 

(ii) In the event that the Company terminates Employee’s employment with Cause, Employee shall be entitled only to the Accrued Obligations. Following such termination of Employee’s employment with Cause, except as set forth in this Section 7(c)(ii), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company with Cause shall be receipt of the Accrued Obligations.

 

(d)  Termination by the Company without Cause . The Company may terminate Employee’s employment at any time without Cause, effective upon Employee’s receipt of written notice of such termination. In the event that Employee’s employment is terminated by the Company without Cause (other than due to death or Disability) and provided that he fully executes an effective Release of Claims as described in Section 7(g), Employee shall be eligible for:

 

(i) The Accrued Obligations;

 

(ii) The Severance Benefits; and

 

(iii) Acceleration of the vesting of 100% of Employee’s then outstanding unvested equity awards, such that all unvested equity awards vest and become fully exercisable or non-forfeitable as of the Date of Termination; provided that such termination without Cause and the Date of Termination occurs within eighteen (18) months after a Sale Event (the “ Accelerated Equity Benefit ”), in which case Employee shall have ninety (90) days from the Date of Termination to

 



 

exercise the vested equity awards.

 

Notwithstanding the foregoing, the Severance Benefits shall immediately terminate, and the Company shall have no further obligations to Employee with respect thereto, in the event that Employee breaches any provision of the Confidentiality Agreement or the Release of Claims. Any such termination of payment or benefits shall have no effect on the Release of Claims or any of Employee’s post-employment obligations to the Company. Following such termination of Employee’s employment by the Company without Cause, except as set forth in this Section 7(d), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, and the Accrued Obligations.

 

In addition, the Severance Benefit set forth in Section 1(l)(i) shall be reduced dollar for dollar by any compensation Employee receives from another employer during the Severance Term. Employee agrees to give prompt notice of any employment during the Severance term and promptly shall respond to any reasonable inquiries concerning his professional activities. If the Company makes overpayments of Severance Benefits, Employee promptly shall return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts. The foregoing shall not create any obligation on the Employee’s part to seek re-employment after the Date of Termination.

 

(e)  Termination by Employee with Good Reason . Employee may terminate his employment with Good Reason by providing the Company thirty (30) days’ written notice setting forth in reasonable specificity the event that constitutes Good Reason, which written notice, to be effective, must be provided to the Company within sixty (60) days of the occurrence of such event. During such thirty (30) day notice period, the Company shall have a cure right (if curable), and if not cured within such period, Employee’s termination will be effective upon the expiration of such cure period, and Employee shall be entitled to the same payments and benefits as provided in Section 7(d) hereof for a termination by the Company without Cause, subject to the same conditions on payment and benefits as described in Section 7(d) hereof. Following such termination of Employee’s employment by Employee with Good Reason, except as set forth in this Section 7(e), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, and the Accrued Obligations.

 

(f)  Termination by Employee without Good Reason . Employee may terminate his employment without Good Reason by providing the Company thirty (30) days’ written notice of such termination. In the event of a termination of employment by Employee under this Section 7(f), Employee shall be entitled only to the Accrued Obligations. In the event of termination of Employee’s employment under this Section 7(f), the Company may, in its sole and absolute discretion, by written notice accelerate such date of termination without changing the characterization of such termination as a termination by Employee without Good Reason. Following such termination of Employee’s employment by Employee without Good Reason, except as set forth in this Section 7(f), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by Employee without Good Reason shall be receipt of the Accrued Obligations.

 

(g)  Release . Notwithstanding any provision herein to the contrary, the payment of the Severance Benefits pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Employee’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims) in accordance with the time limits set forth therein. If Employee fails to execute the Release of Claims in such a timely manner, or timely revokes Employee’s acceptance of such release following its execution, Employee shall not be entitled to any of the Severance Benefits. Further, to the extent that any of the Severance Benefits constitutes “nonqualified deferred compensation” for purposes of Section 409A of the Code, any payment of any amount or provision of any benefit otherwise scheduled to occur prior to the thirty-fifth (35 th ) day following the date of Employee’s termination of employment hereunder, but for the condition on executing the Release of Claims as set forth herein, shall not be made until the first regularly scheduled payroll date following such thirty-fifth (35 th ) day, after which any remaining Severance Benefits shall thereafter be provided to Employee according to the applicable schedule set forth herein.

 

Section 8. Confidentiality Agreement; Cooperation.

 

(a)  Confidentiality Agreement . As a condition of Employee’s employment with the Company under the terms of this Agreement, Employee shall execute and deliver to the Company the Confidentiality Agreement, in the form attached hereto as Exhibit A. The parties hereto acknowledge and agree that this Agreement and the Confidentiality Agreement shall be considered separate contracts. In addition, Employee represents and warrants that he shall be able to and will perform the duties of this position without utilizing any confidential and/or proprietary information that Employee may have obtained in connection with employment with any prior employer, and that he shall not (i) disclose any such information to Aegerion, or (ii) induce any Aegerion employee to use any such information, in either case in violation of any confidentiality obligation, whether by agreement or otherwise.

 

(b)  Litigation and Regulatory Cooperation . During and after Employee’s employment, Employee shall cooperate fully with the Company in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Company employed Employee, provided, that the Employee will not have an obligation under this paragraph with respect to any claim in which the Employee has filed directly against the Company or related persons or entities. The Employee’s full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after Employee’s employment, Employee also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while Employee was employed by the Company, provided Employee will not have any obligation under this paragraph with respect to any claim in which Employee has filed directly against the Company or related persons or entities. The Company shall reimburse Employee for any reasonable out-of-pocket expenses incurred in connection with Employee’s performance of obligations pursuant to this Section 8(b).

 



 

Section 9. Taxes.

 

The Company may withhold from any payments made under this Agreement all applicable taxes, including but not limited to income, employment, and social insurance taxes, as shall be required by law. Employee acknowledges and represents that the Company has not provided any tax advice to him in connection with this Agreement and that Employee has been advised by the Company to seek tax advice from Employee’s own tax advisors regarding this Agreement and payments that may be made to him pursuant to this Agreement, including specifically, the application of the provisions of Section 409A of the Code to such payments. The Company shall have no liability to Employee or to any other person if any of the provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section.

 

Section 10. Additional Section 409A Provisions.

 

Notwithstanding any provision in this Agreement to the contrary:

 

(a) If at the time of the Employee’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Employee is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Employee becomes entitled to under this Agreement on account of the Employee’s separation from service would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six months and one day after the Employee’s separation from service, or (ii) the Employee’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

 

(b) Each payment in a series of payments hereunder shall be deemed to be a separate payment for purposes of Section 409A of the Code. Neither the Company nor Employee shall have the right to accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section 409A.

 

(c) To the extent that any right to reimbursement of expenses or payment of any benefit in-kind under this Agreement constitutes nonqualified deferred compensation (within the meaning of Section 409A of the Code), (i) any such expense reimbursement shall be made by the Company no later than the last day of the taxable year following the taxable year in which such expense was incurred by Employee, (ii) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (iii) the amount of expenses eligible for reimbursement or in-kind benefits provided during any taxable year shall not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other taxable year; provided , that the foregoing clause shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect.

 

(d) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Employee’s termination of employment, then such payments or benefits shall be payable only upon the Employee’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

 

(e) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. While the payments and benefits provided hereunder are intended to be structured in a manner to avoid the implication of any penalty taxes under Section 409A of the Code, in no event whatsoever shall the Company or any of its affiliates be liable for any additional tax, interest, or penalties that may be imposed on Employee as a result of Section 409A of the Code or any damages for failing to comply with Section 409A of the Code (other than for withholding obligations or other obligations applicable to employers, if any, under Section 409A of the Code).

 

Section 11. Successors and Assigns.

 

(a)  The Company . This Agreement shall inure to the benefit of the Company and its respective successors and assigns. This Agreement may be assigned by the Company without Employee’s prior consent.

 

(b)  Employee . Employee’s rights and obligations under this Agreement shall not be transferable by Employee by assignment or otherwise, without the prior written consent of the Company; provided , however , that if Employee shall die, all amounts then payable to Employee hereunder shall be paid in accordance with the terms of this Agreement to Employee’s devisee, legatee, or other designee, or if there be no such designee, to Employee’s estate.

 

Section 12. Waiver and Amendments.

 

Any waiver, alteration, amendment, or modification of any of the terms of this Agreement shall be valid only if made in writing and signed by each of the parties hereto; provided , however , that any such waiver, alteration, amendment, or modification must be consented to on the Company’s behalf by the Board. No waiver by either of the parties hereto of their rights hereunder shall be deemed to constitute a waiver with respect to any subsequent occurrences or transactions hereunder unless such waiver specifically states that it is to be construed as a continuing waiver.

 

Section 13. Severability.

 

If any covenants or such other provisions of this Agreement are found to be invalid or unenforceable by a final determination of a court of competent jurisdiction, (a) the remaining terms and provisions hereof shall be unimpaired, and (b)

 



 

the invalid or unenforceable term or provision hereof shall be deemed replaced by a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision hereof.

 

Section 14. Governing Law and Jurisdiction.

 

This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts without giving effect to the conflict of laws principles of such state. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit. To the extent that any court action is initiated to enforce this Agreement, the parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, Employee (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

 

Section 15. Notices.

 

(a)  Place of Delivery . Every notice or other communication relating to this Agreement shall be in writing, and shall be mailed to or delivered to the party for whom or which it is intended at such address as may from time to time be designated by it in a notice mailed or delivered to the other party as herein provided; provided , that unless and until some other address be so designated, all notices and communications by Employee to the Company shall be mailed or delivered to the Company at its principal executive office, and all notices and communications by the Company to Employee may be given to Employee personally or may be mailed to Employee at Employee’s last known address, as reflected in the Company’s records.

 

(b)  Date of Delivery . Any notice so addressed shall be deemed to be given or received (i) if delivered by hand, on the date of such delivery, (ii) if mailed by courier or by overnight mail, on the first business day following the date of such mailing, and (iii) if mailed by registered or certified mail, on the third business day after the date of such mailing.

 

Section 16. Section Headings.

 

The headings of the sections and subsections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part thereof or affect the meaning or interpretation of this Agreement or of any term or provision hereof.

 

Section 17. Entire Agreement.

 

This Agreement, together with the Confidentiality Agreement attached hereto and the Equity Documents, constitutes the entire understanding and agreement of the parties hereto regarding the employment of Employee. This Agreement supersedes all prior negotiations, discussions, correspondence, communications, understandings, and agreements between the parties (including any offer letter given to Employee) relating to the subject matter of this Agreement; provided however, that Employee remains subject to those conditions set forth in the offer letter regarding completion of an employment application and background and/or reference checks to the Company’s satisfaction, in addition to executing those forms necessary for the processing of such background check.

 

Section 18. Survival of Operative Sections.

 

Upon any termination of Employee’s employment, the provisions of Section 7 through Section 19 of this Agreement (together with any related definitions set forth in Section 1 hereof) shall survive to the extent necessary to give effect to the provisions thereof.

 

Section 19. Counterparts.

 

This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Agreement may be by actual or facsimile signature.

 

Section 20. Gender Neutral.

 

Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.

 

 

AEGERION PHARMACEUTICALS, INC.

 

 

 

 

/s/ Mary Weger

 

By:

Mary Weger

 

Title:

Chief Performance Officer

 

 

 

EMPLOYEE

 

 

 

/s/ Gregory Perry

 

Gregory Perry

 



 

AMENDMENT NO.  1 TO EMPLOYMENT AGREEMENT

 

This Amendment No. 1 to Employment Agreement (this “ Amendment ”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), and Gregory Perry (the “ Employee ”).

 

WHEREAS, Employee and Company are parties to that certain Employment Agreement, dated as of June 26, 2015 (the “ Employment Agreement ); and

 

WHEREAS, Employee and Company have agreed to amend certain provisions of the Employment Agreement;

 

NOW, THEREFORE, in consideration of the mutual promises set forth herein, Company and Employee agree as follows:

 

1.                                       The following new definition shall be added to the Employment Agreement:

 

Retention Bonus Amount ” shall mean any cash retention bonus awarded prior to the Date of Termination.

 

2.                                       The final sentence of Section 7(b) of the Employment Agreement (entitled “Termination Due to Death or Disability”) shall be deleted in its entirety and replaced with the following:

 

“In the event of Employee’s termination as a result of Employee’s death or Disability, Employee or Employee’s estate or beneficiaries, as the case may be, shall be entitled only to the Accrued Obligations and the Retention Bonus Amount, and Employee shall have no further rights to any compensation or any other benefits under this Agreement.”

 


 

3.                                       Section 7(d) of the Employment Agreement (entitled “Termination by the Company without Cause”) shall be deleted in its entirety and replaced with the following:

 

“(d)                            Termination by the Company without Cause. The Company may terminate Employee’s employment at any time without Cause, effective upon Employee’s receipt of written notice of such termination. In the event that Employee’s employment is terminated by the Company without Cause (other than due to death or Disability) and provided that he fully executes and does not revoke an effective Release of Claims as described in Section 7(g), Employee shall be eligible for:

 

(i)                                      The Accrued Obligations;

 

(ii)                                   The Severance Benefits;

 

(iii)                                At the end of the Severance Term, the Retention Bonus Amount; and

 

(iv)                               If such termination without Cause and the Date of Termination occur within eighteen (18) months after a Sale Event (as such term is defined in the Company’s 2010 Stock Option and Incentive Plan), acceleration of the vesting of 100% of Employee’s then outstanding unvested equity awards, such that all unvested equity awards vest and become fully exercisable or non-forfeitable as of the Date of Termination (the “ Accelerated Equity Benefit ”), in which case Employee shall have ninety (90) days from the Date of Termination to exercise the vested equity awards.

 

Notwithstanding the foregoing, the Severance Benefits shall immediately terminate, and the Company shall have no further obligations to Employee with respect thereto, in the event that Employee breaches any provision of the Confidentiality Agreement or the Release of Claims. Any such termination of payment or benefits shall have no effect on the Release of Claims or any of Employee’s post-employment obligations to the Company. Following such termination of Employee’s employment by the Company without Cause, except as set forth in this Section 7(d), Employee shall have no further rights to any compensation or any other benefits under this Agreement. For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment by the Company without Cause shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims.

 

If the Company makes overpayments of Severance Benefits, Employee promptly shall return any such overpayments to the Company and/or hereby authorizes deductions from future Severance Benefit amounts.”

 


 

4.                                       The final sentence of Section 7(e) of the Employment Agreement (entitled “Termination by Employee with Good Reason”) shall be deleted in its entirety and replaced with the following:

 

“For the avoidance of doubt, Employee’s sole and exclusive remedy upon a termination of employment with Good Reason shall be receipt of (i) the Severance Benefits (and, in the case of such a termination within eighteen (18) months after a Sale Event, the Accelerated Equity Benefit), subject to his execution of the Release of Claims, (ii) the Accrued Obligations, and (iii) at the end of the Severance Term, the Retention Bonus Amount, subject to his execution of the Release of Claims.”

 

5.                                       The first sentence of Section 7(g) of the Employment Agreement (entitled “Release”) shall be deleted in its entirety and replaced with the following:

 

“Notwithstanding any provision herein to the contrary, the payment of the Severance Benefits and the Retention Bonus Amount pursuant to subsection (d) or (e) of this Section 7 (other than the Accrued Obligations) shall be conditioned upon Employee’s execution, delivery to the Company, and non-revocation of the Release of Claims (and the expiration of any revocation period contained in such Release of Claims) in accordance with the time limits set forth therein.”

 

6.                                     Other Provisions . The Employment Agreement, as modified by this Amendment, shall remain in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The execution of this Amendment may be by actual or facsimile signature.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 


 

IN WITNESS WHEREOF, the undersigned have executed this Amendment No. 1 to Employment Agreement as a sealed instrument as of the date first above written.

 

AEGERION PHARMACEUTICALS, INC.

 

EMPLOYEE

 

 

 

/s/ Mary Weger

 

/s/ Gregory Perry

By:

Mary Weger

 

Gregory Perry

Title:

Chief Performance Officer

 

Title:

Chief Financial Officer

 


 

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

 

This Amendment No. 2 to Employment Agreement (the “ Second Amendment ”) is made and entered into as of May 3, 2016 by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”) and Gregory Perry (the “ Employee ”), and effective as of February 12, 2016. Capitalized terms not defined in this Second Amendment will have the meanings ascribed to them in the Employment Agreement (as defined below).

 

RECITALS

 

WHEREAS, Employee and the Company entered into that certain Employment Agreement dated as of June 26, 2015, as amended November 5, 2015 (together, the “ Employment Agreement ”), which addresses the terms and conditions of Employee’s employment;

 

WHEREAS, Employee and the Company have agreed to further amend certain provisions of the Employment Agreement; and

 

WHEREAS, Employee and the Company each acknowledge and reaffirm their obligations under the Employment Agreement, as amended by this Second Amendment.

 

NOW, THEREFORE, in consideration of the foregoing premises and of the mutual covenants, terms, provisions, and conditions set forth herein, Employee and the Company hereby agree as follows:

 

1. Position .   Section 3(a) of the Employment Agreement is hereby amended by deleting the reference to “Chief Financial Officer” and inserting “Chief Financial and Administration Officer” in its place.

 

2. Base Salary Section 4(a) of the Employment Agreement is hereby amended by deleting the reference to “$16,250 ($390,000)” and inserting “Eighteen Thousand Seven Hundred and Fifty Dollars ($18,750) (Four Hundred Fifty Thousand Dollars ($450,000) on an annualized basis)” in its place.

 

3. Target Bonus .  Section 4(b)(i) of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

 

Employee will be eligible to earn an annual target bonus of up to fifty percent (50%) of his Base Salary (the “ Target Bonus ”).  The actual amount of such bonus, if any, including any overachievement component, will be determined by the Board and Employee’s manager in their sole discretion, based upon Company performance and any other factors that the Board, in its discretion, deems appropriate. Typically, bonuses, if any, are paid out no later than March 15 of the year following the applicable bonus year.  Employee must be employed by the Company at the time of any such bonus payment in order to be eligible to receive any such payment.

 


 

4. Incentive Payments .  Section 4 of the Employment Agreement is hereby amended by adding the following the new Section 4(e):

 

(e) Incentive Payments .  In addition to the Target Bonus, Employee is eligible to receive a series of incentive payments as set forth in clauses (i) through (iv) below (each, an “ Incentive Payment ” and together, the “ Incentive Payments ”); provided, however , that if a Sale Event (as defined in the Company’s 2010 Stock Option and Incentive Plan) occurs prior to December 31, 2016, any unpaid Incentive Payments will become earned upon the closing of a Sale Event and will be paid to Employee within thirty (30) days of the closing of the Sale Event, regardless of whether the underlying performance goals have been met. To be eligible to be paid any Incentive Payment, Employee must remain continuously employed by the Company through the date that the payment is earned.  In the event Employee remains continuously employed through such earned date(s), he shall be paid such Incentive Payment(s) at the date(s) described herein, regardless of whether Employee’s employment terminates after the earned date but before the payment date, and regardless of the timing or reason for such termination.

 

(i) Resolution of Regulatory Litigation. If there is public disclosure by the Company of an agreement in principle to resolve the U.S. Department of Justice and the Securities and Exchange Commission investigations on or before December 31, 2016, the Employee will be deemed to have earned as of the date of such public disclosure an Incentive Payment in the amount of $250,000, which the Company shall pay to Employee within thirty (30) days following the date of such public disclosure.

 

(ii) Reconfiguration. If, on or before February 28, 2016, Employee satisfactorily completes the reconfiguration of the Company (which will include without limitation an expansion of current responsibilities for coordination of supply chain and program management), as determined by the Board in its sole discretion, the Company will pay Employee an Incentive Payment in the amount of $100,000 within thirty (30) days following the public announcement of such reconfiguration.

 

(iii) Business Development. If, on or before December 31, 2016, the Company completes a business development deal resulting in the Company’s access to a new product or portfolio of products, the Employee will be deemed to have earned as of the date of such deal closing an Incentive Payment in the amount of $100,000, which the Company shall pay to Employee within thirty (30) days following the closing of any such deal.

 

(iv) Satisfactory/Timely Completion of Audit and 10-K Filing . If the Company’s financial audit in respect of fiscal year 2015 is completed and the Company’s 10-K is filed on or prior to March 15, 2016, the Company will pay Employee an Incentive Payment in the amount of $85,000 within thirty (30) days following the filing of the 10-K.

 

2


 

5. Miscellaneous .  Except as expressly amended herein, the Employment Agreement will continue in full force and effect in accordance with its original terms.  This Second Amendment may not be modified or amended, and no breach will be deemed to be waived, unless agreed to in writing by Employee and a duly authorized designee of the Company.  The headings and captions in this Second Amendment are for convenience only and in no way define or describe the scope or content of any provision of this Second Amendment.  This Second Amendment is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts without giving effect to any conflict of laws principles that would result in the application of the laws of any other jurisdiction. This Second Amendment may be executed in one or more counterparts, each of which will be an original and all of which together will constitute one and the same instrument.

 

[Remainder of page intentionally left blank.]

 

3


 

IN WITNESS WHEREOF, this Second Amendment has been executed by the Company, by its duly authorized representative, and by Employee, as of the date first written above.

 

AEGERION PHARMACEUTICALS, INC.

 

 

 

 

By:

/s/ Mary Szela

 

Name: Mary Szela

 

Title: Chief Executive Officer

 

 

 

 

 

Accepted and Agreed:

 

 

 

 

 

/s/ Gregory Perry

 

Gregory Perry

 

 

Signature Page to Second Amendment to G. Perry Employment Agreement

 

 


 

SCHEDULE “B”

 

GENERAL RELEASE AND WAIVER OF CLAIMS

 

In exchange for the severance benefits to be provided to me under the employment agreement between me and Novelion Services USA, Inc. (“Novelion Services”), dated as of November 28, 2016 (the “Employment Agreement”), to which I would not otherwise be entitled, on my own behalf and that of my heirs, executors, administrators, beneficiaries, personal representatives and assigns, I agree that this General Release and Waiver of Claims (the “Release of Claims”) shall be in complete and final settlement of any and all causes of action, rights and claims, whether known or unknown, accrued or unaccrued, contingent or otherwise, that I have had in the past, now have, or might now have, in any way related to, connected with or arising out of my employment or its termination, under the Employment Agreement, or pursuant to Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, the Worker Adjustment and Retraining Notification Act, the Employee Retirement Income Security Act, the wage and hour, wage payment and fair employment practices laws and statutes of the Commonwealth of Massachusetts (each as amended from time to time), and/or any other federal, state or local law, regulation or other requirement and, if the employment laws of Canada apply to my employment, the Ontario and British Columbia Employment Standards Acts, the Ontario and British Columbia Human Rights Codes, and any other applicable Canadian or provincial law, regulation or other requirement (each as amended from time to time) (collectively, the “Claims”), and I hereby release and forever discharge Novelion Services, its Affiliates (as defined in the Employment Agreement, and including for certainty and without limitation QLT Inc. and Aegerion Pharmaceuticals, Inc.), and all of their respective past, present and future directors, shareholders, officers, members, managers, general and limited partners, employees, employee benefit plans, administrators, trustees, agents, representatives, successors and assigns, and all others connected with any of them (the “Releasees”), both individually and in their official capacities, from, and I hereby waive, any and all such Claims. This release shall not apply to (a) any claims that arise after I sign this Release of Claims, including my right to enforce the terms of this Release of Claims; (b) any claims that may not be waived pursuant to applicable law; (c) any right to indemnification that I may have under the certificate of incorporation or by-laws of Novelion Services, and any indemnification agreement between me and Novelion Services or any insurance policies maintained by Novelion Services; or (d) any right to receive any vested benefits under the terms of any employee benefit plans and my award agreements thereunder.

 

I agree that the Releasees have satisfied all obligations to me under the legislation referred to in the previous paragraph in relation to my employment and the cessation of my employment, and I have considered any and all human rights complaints, concerns, or issues arising out of or in respect to my employment with Novelion Services, I am aware of my rights under the legislation referred to in the previous paragraph, and I confirm that I am not asserting such rights or advancing a human rights claim or complaint against the Releasees.

 

Nothing contained in this Release of Claims shall be construed to prohibit me from filing a charge with or participating in any investigation or proceeding conducted by the federal Equal Employment Opportunity Commission or a comparable state or local agency, provided, however, that I hereby agree to waive my right to recover monetary damages or other individual relief in any charge, complaint or lawsuit filed by me or by anyone else on my behalf.

 



 

In signing this Release of Claims, I acknowledge my understanding that I may consider the terms of this Release of Claims for up to [twenty-one (21) /forty-five (45)] 1  days from the date I receive it and that I may not sign this Release of Claims until after the date my employment with Novelion Services terminates. I also acknowledge that I am hereby advised by Novelion Services to seek the advice of an attorney prior to signing this Release of Claims; that I have had sufficient time to consider this Release of Claims and to consult with an attorney, if I wished to do so, or to consult with any other person of my choosing before signing; and that I am signing this Release of Claims voluntarily and with a full understanding of its terms.

 

I further acknowledge that, in signing this Release of Claims, I have not relied on any promises or representations, express or implied, that are not set forth expressly in the Release of Claims. I understand that I may revoke this Release of Claims at any time within seven (7) days of the date of my signing by written notice to the Board of Directors of Novelion Services and that this Release of Claims will take effect only upon the expiration of such seven-day revocation period and only if I have not timely revoked it.

 

Intending to be legally bound, I have signed this Release of Claims under seal as of the date written below.

 

 

Signature:

 

 

 

 

 

 

 

 

 

 

 

Name:    Gregory Perry

 

 

 

 

 

 

 

 

 

 

 

Date Signed:

 

 

 

 


1   To be determined by Novelion Services at the time of termination.

 



 

SCHEDULE “C”

 

CONFIDENTIALITY, ASSIGNMENT OF INTELLECTUAL PROPERTY AND NON-COMPETITION AGREEMENT

 

[See attached]

 



 

NOVELION SERVICES USA, INC.

 

Employee Confidentiality, Assignment of Intellectual Property and Non-Competition Agreement

 

In consideration and as a condition of my employment or continued employment by Novelion Services USA, Inc. (the “Company”), I agree as follows:

 

1.                                       Employee Acknowledgements .  I acknowledge that I will be provided, and/or have been provided, with trade secrets and/or valuable confidential business information belonging to the Company and/or its Affiliates (as defined in paragraph 19), and have developed and/or will develop substantial relationships with prospective and existing customers and clients of the Company and its Affiliates, and, as a result, shall benefit from the good will of the Company and its Affiliates. I also acknowledge that the Company and its Affiliates have invested substantial resources in the development of their trade secrets, confidential business information, client relationships and good will and in recruiting, hiring and training their professionals and staff. I further acknowledge that I have received and/or will receive substantial training from the Company and its Affiliates. I hereby acknowledge and agree that the Company and its Affiliates have a legitimate interest in protecting their substantial investment in their development of trade secrets, confidential information, good will and a highly trained staff and that the covenants to which I agree to be bound herein are necessary to protect such legitimate interests.

 

2.                                       Proprietary Information .  I agree that all information, whether or not in writing, concerning the business, technology, business relationships or financial affairs of the Company and its Affiliates which the Company (or applicable Affiliate) has not released to the general public (collectively, “Proprietary Information”) is and will be the exclusive property of the Company (or applicable Affiliate). By way of illustration, Proprietary Information may include information or material which has not been made generally available to the public, such as: (a) corporate information, including plans, strategies, methods, policies, resolutions, negotiations or litigation; (b) marketing information, including strategies, methods, customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists; and (d) operational and technological information, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas, discoveries, inventions, improvements, concepts and ideas; and (e) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation structure, performance evaluations and termination arrangements or documents. Proprietary Information also includes information received in confidence by the Company or its Affiliates from customers or suppliers or other third parties.

 

3.                                       Recognition of Company’s Rights . I will not, at any time, without the Company’s prior written permission, either during or after my employment, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of my duties as an employee of the Company. I will cooperate with the Company and its Affiliates and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all copies of Proprietary Information in my possession or control upon the earlier of a request by the Company or termination of my employment.

 

4.                                       Rights of Others .  I understand that the Company and its Affiliates are now and may hereafter be subject to nondisclosure or confidentiality agreements with third persons which require the Company (or applicable Affiliate) to protect or refrain from use of proprietary information. I agree to be bound by the terms of such agreements in the event I have access to such proprietary information.

 

5.                                       Commitment to Company: Avoidance of Conflict of Interest . While an employee of the Company, I will devote my full-time efforts to the Company’s business and I will not engage in any other business activity that conflicts with my duties to the Company (including the services the Company provides to its Affiliates). I will advise the Chief Executive Officer of the Company at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee of the Company. I will take whatever action is requested of me by the Company to resolve any conflict or appearance of conflict which it finds to exist.

 

6.                                       Developments . I will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship, whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction during the period of my employment (collectively, the “Developments”). I acknowledge that all work performed by me is on a “work for hire” basis, and I

 



 

hereby do assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company (or any Affiliate designated by the Company) and its successors and assigns all my right, title and interest in all Developments that: (a) relate to the business of the Company or its Affiliates or any customer of the Company or its Affiliates or any of the products or services being researched, developed, manufactured or sold by the Company or its Affiliates or which may be used with such products or services; or (b) result from tasks assigned to me by the Company; or (c) result and/or are developed during or after my employment from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company or its Affiliates (collectively, “Company-Related Developments”), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (“Intellectual Property Rights”).

 

To preclude any possible uncertainty, I have set forth on Exhibit A attached hereto a complete list of Developments that I have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of my employment with the Company that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (“Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. I have also listed on Exhibit A all patents and patent applications in which I am named as an inventor, other than those which have been assigned to the Company (“Other Patent Rights”). If no such disclosure is attached, I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company or Affiliate product, process or machine or other work done for the Company or an Affiliate, I hereby grant to the Company (or any Affiliate designated by the Company) a nonexclusive, royalty-free, paid-up, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use, sell, offer for sale and import such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company’s prior written consent.

 

This Agreement does not obligate me to assign to the Company of any of its Affiliates any Development which, in the sole judgment of the Company, reasonably exercised, is developed entirely on my own time and does not relate to the business efforts or research and development efforts in which, during the period of my employment, the Company or its Affiliates actually are engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company or its Affiliates. However, I will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion. I understand that to the extent this Agreement is required to be construed in accordance with the laws of any jurisdiction which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this paragraph 6 will be interpreted not to apply to any invention which a court rules and/or the Company agrees, falls within such classes. I also hereby waive all claims to any moral rights or other special rights which may have or accrue in any Company-Related Developments or Intellectual Property Rights.

 

7.                                       Documents and Other Materials .  I will keep and maintain adequate and current records of: (a) all Proprietary Information and Company-Related Developments developed by me during my employment; and (b) all documentation regarding any Intellectual Property Rights, which relate to such Proprietary Information and Company-Related Developments. Such records will be available to and remain the sole property of the Company (or applicable Affiliate of the Company) at all times.

 

All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, or other written, photographic or other tangible material containing Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company (or applicable Affiliate) to be used by me only in the performance of my duties for the Company. Any property situated on the premises of the Company or its Affiliates, owned or purchased by the Company or its Affiliates, disseminated by the Company or its Affiliates, and/or used or created by me for business purposes in the course of my duties for the Company, including without limitation computers, email accounts, cell phone records and text messages, disks and other storage media, filing cabinets or other work areas, is the property of the Company (or, if applicable, an Affiliate) and is subject to inspection by the Company at any time with or without notice. In the event of the termination of my employment for any reason, I will deliver to the Company all Company and Affiliate property, including, without limitation, all Proprietary Information, all documents related to Company-Related Developments, all computers, keys, passwords, cell phones, entry cards, files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, or other written,

 

2



 

photographic or other tangible material, and will not take or keep in my possession any Company or Affiliate property or any copies (electronic or hard-copy) of such property.

 

8.                                       Enforcement of Intellectual Property .  I will cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights in Company-Related Developments. I will sign, both during and after the term of this Agreement, all papers, including without limitation copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its (or any Affiliate’s) rights and interests in any Company-Related Development. If the Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and appoint each officer of the Company as my agent and attorney-in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its (or any Affiliate’s) rights and interests in any Company-Related Development.

 

9.                                       Non-Competition and Non-Solicitation . In order to protect the Proprietary Information and good will of the Company and its Affiliates, during my employment and for a period of twelve (12) months following the termination of my employment for any reason (the “Restricted Period”), I will not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the world that develops, manufactures or markets any products, or performs any services, that are competitive (directly or indirectly) with the products or services of the Company or its Affiliates, or products or services that the Company or its Affiliates have under development or that are the subject of active planning at any time during the last 24 months of my employment; provided that this shall not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company. In addition, during the Restricted Period, I will not, directly or indirectly, in any manner, for any purpose that is competitive with or detrimental to the business of the Company or an Affiliate, (a) call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or its Affiliates, or any suppliers thereof, and/or (b) solicit, entice, or attempt to persuade any other employee or consultant of the Company or an Affiliate to leave the Company or Affiliate for any reason. I acknowledge and agree that if I violate any of the provisions of this paragraph 9, the running of the Restricted Period will be extended by the time during which I engage in such violation(s).

 

10.                                Government Contracts .  I acknowledge that the Company and/or its Affiliates may have from time to time agreements with other persons or governmental authorities which impose obligations or restrictions on the Company and/or its Affiliates regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under paragraph 6, I also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be held by the particular governmental authority under any contract between the Company and the given governmental authority.

 

11.                                Prior Agreements .  I hereby represent that, except as I have fully disclosed previously in writing to the Company, I am not bound by the terms of any agreement with any previous employer (other than Aegerion Pharmaceuticals, Inc.) or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party. I further represent that my performance of all the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not disclose to the Company or its Affiliates or induce the Company or its Affiliates to use any confidential or proprietary information or material belonging to any previous employer (other than Aegerion Pharmaceuticals, Inc.)  or others.

 

12.                                Remedies Upon Breach .

 

(a)                                  Equitable Relief. I understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and its Affiliates and I consider them to be reasonable for such purpose. Any breach of this Agreement is likely to cause the Company and its Affiliates substantial and irrevocable damage and therefore, in the event of such breach, the Company and/or any Affiliate affected by such breach, in addition to such other remedies which may be available, will be entitled to seek specific performance and other injunctive relief, without the posting of a bond.

 

(b)                                  Indemnification. If I violate this Agreement, in addition to all other remedies available to the Company and any affected Affiliates at law, in equity, and under contract, I agree that I am obligated to pay all the Company’s (or, if applicable, Affiliate’s) costs of enforcement of this Agreement, including attorneys’ fees and expenses. I also agree that I will

 

3



 

defend, indemnify and/or hold the Company and its Affiliates harmless from and against any and all liabilities, losses, damages, claims or demands whatsoever (including expenses, court costs and reasonable attorneys’ fees) asserted against or incurred by the Company or any Affiliate as a result of or by reason of the Company or such Affiliate having to defend any claim arising from my use of proprietary or trade secret information of a prior employer or my breach of a restrictive covenant with any prior employer, and from any damages resulting from a final judgment or reasonable settlement of such claims. This indemnification shall include, but not be limited to, claims for infringement of patents, trademarks or copyrights, misappropriation of trade secrets or confidential information, and/or breach of any restrictive covenants, and is without prejudice to any other rights held by, or remedies available to, the Company or its Affiliates at law.

 

13.                                Use of Voice, Image and Likeness . During the period of my employment, I give the Company and its Affiliates permission to use any and all of my voice, image and likeness, with or without using my name, in connection with the products and/or services of the Company and/or its Affiliates, for the purposes of advertising and promoting such products and/or services and/or the Company and/or its Affiliates, and/or for other purposes deemed appropriate by the Company in its reasonable discretion, except to the extent expressly prohibited by law.

 

14.                                Publications and Public Statements . I will obtain the Company’s written approval before publishing or submitting for publication any material that relates to my work at the Company (including in connection with its Affiliates) and/or incorporates any Proprietary Information.

 

15.                                No Employment Obligation . I understand that this Agreement does not create an obligation on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment agreement signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated by the Company or me at any time and for any reason, with or without cause.

 

16.                                Survival and Assignment by the Company .  I understand that my obligations under this Agreement will continue in accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the right to assign this Agreement to its Affiliates, successors and assigns. I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time of such transfer.

 

17.                                Updating Information to the Company: Disclosure to Future Employers . For twelve (12) months following termination of my employment, I will (a) notify the Company of any change in my address and of each subsequent employment or business activity, including the name and address of my employer or other post-Company employment plans and the nature of my activities, and (b) provide a copy of this Agreement to any prospective employer, partner or co-venturer prior to entering into an employment, partnership or other business relationship with such person or entity.

 

18.                                Reimbursement .  I hereby authorize the Company at any time during or after the term of my employment to withhold from any amounts otherwise owed to me (including, but not limited to, salary, bonus, severance, commissions and expense reimbursements) to the fullest extent permitted by applicable law: any and all amounts due to the Company from me, including, but not limited to, cash advances, draws, travel advances, overpayments made by the Company to me, amounts received by me due to the Company’s error, unpaid personal credit card or phone charges or any other debt I owe to the Company for any reason, including amounts with respect to misuse or misappropriation of Company assets or breach of this Agreement.

 

19.                                Application to Affiliates .  I acknowledge that my duties as an employee of the Company may include providing certain management services to QLT Inc., Aegerion Pharmaceuticals, Inc., and other current or future affiliates of the Company within the meaning of the Delaware General Corporation Law (collectively the “Affiliates” and each an “Affiliate”), on behalf of the Company.  I agree that each such Affiliate will have the same rights that the Company has under this Agreement (including the right to indemnification and other remedies under paragraph 12), and that I will have the same obligations to each Affiliate as I have to the Company under this Agreement, as if such Affiliate was a signatory to this Agreement instead of the Company, except that if there is any conflict between my obligations under this Agreement to the Company and to one or more of its Affiliates, my obligations to the Affiliate will prevail.  I acknowledge to each Affiliate that it has direct rights against me under this Agreement. To the extent required by law to give full effect to these direct rights, I acknowledge and agree that the Company is and will be deemed to be acting as agent or trustee on behalf of and for the benefit of each Affiliate.

 

4



 

20.                                Severability .  In case any provisions (or portions thereof) contained in this Agreement shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

 

21.                                Interpretation .  This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted, enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Suffolk County, Massachusetts for purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction or venue in those courts.

 

[Remainder of this page intentionally left blank]

 

5



 

I UNDERSTAND THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, I CERTIFY THAT I HAVE READ IT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY.

 

IN WITNESS WHEREOF, the undersigned has executed this Employee Confidentiality, Assignment of Intellectual Property and Non-Competition Agreement as a sealed instrument as of the date set forth below.

 

 

Signed:

/s/ Gregory Perry

 

 

 

 

 

 

 

Name:

Gregory Perry

 

 

 

 

 

 

 

Date:

November 28, 2016

 

 



 

EXHIBIT A

 

To:

Novelion Services USA, Inc. (the “Company”)

 

 

 

 

From:

Gregory Perry

 

 

 

 

Date:

 

 

 

SUBJECT:                                      Prior Inventions

 

The following is a complete list of all inventions or improvements that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company:

 

No inventions or improvements

 

See below:

 

 

Additional sheets attached

 

The following is a list of all patents and patent applications in which I have been named as an inventor:

 

None

 

See below:

 

 


Exhibit 10.7

 

 

AEGERION PHARMACEUTICALS, INC.
101 MAIN STREET
SUITE 1850

CAMBRIDGE, MA 02142

 

May 25, 2016

 

Personal and Confidential

 

Barbara Y. Chan

621 Saw Mill Brook Parkway

Newton, MA 02459

 

RE:  Employment Offer

 

Dear Barbara,

 

Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) is pleased to offer you the full-time position of Vice President, Chief Accounting Officer, reporting to Greg Perry, CFO.  We are excited about the prospect of you joining our team, and look forward to the addition of your professionalism and experience to help the Company achieve its goals.  You are scheduled to begin your “at-will” employment with the Company on or before June 1, 2016.

 

Compensation and Benefits

 

You will be paid an initial semi-monthly salary of $11,041.67 ($265,000.00 on an annualized basis) (the “Base Salary”), which will be paid in accordance with the Company’s normal payroll practices as established or modified from time to time.  You are eligible to accrue up to 4 weeks’ vacation, which is accrued monthly in accordance with company policy.

 

In addition to your Base Salary, you will be eligible to earn an annual target bonus of up to 30% of your Base Salary.  The actual amount of such bonus, if any, will be determined by the Company’s Board of Directors (the “ Board ”) and your manager in their sole discretion, based upon your achievement of a series of mutually agreed upon performance milestones.  Your achievement of such milestones shall be determined by the Board and your manager in their sole discretion.  The bonus, if any, shall be paid pro-rata at a time and in a manner as determined by the Company in its sole discretion.  You must be employed by Aegerion at the time of any such bonus payment in order to be eligible for any such payment. Typically, bonuses, if any, are paid out no later than March  31 of the year following the applicable bonus year.

 

5/25/2016

PROPRIETARY AND CONFIDENTIAL

1

 

 



 

In addition to your Base Salary compensation and bonus eligibility, it is anticipated that you will be granted an option to purchase 26,000 shares of the Company’s common stock under the Company’s Inducement Award Stock Option Plan, subject to approval by the Chief Executive Officer.  The exercise price of the options will be at fair market value on the grant date.  The terms of this grant shall be subject to and governed by a stock option agreement between you and the Company.

 

During employment, you also will be eligible to participate in the Company’s benefits programs to the same extent as, and subject to the same terms, conditions and limitations applicable to, other employees of the Company of similar rank and tenure.  These benefits presently include:  eligibility to accrue vacation time, paid holidays, a 401(k) plan and contributory health/dental/vision insurance.  For a more detailed understanding of the benefits and the eligibility requirements, please consult the summary plan descriptions for the programs which will be made available to you during your new hire orientation.  Please note that the Company may modify compensation and benefits at its discretion.

 

In addition, you represent and warrant that your employment with the Company and the performance by you of your duties as an employee of the Company do not and will not breach or contravene (i) any agreement or contract (including, without limitation, any employment or consulting agreement, any agreement not to compete or any confidentiality or nondisclosure agreement) to which you are a party, or (ii) any obligation you may otherwise have under applicable law to any former employer or to any person to whom you have provided consulting services.  You further represent and warrant that you have delivered or disclosed, as the case may be, to the Company all agreements, contracts and obligations relevant to clauses (i) and (ii) above.  Lastly, you represent and warrant that you shall be able to and will perform the duties of this job without utilizing the confidential and proprietary information of any previous employer and that you shall not disclose any such information to Aegerion.

 

Please note that as conditions of this offer and your employment you will need to complete an employment application and background and/or reference checks to the Company’s satisfaction, and you will need to execute the forms necessary for the processing of such background check.  Moreover, please bring with you on your first day of employment for purposes of completing the I-9 form sufficient documentation to demonstrate your eligibility to work in the United States.  This verification must occur by the third day of your employment.

 

General

 

The above terms are not contractual.  They are a summary of our initial employment relationship and are subject to later modification by the Company, except for the Company’s at-will policy, which cannot be modified.  Please note that nothing in this offer letter is a promise or guarantee of employment for any specific period of time or continued employment.  In this regard, the Company has found that an at-will relationship is in the best interests of both the Company and

 

5/25/2016

PROPRIETARY AND CONFIDENTIAL

2

 

 



 

its employees.  As an at-will employee, either you or the Company can terminate your employment at any time and for any reason or no reason, with or without prior notice.

 

We look forward to having you join Aegerion.  We hope that you will be a very valuable contributor to our team going forward and look forward to receiving your signed acceptance of this letter within seven (7) days of the date hereof.

 

Sincerely,

 

 

 

 

By:

Brian M. Thomson [signed]

 

 

 

 

Title:

Sr. Director, Talent Acquisition, Human Resources

 

 

 

 

 

 

 

Accepted and agreed:

 

 

 

 

 

 

By:

/s/ Barbara Chan

 

 

 

 

Date:

May 25, 2016

 

 

5/25/2016

PROPRIETARY AND CONFIDENTIAL

3

 

 


Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)          Registration Statement (Form S-8 No. 333-190221) filed by QLT Inc. pertaining to the Amended and Restated QLT 2000 Incentive Stock Plan

(2)          Registration Statement (Form S-8 No. 333-100070) filed by QLT Inc. pertaining to the QLT 2000 Incentive Stock Option Plan

(3)          Registration Statement (Form S-8 No. 333-120657) filed by QLT Inc. pertaining to the Atrix Laboratories, Inc. 2000 Stock Incentive Plan (as amended and restated), the Atrix Laboratories, Inc. Non-Qualified Stock Option Plan (as amended) and the Atrix Laboratories, Inc. Amended and Restated Performance Stock Option Plan (as amended), each as assumed by QLT Inc.

(4)          Registration Statement (Form S-8 No. 333-162465) filed by QLT Inc. pertaining to the Amended and Restated QLT 2000 Incentive Stock Option Plan

 

of our reports dated March 15, 2016, with respect to the consolidated financial statements of Aegerion Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Aegerion Pharmaceuticals, Inc. included in the Annual Report on Form 10-K of Aegerion Pharmaceuticals, Inc. for the year ended December 31, 2015 filed with the Securities and Exchange Commission, which are incorporated by reference in this Current Report on Form 8-K of Novelion Therapeutics Inc.

 

/s/ Ernst & Young LLP

 

 

 

Boston, Massachusetts

 

December 5, 2016

 

 


Exhibit 99.2

 

 

Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class Action
Shareholder Lawsuit

 

Novelion Therapeutics Announces One-For-Five Reverse Stock Split

 

Vancouver, B.C., December 5, 2016 — Novelion Therapeutics Inc.  (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (the “Company”), today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsidiary of Novelion, entered into an agreement in principle to settle all claims in the class action shareholder lawsuit pending in the United States District Court for the District of Massachusetts (the “Class Action Litigation”).

 

The agreement provides for an aggregate settlement payment by or on behalf of Aegerion of $22.25 million. The Company expects $22 million of the settlement will be funded by Aegerion’s insurance proceeds and $250,000 will be funded by Aegerion. The settlement would include the dismissal of all claims against Aegerion and the named individuals in the Class Action Litigation without any liability or wrongdoing attributed to them. The settlement remains subject to further documentation, court approval, and other customary conditions, including Aegerion’s right to terminate the settlement in the event an agreed upon percentage of class members do not participate.

 

“We are encouraged by our continued execution on yet another important strategic initiative,” said Chief Executive Officer Mary Szela. “Under Novelion’s new management team, which has been significantly strengthened by recent hires in key leadership positions, the Company’s subsidiary, Aegerion, has now entered into an agreement in principle to settle the Class Action Litigation, demonstrably reduced its cost structure, and stabilized its balance sheet via the QLT merger.”

 

Novelion also announced plans to undertake a reverse stock split of its common shares on the basis of a consolidation ration of one for five (1:5) (the “Consolidation”). The Consolidation is expected to take effect on or about December 16, 2016.  The purpose of the Consolidation, which was approved by Novelion’s new board of directors, is to increase the per share trading price of Novelion’s common shares in order to eliminate non-fundamentally related trading restrictions on many investors.

 

Ms. Szela continued, “The reverse stock split is driven purely from a position of revitalized strength, and aims to provide a compelling investment opportunity to a larger breadth of institutional investors that may otherwise be prohibited from investing in lower price-per-share equities.”

 



 

 

The Company will seek approval from the Toronto Stock Exchange (“TSX”) to effect the Consolidation and has provided notification of the Consolidation to NASDAQ.

 

Subject to TSX approval, every five common shares issued and outstanding immediately prior to the effective date of the Consolidation will automatically convert into one common share. As a result of the Consolidation, the approximate number of issued and outstanding common shares will be reduced from 92,653,562 to 18,530,712. Each shareholder’s percentage ownership in the Company and proportional voting power will remain unchanged after the Consolidation, except for minor changes and adjustments resulting from the treatment of fractional shares. No fractional shares will be issued in connection with the Consolidation and any fractional shares that would have otherwise been issued will be rounded down to the nearest whole number, therefore no cash will be received in lieu of fractional shares. Proportional adjustments will be made to the Company’s outstanding stock options, warrants and restricted stock units, as well as to the conversion rate for the outstanding convertible notes of the Company’s wholly-owned subsidiary, Aegerion Pharmaceuticals.

 

About Novelion Therapeutics Inc.

 

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The Company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. Aegerion is planning to file a Marketing Authorization Application in the EU in December 2016 for metreleptin to treat generalized lipodystrophy and a subset of partial lipodystrophy. Aegerion recently received approval for lomitapide in Japan and plans to launch in January of 2017.

 

Forward-Looking Statements

 

Certain statements in this press release may constitute “forward looking information” within the meaning of applicable Canadian and United States securities laws. Forward looking statements include statements regarding the Consolidation, including the anticipated effective date, expectations about the settlement of the Class Action Litigation and expectations about insurance proceeds available for such settlement, plans for filing for approval of metreleptin and plans to launch Juxtapid in Japan. These statements are often, but not always, made through the use of words or phrases such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “would,” “could,” and “potential,” and similar expressions. All such forward looking statements involve assumptions that, although believed to be reasonable based on information

 



 

 

currently available to management, are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. You should not place undue reliance on any such forward-looking statements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking statements are the timing to effect the Consolidation and the potential that regulatory approvals for the Consolidation will not be received within the expected time frames; the terms of the agreement in principle related to the Class Action Litigation, including the payment amount and availability of insurance, could be amended and the amount and terms of any final settlement may be substantially higher and less favorable than we anticipate based on the terms of the preliminary agreement in principle.; the possibility that the court may materially alter or fail to approve the terms of the Class Action Litigation; the possibility that the anticipated benefits and synergies from the proposed merger cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Aegerion and QLT operations will be greater than expected; the risk that market acceptance of lomitapide and metreleptin in Japan and Europe, respectively, may be lower than we expect; the risk that the conversion of prescriptions for JUXTAPID or MYALEPT into patients on therapy may be lower than we expect or the drop-out rate may be higher than we expect; the risk that the prevalence of the diseases Aegerion’s products treat, or that we are pursuing treatment for, may be lower than we estimate, and that it may be more difficult to identify patients than we expect; the risk that the side effect profile or other results for Aegerion’s products in commercial use and in further clinical studies are inconsistent, in scope and severity, with the side effect profile and other results observed in the pivotal study of each drug; the risk that the negative impact of the launch of PCSK9 inhibitors on JUXTAPID sales will be greater than we currently expect, particularly in the U.S., where the negative impact has been greater than we expected to date, or that other competitive products will negatively impact our results; the risk that private or government payers may refuse to reimburse Aegerion’s or our products, or may impose onerous restrictions that hinder reimbursement or significantly limit or cap the price Aegerion or we charge or the number of reimbursed patients who receive products; the risk that revisions to the JUXTAPID Risk Evaluation and Mitigation Strategies (REMS) Program may negatively impact U.S. sales; the risk that Aegerion’s business may be negatively impacted if there are more Medicaid patients prescribed MYALEPT than we expect; the risk that named patient sales in Brazil and other key countries outside the U.S. may not be at the levels we expect; the risk that regulatory authorities in regions or countries where either of Aegerion’s products is not yet approved may refuse to approve such products or additional indications for such products, such approvals are not made on a timely basis or such approvals impose significant restrictions or require additional development; the risk that exchange rates will negatively impact the amount of net product sales recognized; the risk that the initiation of future clinical trials may be delayed; the risk that we will not be successful in our lifecycle management or business development efforts; the risk that Aegerion’s and our patent portfolios and marketing and data exclusivity may not be as strong as we anticipate; the risk of unexpected manufacturing issues affecting future supply; the risk that Aegerion incurs more costs than we expect in responding to

 



 

 

investigations, defending litigation and resolving litigation; the risk that any of the foregoing may cause product sales revenue to be lower than we expect, or that we may incur unanticipated expenses in connection with our activities; the risk that we may not be able to successfully execute strategic plans, including our cost-reduction program; and the other risks inherent in the commercialization, drug development and regulatory approval process. In addition, Aegerion’s agreement in principle with the U.S. Department of justice (“DOJ”) and the U.S. Securities and Exchange Commission (“SEC”) relating to the investigations by these agencies and the terms of potential final settlements with these agencies include risks associated with the required approvals of final settlement terms by relevant government agencies, such as the proposed settlement with the DOJ being subject to approval of supervisory personnel within the DOJ and relevant federal and state agencies and approval by a U.S. District Court judge of the criminal plea and sentence and the civil settlement agreement, and the proposed settlement with the SEC being subject to review by other groups in the SEC and approval by the Commissioners of the SEC.  The terms of the preliminary agreements in principle may change following further negotiations.  The amount and terms of any final settlement may be substantially higher and less favorable than we anticipate based on the terms of the preliminary agreements in principle.  Final settlement terms could include the imposition of additional penalties, further limiting Aegerion’s ability to conduct its business as currently conducted and as planned to be conducted. Additionally, the DOJ and the SEC each likely will outline their views of the factual background in connection with any final settlement.  The government’s recitation of their assessment of the background could lead to additional legal claims or investigations by state government entities or private parties and may have adverse effects on the Class Action Litigation, commercial operations and contracts.  For additional disclosure regarding these and other risks we face, see the disclosure contained in the “Risk Factors” section of Aegerion’s Quarterly Report on Form 10-Q filed on November 4, 2016, QLT’s Annual Report on Form 10-K filed on February 25, 2016 (and amended on April 29, 2016) and Quarterly Report on Form 10-Q filed on November 1, 2016 and each company’s other public filings with the SEC, available on the SEC’s website at http://www.sec.gov. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by law.

 

Investors and others should note that we communicate with our investors and the public using www.novelion.com, including, but not limited to, company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference calls transcripts and webcast transcripts. The information that we post on these websites could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in this release or any filing under the Securities Act of 1933, as amended.

 

CONTACT:

 

Amanda Murphy, Associate Director, Investor & Public Relations

 



 

 

Aegerion Pharmaceuticals, a Subsidiary of Novelion

857-242-5024

Amanda.murphy@aegerion.com